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SUMMARY 
 
Despite improvements in risk factor awareness, diagnosis and enhanced management 
strategies, the incidence and five year survival of colorectal cancer, has remained largely 
unchanged over the last twenty years.  As with many epithelial cancers, a preponderance of 
new colorectal cancer diagnoses occur in the over sixty five age group, making 
chronological age a strong risk factor.  Given this indelible link between ageing and cancer 
in general, genetic pathways which are implicated in one process could influence the other. 
Thus, an understanding of the biology of ageing and factors which regulate it may provide 
insight into cancer pathogenesis.  
 
Telomeres are nucleo-protein complexes sited at the ends of all chromosomes and have a 
critical function in the protection of the genome. Telomeres are implicated in the ageing 
process as a result of the inadequacies of the DNA replication machinery in somatic cells 
meaning that a section of telomeric DNA sequence is lost during each round of cell 
division, thus telomere length reduces with age and is a putative marker of biological 
ageing. Control of telomere length is complex and involves interplay between a number of 
genetic and environmental factors, of which oxidative stress is particularly important. 
However, critically short and hence dysfunctional telomeres have been implicated in 
cancer development through an inability to maintain genomic intergrity and an effect on 
senescence.  
 
Telomeres play an integral role in the sensing and repair of DNA damage, however, cells 
must possess a finely tuned mechanism through which they can sense DNA damage and 
initiate a response. This usually involves the activation of cell cycle checkpoints, either 
temporarily to allow repair, or on an irreversible basis to prevent the clonal expansion of 
cells with deleterious mutations. If the damage is deemed irrepairable apoptotic pathways 
are initiated.  The sirtuins are a group of genes first discovered and shown to control 
longevity in saccharomyces cerevisiae. Intense work has defined seven mammalian 
homologs termed SIRT1-7 which vary in their sub-cellular localisation, and have critical 
cellular functions ranging from the control of apoptosis, mitochondrial biogenesis, glucose 
and lipid metabolism, maintenance of genomic integrity and cell cycle control. Given these 
functions it is therefore no surprise that aberrancy of sirtuin expression is implicated in 
ageing and its commonly related diseases, particularly cancer. The aim of this study was 
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therefore, to determine if patients with colorectal cancer display aberrancy of ageing 
related factors, namely telomere biology and sirtuin expression. 
 
This study was undertaken using two sources of material for investigation. Quantitative-
PCR was utilised to measure telomere length in the peripheral blood leucocytes of 64 
colorectal cancer patients and 1348 controls. In addition, telomere length was similarly 
measured in colorectal cancer tumour and normal adjacent tissue. Telomere length was 
then correlated with a number of clinical and pathological parameters to determine 
diagnostic or prognostic utility. Furthermore, an attempt was made to establish whether 
telomere lengths were reflected in circulating mediators of inflammation and redox control 
factors, including fetuin-A a circulating modulator of calcium homeostasis. Sirtuin relative 
transcriptional expression (SIRT1-7) was then measured in the tumour and normal tissue 
samples. Clinically relevant information was derived by analysing the SIRT1-7 
transcriptional data in terms of clinico-pathological, inflammatory and outcome variables. 
Finally, sirtuin expression was correlated with other factors known to be involved with 
biological ageing to determine any potential association. 
 
Colorectal cancer patients had significantly shorter telomeres in their peripheral blood 
leucocytes (adjusted mean RelT/S=0.61) compared with chronologically older controls 
(mean age 75, adjusted mean RelT/S=0.70) (ANCOVA, p=0.004), indicating colorectal 
cancer patients were biologically older than their control counterparts. In addition, 
telomere length in tumour tissue (median=0.43, IQR=0.40) was significantly shorter than 
adjacent normal tissue (median=0.65, IQR=0.28) (p=0.004). Patients with low plasma 
fetuin-A levels were shown to have significantly shorter telomeres (p=0.041) and patients 
with rectal tumours had significantly higher levels of fetuin-A than those with colonic 
tumours (p=0.045). There was no correlation between telomere length and other redox 
factors, namely anti-oxidant vitamins, micronutrients and divalent cations. There was, 
however, a significant association between telomere length and systemic inflammation as 
determined by the neutrophil to lymphocyte ratio.  
 
SIRT 1-7 were differentially expressed between tumour and normal tissue, with significant 
attenuation evident in tumour samples when compared with normal tissue (p<0.0001 
except SIRT2 p=0.003). SIRT2 (p=0.021) and SIRT4 (p=0.027) expression in tumour 
samples, was significantly associated with anatomical tumour site and pathologically 
determined nodal status respectively. Whilst, SIRT3 expression in normal tissue correlated 
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with pro-inflammatory status, indicated by higher serum CRP levels. Finally, there was a 
significant inverse relationship with colorectal cancer tissue telomere length and SIRT3. 
When overall survival was considered, Kaplan-Maier analysis revealed a significant 
difference in survival in relation to SIRT4 expression levels.   
 
We have observed that patients with colorectal cancer display clear evidence of telomere 
attrition compared with controls. This is congruent with accelerated biological ageing in 
the pathogenesis of colorectal cancer and indicates cancer patients have ‘more miles on the 
clock’. An imbalance in redox control mechanisms and calcium homeostasis may be a 
contributing factor to telomere dynamics in these patients. The demonstration of attenuated 
sirtuin expression in colorectal cancer suggests a role as potential tumour suppressors and 
provides further evidence implicating biological ageing in the oncogenic process. 
Furthermore, plasma fetuin-A and tissue SIRT2 expression levels can be used to 
distinguish between colon and rectal cancers, providing further information regarding the 
molecular characteristics of these tumours. Telomere biology and the sirtuins could both 
play a pivotal role in the MTR (Mitochondria Telomere Ribosome biogenesis) paradigm, 
aberrancy of which could explain the apparent link between biological ageing and cancer. 
Enhancement of the understanding of the determinants of telomere length could mean that 
manipulation could lead to reduced colorectal cancer risk at the population level. In 
addition, the data provided in this thesis strengthens the evidence base which suggests that 
targeting individual sirtuins could be a future chemotherapeutic strategy, or indeed prove 
useful as markers of prognosis.  
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CHAPTER 1:  INTRODUCTION 
1.1 Ageing  
Interest in the field of ageing has increased exponentially in the last few decades. The 
reasons for this are multi-factorial and include intellectual curiosity, significant 
observations stimulating new and more complex discoveries, and probably most 
importantly the increase in the average human lifespan as a result of ‘epidemiological 
transition’. This transition has occurred in two stages the first of which resulted from 
improvements in public health and the development of antibiotics in the middle of the last 
century, along with a reduction in cardiovascular disease in the 1970’s and 80’s (Omran 
1971). This increase in population longevity has major implications for public health and 
global expenditure on ageing related maladies including cancer. Therefore, improvements 
in the knowledge base surrounding the ageing process could improve our ability to predict 
further fluctuations in lifespan, whilst identifying key determinants of lifespan could lead 
to the development of targeted interventions in some of the major pathological conditions 
inexorably linked to the ageing process, particularly cancer. It has been apparent from the 
earliest days of ageing research, that ageing is a complex multi-factorial process 
determined by a number of different extrinsic (environmental) and intrinsic (genetic) 
mechanisms which control the rate of ageing as well as the phenotype.  
Ageing itself has several definitions which broadly converge on the concept of increase in 
molecular chaos over time manifest as a detrimental change in phenotype culminating in 
an exponential increase in the likelihood of mortality (Shiels 1999).  The concept of 
increase in death rate with age was first proposed by Gompertz (1825). Two main concepts 
emerge from this broad definition: 
Chronological age;  defined as the time elapsed since birth 
Biological age; characterises the general condition of an individual at a certain time 
of his chronological age, which is marked by physical, psychical and 
social characteristics (Ries & Pöthig 1984). 
Whilst this definition of biological ageing concerns the individual as a whole it can be 
scaled down to the cellular level, where it could describe the general condition of the 
molecular machinery maintaining cellular homeostasis. When the two concepts of ageing 
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are compared they rarely equate with biological age subject to a variety of intrinsic and 
extrinsic forces which determine the level of damage accrued over time and the ability to 
counterbalance it (Karasik et al, 2005). The intrinsic forces which contribute to biological 
ageing include genetics, methods of maintaining genomic stability, epigenetic phenomena 
such as methylation or accumulation of anomalous proteins with the ability to resist normal 
degradation pathways (Kirkwood 2008). Extrinsic forces comprise a variety of 
environmental factors including nutrition, exercise, socioeconomic status and smoking that 
act to alter the rate of biological ageing. Aberrancy of any of these broad intrinsic factors 
or manipulation of extrinsic factors could therefore alter the course of biological ageing in 
a positive (deceleration) or negative (acceleration) fashion and provides the basic 
framework for ageing research ranging from the population to the molecular level.   
 
1.1.1 Ageing as an Evolutionary Concept  
Evolutionary concepts of ageing were devised in an attempt to answer fundamental 
questions such as ‘Why do we age’ and ‘Why do we live as long as we do’?  
1.1.1.1 Accumulated Mutations Theory 
Medawar first proposed this theory in 1952. The central theme is the idea that detrimental, 
late acting mutations may accumulate in the population and ultimately lead to growth 
arrest and pathology (Medawar 1952). The basis for these observations was the expansion 
of the knowledge surrounding Huntington’s disease. In the present day when there is 
relatively little risk of extrinsic pressures on mortality such as that from infectious disease 
or predation there is no real selection pressure to remove these late acting deleterious 
mutations  
1.1.1.2 Antagonistic Pleiotropy Theory 
This theory, also called the ‘trade-off theory’ espouses that genes exist which can have 
beneficial effects earlier in life but harmful effects later. The aim of optimal health earlier 
in life is to allow reproduction (Williams 1957). However, this theory has limited 
application in the modern human population where limited extrinsic pressures prevent 
early mortality thereby allowing the late onset deleterious effects to manifest. A 
physiological example of this theory would be the requirement of the prostate gland on 
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androgens for normal function, however later in life androgen exposure may contribute to 
the risk of prostate cancer (Imamoto et al, 2008). 
1.1.1.3 Disposable Soma Theory 
This theory argues that the investment in durability and maintenance of somatic tissues are 
predicted to keep the body in good repair through the normal expectation of life in the wild 
with some degree of reserve capacity (Kirkwood 1977, Kirkwood 2008). Essentially, the 
somatic organism is effectively maintained to allow reproductive success and once this has 
occurred becomes disposable, manifesting in ageing phenotypes. However, the 
reproductive tissues must be maintained to a level that allows accurate replication and 
passage of genetic material across a number of generations. This theory explains inter-
species variation in lifespan. The higher the extrinsic mortality rate of a species, the less 
energy should be invested in somatic maintenance and more towards reproduction, 
culminating in shortened lifespan (Kirkwood 2002).  
The previous two theories state the evolution of ageing results from gene action. In 
contrast, the disposable soma theory predicts that ageing evolves by genetic neglect, 
resulting in accumulation of molecular damage and eventually giving rise to age-related 
frailty and disease.  
 
1.1.2 Molecular & Cellular Mechanisms of Ageing  
Within the framework of the evolutionary theories of ageing described above there are a 
number of potential mechanistic pathways contributing to the decline in molecular and 
cellular viability associated with the ageing phenotype. These are varied and not mutually 
exclusive hence it is unlikely that any one acts independently (Table 1.1). 
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Table 1.1: Table summarising the key features of the main molecular and cellular mechanisms of 
ageing. 
 
Concept Key Features References 
Genetics • MZ twin lifespan more concordant than DZ. 
 
• Implicated genes include insulin/IGF1, FOXO 
and APOE, also chromosome 11p15.5. 
 
(vB Hjelmborg et al, 
2006) 
(Puca et al, 2001, Starr et 
al, 2008, Flachsbart et al, 
2009, Pawlikowska et al, 
2009)  
Senescence • Initiated by the observation of cessation of 
division by cells in culture after a certain number 
of replication cycles, termed the Hayflick limit. 
• Progressed by subsequent discovery that 
telomere attrition is a major driver of senescence 
and telomere length shortens with chronological 
age as a result of the end replication problem. 
• Senescent cells alter organ function and may 
contribute to the ageing phenotype.  
(Hayflick & Moorhead 
1961) 
 
 
 
(Olovnikov 1973, 
Aubert& Lansdorp 2008) 
(Campisi 2005, Campisi& 
d'Adda di Fagagna 2007) 
Genomic Instability • Maintenance of genomic integrity essential to 
prevent development of deleterious mutations 
which could contribute to the ageing process. 
• Checkpoint proteins (Chk1 & Chk2) monitor the 
genome and can halt cell cycle progression at 
either the G1/S or G2/M transition points, to 
allow the damage to be assessed and the requisite 
response elicited (repair, apoptosis or 
senescence).  
• DSB repaired via ATM and Chk2 pathway, 
single strand breaks via ATR and Chk1, 
downstream targets of both pathways include 
p53 and DNA repair proteins e.g. Ku. 
(Baute & Depicker 2008) 
 
 
(Stracker et al, 2009) 
 
 
 
 
 
(Baute & Depicker 2008, 
Smith et al, 2010, 
Warmerdam et al, 2010)  
Cumulative oxidative 
Burden 
• Free radical theory of ageing states that longevity 
is limited as a result of cumulative damage to 
DNA and other macromolecules by reactive 
oxygen species (ROS). It is theorised that long-
lived individuals have an augmented stress 
resistance capacity or produce less ROS. 
• Over-expression of SOD in model organisms can 
increase longevity. 
(Harman 1956) 
 
 
 
 
 
( Moskovitz et al, 2001, 
Salmon et al, 2009) 
Mitochondrial theory • Mitochondria are the main source of ROS in the 
cell and as such play a key role in the balance 
between oxidative damage and repair. 
Dysfunctional mitochondrial metabolic 
processes produce an excess of ROS via mutated 
mitochondrial DNA amongst other mechanisms. 
• Murine models of mutated mitochondrial DNA 
display evidence of accelerated ageing. 
(Edgar et al, 2009, Edgar 
& Trifunovic 2009) 
Nutrient Sensing 
pathways 
• Nutrient sensing is a key evolutionary conserved 
process which stimulates homeostatic 
modification to gain a survival advantage for 
organisms at times of low nutrient intake, 
allowing the potential for reproduction to be 
maintained. Two main pathways include:  
1. Insuin/IGF1- proliferation, protein synthesis, and 
the capacity to resist stress. These functions are 
facilitated through a complex cascade of kinases 
 
 
 
 
 
 
(Salminen & Kaarniranta 
2010) 
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such as the PI3-K/Akt/FOXO pathway 
2. mTOR- integrates cellular response with nutrient 
and energy levels through interaction with 
AMPK, responses include protein synthesis and 
ribosome biogenesis, autophagy, and 
mitochondrial activity. mTOR inhibition in 
murine models  
 
 
(Harrison et al, 2009, 
Zoncu et al, 2011) 
Epigenetics • Epigenetic phenomena are modifications to 
genes such that expression is altered without 
changes to the DNA sequence. This leads to 
aberrancy of gene expression most commonly 
resulting from chromatin remodelling due to 
processes such as DNA methylation and histone 
modification by methylation and acetylation.  
• The pattern of epigenetic modifications and 
chromatin structure is dynamic and varies 
throughout the lifespan of an organism- 
hypermethylation leads to suppression of 
expression of target genes with hypomethylation 
augmenting responsiveness. 
(Gravina& Vijg 2010) 
Stem Cell • Stem cells in adult tissues are responsible for the 
maintenance of function and structural integrity, 
due to differentiation or replenishment. 
Attenuation of stem cell function may contribute 
to the decline in tissue integrity and organ 
dysfunction associated with ageing. 
• Relationship with altered telomere biology and 
reduced capacity to facilitate DNA repair. 
(Charville & Rando 2011) 
 
 
 
 
 
(Flores& Blasco 2010, 
Rube et al, 2011) 
 
Calorie Restriction can Increase Lifespan 
Caloric restriction (CR) was first demonstrated to influence longevity in rodent studies 
performed in the 1930’s, since then a plethora of studies have replicated these findings in a 
number of different model systems from yeast to non-human primates (Kaeberlein et al, 
2004, Colman et al, 2009). CR stimulates a number of molecular adaptations which lead to 
robust changes in whole organism patho-physiology. Major changes induced by CR 
include reduction in body weight, body temperature and metabolic rate (Redman & 
Ravussin 2011, Rochon et al, 2011). Whilst endocrinological responses include improved 
glucose tolerance and insulin sensitivity, equivalent serum IGF-1, reduced T3 and 
increased cortisol (Redman et al, 2008). 
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1.2 Ageing and Cancer 
 
1.2.1 Trajectories of Ageing 
 
A recurring theme through the evolutionary concepts of ageing is one of degeneration in 
function as time progresses. Three trajectories of ageing have been described (Weinert & 
Timiras 2003). 
 
1. First, ageing characterised by disease and disability. 
2. Second, ‘usual’ ageing characterised by some decline in function but no overt 
pathology. 
3. Third, ‘successful’ ageing where there is little or no evidence of pathology and no 
decline in function. 
 
Ageing is deemed successful when an individual is free from disease and disability, has 
high cognitive and physical functioning, and engages in social and productive activities. 
Clearly a spectrum exists across the range of ageing phenotypes. As our adaptive and 
homeostatic mechanisms decline in function so the probability of disease and pathology 
increases. Although disease is not considered a prerequisite in the process of ageing a 
number of pathologies occur at a much higher frequency in older individuals. One of the 
most obvious examples is cancer. 
 
1.2.2 Common Mechanisms in Ageing & Cancer 
 
Cancer is to all intent and purposes a disease of ageing with 77% of all new diagnoses 
made in patients over the age of 55. This is mainly due to an excess of epithelial cancers, 
particularly breast, lung, colon and prostate, as opposed to those of mesenchymal or 
haematopoietic origin. For this reason age is considered the most potent of all carcinogens. 
The lack of a concomitant increase in tumours of diverse types with age suggests a 
complex relationship (DePinho 2000). 
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Age-related diseases are generally thought to result from a decline in tissue structure and 
function, an overall degenerative process. However, despite being considered a disease of 
ageing, cancer is paradoxically a gain of function disease, with cells acquiring the ability to 
hyper-proliferate and ultimately migrate. Mammalian species including humans have 
evolved the ability to renew somatic tissues which evidently confers an advantage, with the 
ability to repair damaged tissue to restore function. This ability, however, also gives rise to 
an elevated cancer risk as DNA replication is not fullproof thus potentially increasing the 
risk of oncogenic mutations. In addition to mutational load, cancer development also 
requires specific gene silencing through epigenetic regulation and a permissive 
environment in which cellular growth is encouraged. In order to prevent cancer formation a 
number of tumour suppressive mechanisms have evolved.  
 
1.2.2.1 Tumour Suppressor Mechanisms 
Tumour suppressors can be broadly categorised into two distinct groups. Caretaker tumour 
suppressors act on the genome to prevent or repair DNA damage. Mutations are therefore 
suppressed and risk of neoplastic transformation reduced. Examples of caretaker tumour 
suppressor genes include BRCA1/BRCA2, ATM and deleted in breast cancer-1. As 
deleterious events are reduced by caretaker tumour suppressors longevity is increased (van 
Heemst et al, 2007). 
 
The second main group of tumour suppressors are termed gatekeepers. These function to 
eliminate potentially cancerous cells by initiating senescence, thereby preventing further 
growth or division, or stimulating apoptosis. The gatekeeper tumour suppressor which has 
come under the most scrutiny is p53, due to its pervasive presence in many of the pathways 
controlling both cancer and ageing it deserves special mention. 
 
p53- a gatekeeper tumour suppressor 
p53 is a multi-functional transcription factor which regulates the transcription of a huge 
number of genes related to cellular processes such as response to stress, cell cycle 
checkpoint regulation, DNA repair and angiogenesis. Clearly these processes are 
fundamental to the initiation and progression of oncogenesis and it is therefore no surprise 
that p53 is mutated in almost 60% of human cancers (Vogelstein et al, 2000). The tumour 
suppressor effect of p53 arises as a result of activation of the ATM/ARF pathway by DNA 
damage or alternatively critically short telomeres. This propagates a response in which 
human double minute-2 (HDM2) is sequestered and its negative feedback relationship with 
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p53 reversed. The resulting increase in p53 expression facilitates either senescence or 
apoptosis. The decision as to which fate a cell is subjected to is not fully understood and 
likely to result from the damage stimulus and tissue type (Zuckerman et al, 2009).  
 
Recently p53 has been implicated as a regulator of the ageing process, in addition to its 
well described effect as a tumour suppressor. One might expect that as a potent tumour 
suppressor the effect on longevity would be simply that lifespan is extended as a result of a 
reduced incidence of cancer. However, p53 gain of function mutant mice exhibit an 
extraordinary resistance to cancer but died prematurely, exhibiting signs of accelerated 
ageing. Thus p53 over-expression results in a chronic engagement of DNA damage 
signalling which results in accelerated ageing phenotype and therefore has a marked pro-
ageing effect. (Tyner et al, 2002, Maier et al, 2004). Further complicating matters is the 
possibility that gatekeeper tumour suppressor genes including p53 could exert an 
antagonistic pleiotropic effect. In young individuals these genes have a beneficial effect by 
preventing the development of cancer. However, as lifespan progresses this effect can 
become deleterious and promote the ageing phenotype. In evolutionary terms because we 
are no longer subject to extrinsic hazards which curtail our lifespan (predation, infection 
etc) we now live longer, and as such are genetically exposed to the delayed detrimental 
effects of genes which are beneficial to younger organisms (Campisi 2005).  
 
It is clear the relationship between ageing and cancer is not a simple one to rationalise and 
that multiple layers of pathways controlling both processes exist. The initial underlying 
stimulus for both processes appears to be similar with disruption of genomic integrity, 
either within the genome in general or at the telomere. The response to this damage is 
integrated through the many of the same pathways such as p53, ATM/ARF and nutrient 
sensing pathways such as mTOR or the sirtuins. It is clear however, that the end 
phenotypes are distinct and that regulation of these pathways at the genetic, epigenetic and 
post-transcriptional level is responsible for these differences.    
 
 
 
1.2.3 Colorectal Cancer 
Colorectal cancer is the third most common cancer in the UK with 41,000 new cases 
diagnosed in 2009, and accounts for 14% of all new cases of cancer in general. Incidence 
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rates are approximately 75 / 100,000 in men and 59 / 100,000 in women, this difference is 
explained by a higher incidence of rectal cancer in men. Pertinent to this thesis is the fact 
that 72% of bowel cancers develop over the age of 65, making age a strong risk factor for 
the disease. This age related increase peaks between 75 and 80 where it remains at 500 
new cases / 100,000 in men and 338 / 100,000 in women. Incidence rates have remained 
on the whole static over the last twenty years, with survival rates doubling. However, 
overall five year survival is relatively poor at only 50% in both males and females (Cancer 
Research UK 2010). A short discussion of some of the common issues and terms with 
regards to CRC and pertinent to this thesis will now follow.  
1.2.3.1 Diagnosis and Staging 
Currently in the UK the pathways through which patients with CRC reach a diagnosis are 
altering. In the past symptomatic patients would be referred by their primary care physician 
generally with symptoms such as altered bowel habit, rectal bleeding, weight loss or local 
symptoms such as tenesmus. In addition to this group of patients there are a constant 
proportion of patients with CRC who present as an emergency with acute symptoms in 
relation to disease progression leading to bowel obstruction, perforation or acute 
haemorrhage (Crozier et al, 2009). The presentation of patients with symptoms whether 
emergent or otherwise has historically meant that a large proportion of patients present at a 
late stage when the chances of curative intervention are dramatically diminished. In an 
attempt to combat this phenomenon the National Bowel Screening Programme was 
recently implemented. This was done so on the basis of a number of trials which have 
shown that bowel screening for CRC by faecal occult blood testing can reduce mortality, 
with the most recently published UK trial showing a reduction in CRC specific mortality of 
13% (Scholefield et al, 2011). Based on this, and similar evidence the National Bowel 
Screening programme was initiated, which in Scotland involves an invitation from the age 
of 50-74 to submit a biennial faecal occult blood test. Should this prove positive patients 
are then invited to undergo a colonoscopy to visualise the mucosa of the colo-rectum, 
biopsy any abnormal areas or perform polypectomy. 
Staging of colorectal cancer is a fundamentally important process as the pre-operative 
staging of the disease will determine the treatment modality and the prognosis on an 
individual basis. For patients with colon cancer this involves a computed tomography (CT) 
scan to determine spread of disease to distant organs and some indication of local invasion. 
25 
 
Patients diagnosed with rectal cancer will undergo an additional MRI scan of the pelvis to 
determine the extent of local invasion. The TNM and Dukes classification are the most 
commonly used staging systems (Table 1.2). Both of these are pathologically determined 
therefore full assessment can only be made after surgical resection and pathological 
analysis of the tumour specimen.  
Table 1.2: Table summarising the components of the TNM and modified Dukes classification of 
colorectal cancer. 
TNM Classification Modified Dukes 
Classification 
 
Stages 
 
T N M Stages  
Stage 0 Tis N0 M0  
Disease confined 
to the bowel wall 
or adjacent 
structures 
Stage I T1 N0 M0 A 
T2 N0 M0 B1 
Stage II T3 N0 M0 B2 
T4 N0 M0 B2 
Stage III T1,T2 N1 or N2 M0 C1 Node positive 
disease T3,T4 N1or N2 M0 C2 
Stage IV Any T Any N M1 D Metastatic disease 
Details of T-stage given in Figure 1.9, Tis = in situ disease (not fully invasive), N1 = 1-3 positive lymph nodes, N2 = ≥ 4 
 
1.2.3.2 Pathological Concerns 
Tumour Site & Molecular Characteristics 
As depicted in Figure 1.1 the spread of distribution of tumours throughout the colo-rectum 
favours a predilection for the left or distal region with a ratio of approximately two thirds 
to one third. Distal (left colon and rectal) cancers are generally defined as those distal to 
the splenic flexure, with proximal (right and transverse) cancers the converse.  
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Figure 1.1: Distribution of tumour site throughout the colorectum (Cancer Research UK 2010).  
Recent interest in tumour site has lead to the discovery that there are particular clinical and 
molecular characteristics associated with the site of the tumour, meaning that CRC is now 
considered a heterogeneous disease. Initial characterisation was made on the basis that 
colon and rectal cancers were distinct entities but it now seems that proximal versus distal 
cancer is a more appropriate differentiation, however as molecular characterisation evolves 
this may also change (Minoo et al, 2010). The fundamental molecular difference lies in the 
driver of oncogenesis with proximal tumours generally initiated by dysfunctional mismatch 
repair pathways resulting in microsatellite instability, poor differentiation, mucinous 
histology and lymphocytic infiltration. Furthermore, these tumours are more likely to be 
hereditary resulting from an inherited mutation of one of the mismatch repair genes, most 
commonly MSH2.  Distal and rectal tumours are more likely to result from transformation 
within an adenomatous polyp via the adenoma-carcinoma sequence (discussed in due 
course), more likely to be microsatellite stable, have a higher frequency of KRAS mutation 
and more likely to be sporadic (Gordon 2007, Cunningham et al, 2010) 
Adenoma-Carcinoma Sequence 
This represents the proliferation of a single epithelial cell, to a benign polyp and 
sequentially on to a malignant neoplasm through a well defined series of genetic 
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mutational events (Figure 1.2). This was termed the adenoma-carcinoma sequence and 
characterised by the seminal work of Fearon and Vogelstein (Fearon & Vogelstein 1990). 
The clinical significance of the adenoma-sequence is that it takes approximately 7 years for 
normal epithelium to develop into a malignant lesion thus meaning that intervention to 
remove polyps should in theory prevent the development of invasive cancer, this provides 
the basic rationale behind the National Bowel Screening Programme (Gordon 2007). 
 
 
Figure 1.2: The sequence of genetic events and chromosomal site of progress through the adenoma-
carcinoma sequence. Taken from Gordon (2007). DCC- deleted in colorectal cancer 
 
1.2.3.3 Management Strategies  
The principle behind the surgical management with curative intent of CRC is resection of 
the tumour with adequate resection margins and sufficient lymphadenectomy to allow 
accurate staging of the disease. Surgical management of rectal cancer involves total 
excision of the mesorectum (TME) and adequate distal resection margins, if the lesion is 
too close to the anal verge to allow anastamosis the sphincter complex is resected and an 
end colostomy formed. As mentioned previously patients with rectal cancer undergo an 
additional staging pelvic MRI to assess the degree of local invasion of the tumour (Figure 
1.3). If on the basis of preoperative staging circumferential resection margins are deemed 
compromised patients are offered neoadjuvant therapy with either radiotherapy alone or in 
28 
 
combination with 5-fluorouracil based chemotherapy to downstage the disease and 
increase the likelihood of curative resection (Sebag-Montefiore et al, 2009, Cunningham et 
al, 2010). Generally patients who are lymph node positive (Dukes C) are offered post-
operative adjuvant chemotherapy to reduce the likelihood of systemic recurrence. 
Depending on the functional status of the patient combinations of either platinum or 5-
fluorouracil based chemotherapeutic regimens are employed (IMPACT Investigators 
1995). Dukes B or node negative patients prove more complex as the benefits of 
chemotherapy are less well established with only small gains in survival (Quasar 
Collaborative Group et al, 2007). The discovery during staging of metastatic disease does 
not preclude surgical intervention as synchronous or staged resection of the primary 
tumour and liver resection can be undertaken (Moug et al, 2010). 
 
A B C 
   
Figure 1.3: A Schematic representation of the layers of the colonic and rectal wall. B T-stage 
characterisation of colorectal cancer: T1- confined to submucosa, T2- extends beyond muscularis propria, 
T3- invades into subserosa T4- extends beyond subserosa and into adjacent structures.  (Brown et al, 1999). 
C MRI representation of T3 rectal cancer, lesion extension into subserosa indicated by the arrow (Kim et al, 
2004). 
 
It is clear that there are a number of areas of colorectal cancer biology and management 
where ambiguities lie, and which would benefit from an expansion of current knowledge. 
Obvious areas include the further molecular characterisation of tumours from different 
sites in the colo-rectum and identification of patients who are deemed to have poorer 
prognosis and may benefit from alteration of traditional follow-up and treatment strategies. 
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The clear increase in risk of CRC with age could provide a platform from which to further 
investigate the link between biological ageing and CRC. This thesis looked specifically at 
the role of telomere biology and sirtuin expression, the remainder of this introduction will 
outline the background of these two important areas of ageing and cancer biology. 
 
 
1.3 Telomere Biology 
In recent years the body of work surrounding telomere biology has increased 
exponentially. Furthermore, as the intricacies of the functional processes controlled by the 
telomere complex become more apparent, the role of telomere biology in the ageing 
process becomes more defined. Altered telomere biology has now been associated with a 
variety of age related pathologies from heart disease to cancer. A discussion of the 
structure and function of the telomere complex, along with control mechanisms 
determining telomere length (TL) will now follow, as will the relationship between TL and 
cancer.  
 
1.3.1 Telomere Structure 
The term telomere was first coined by Herman Muller during his seminal work with fruit 
flies, from the Greek meaning of ‘end’- telos and ‘part- meros. Both he and Barbara 
McLintock working with maize proposed that chromosome ends possess special structures 
required for chromosome stability and that without them chromosomes would fuse leading 
to breakages (McClintock 1939). 
1.3.1.1 Telomere DNA Structure 
The basic structure of the telomere is that of a nucleo-protein complex consisting of 
telomeric DNA and a number of bound proteins which are vital for the regulation of TL 
and the functionality of the telomere. Telomeric DNA structure consists of tandem repeats 
of G-rich sequences (TTAGGG)n (Moyzis et al, 1988). Investigation of the telomere 
structure using electron microscopy revealed the presence of large loops. These loops were 
dependent on the 3’G-strand overhang, which were tucked back inside the double stranded 
DNA and termed t-loops. Further analysis revealed the presence of a further loop structure 
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termed the d-loop (Greider 1999) (Figure 1.4). This ‘displacement’ loop is formed by 
single stranded DNA invasion of a double stranded sequence and base pairs with one of the 
strands. In the telomere this sequence extends for approximately 100-200 base pairs with 
the TTAGGG G-strand base paired to the CCCTAA sequence (Griffith et al, 1999a). The 
function of this loop structure is to enhance the ability of the telomere to protect the 
chromosome end from being recognised as a DNA break. This is not hard to envisage 
given the now ‘hidden’ 3’ overhang.  
 
 
Figure 1.4: Demonstration of the classical and newer ‘loop’ structure of the telomere. The original 
proposition of the telomere structure was that of a linear double stranded structure with a 3’ 
overhang on the G-strand and telomere-associated proteins positioned along its length. 
(Greider 1999).  
 
1.3.1.2 Telomere Associated Proteins 
Combined with the DNA structure of the telomere are a variety of proteins and enzymes, 
which confer structural integrity on the telomere, are responsible for elongation of 
telomeric DNA and aid in the functionality of the telomeric complex. Some of these 
proteins are permanently bound to the complex whereas others have a more dynamic 
relationship depending on cellular conditions such as stress and DNA damage. A 
schematic diagram of the most important telomere associated proteins is shown below 
(Figure 1.5). 
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Figure 1.5: Telomeric structure, including the major associated proteins (Hodes et al, 2002). 
Telomerase 
Telomerase is a specialised unique enzyme which is responsible for the elongation of the 
telomeric TTAGGG repeat sequences. It was first described in tetrahymena thermophilia 
and is composed of three core subunits; the first is the reverse transcription protein termed 
TERT and encoded by the hTERT gene located on chromosome 5p.15.33. Secondly, the 
RNA template for the TTAGGG sequence termed TERC, the hTERC (or hTR) gene is 
positioned at 3q21-q28. Finally, the third subunit is defined on a species specific basis 
which in humans is dyskerin, this is required for accurate folding and structural stability of 
the telomerase complex (Greider & Blackburn 1987, Morin 1989, Cohen et al, 2007) 
(Figure 1.6).  
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Figure 1.6: Diagram of the telomerase structure. NOP10, NHP2 and GAR1 are subunits of the 
dyskerin complex and are required for the correct processing of telomerase. hTR is 
interchangeable with hTERC. Adapted from (Armanios 2009) 
 
Shelterin 
Shelterin is a complex of six proteins composed of TRF1, TRF2, TIN2, Rap1, TPP1 and 
Pot1 (Figure 1.5), with all six proteins found in a single complex in fractionated nuclear 
extracts. TIN2 is considered to be the most important constituent of the complex due to its 
ability to tether TPP1/Pot1 to TRF1 and TRF2, whilst also linking TRF1 to TRF2 (de 
Lange 2005). Shelterin shows great specificity for the TTAGGG sequence of telomeric 
DNA by virtue of multiple recognition folds within the structure of TRF1, TRF2 and Pot1 
(Court et al, 2005). Shelterin is thought to shape the telomeric structure by encouraging the 
formation of the t-loop, a function particularly dependent on TRF2, given its ability to 
remodel artificial telomeric substrate into loops in vitro (Stansel et al, 2001). The presence 
of shelterin and the t-loop configuration function together to form a ‘cap’ on the telomere 
which functions to protect the chromosome end. Shelterin also contributes to the 
maintenance of TL and the DNA damage response mechanism.  
Dynamic Telomere Associated Proteins 
This is a substantial group of proteins which transiently bind to the telomere and shelterin 
complex. Many of these proteins have a dual role in regulating the DNA damage response 
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in addition to contributing to the maintenance of optimal TL. Some of these proteins and 
their key functions are listed in the table below. 
 
Table 1.3: Table listing some of the major transient telomere associated proteins with their binding 
targets and function. 
Protein Binding Site Function 
 
Tankyrase TRF1 TRF1 down-regulation with resulting increased 
activity of telomerase and positive regulation of 
telomere length 
 
DNA-PK TRF1 Aids in creation of t-loops 
 
DNA-PKcs TRF2 Signals short telomeres as DNA damage 
 
Ku70/86 dsDNA Inhibits telomerase 
Recruits DNA-PKcs 
Recruits/stimulates WRN/MRN 
Regulates Atm 
 
MRN 
Mre11 
Rad50 
NBS1 
 
TRF2 
TRF2 
TRF1/2 
Modulates Atm 
t-loop stabilisation 
stimulates Mre11 activity 
Unpairing/opening t-loop 
 
WRN TRF2 Unwinds 3’ loop 
 
BLM TRF1 Unwinds dsDNA 
 
RPA ssDNA Prevents re-annealing 
 
Atm TRF2 DNA damage signalling 
 
ERCC1 TRF2 Removes G-overhang 
 
BRCA1 TRF1 Regulates transcription hTERT 
 
 
DNA-PK, DNA-protein kinase; DNA-PKcs, DNA-protein kinase catalytic subunit; dsDNA, double stranded DNA; Mre11, meiotic 
recombination 11; NBS1, Nijmegen breakage syndrome 1; WRN, Werner syndrome; BLM, Bloom syndrome; RPA, Replication protein 
A; ssDNA, single stranded DNA; Atm, Ataxia-Telangiectasia-mutated; ERCC1, Excision repair cross-complementing 1; BRCA1, Breast 
cancer associated 1  
 
1.3.2 Maintenance of Telomere Length 
1.3.2.1 Telomere Dynamics 
Maintenance of TL is critical to telomere functionality as upon reaching a critically short 
length a series of responses are elicited which can ultimately lead to the removal of the cell 
from the population. Therefore, a number of mechanisms have evolved to maintain TL at a 
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constant length. However, this is complicated by the fact that one of the key mechanisms 
for maintaining TL, the enzyme telomerase,  is ‘switched off’ in somatic cells meaning that 
as they replicate TL shortens, this observation lead to the concept of TL reflecting the 
replicative capacity of the cell and functioning as a mitotic clock. This link with replicative 
capacity is not limited to the cellular level as TL also reduces with increasing 
chronological age, a process which can be altered by a number of intrinsic and extrinsic 
factors.   
Maintenance of TL is a complex process which is reflected by the fact that TL is highly 
variable. Average TL in normal human population varies between 5-10Kb but this can vary 
on an individual basis between organ systems, cells and even between chromosomes. 
Variability within individuals was demonstrated by Takubo et al (2002) who showed that 
the longest telomeres were evident in the myocardium with the shortest in the liver and 
renal cortex. This may reflect the replicative and rejuvenative capacity of these organs, 
with non-replicative tissues retaining baseline TL (Takubo et al, 2002). The heterogeneity 
of TL has recently been partially characterised in a longitudinal study following 635 
volunteers over a 5-10 year period. The rate of change in TL was highly variable with 
some individuals seemingly gaining in TL, however a shorter TL at baseline was translated 
into a more rapid loss of TL overall. The authors therefore conclude that factors other than 
the end-replication problem influence TL dynamics (Aviv et al, 2009). 
1.3.2.2 End Replication Problem 
The end replication problem suggests that TL reduces with every round of cell division 
until a critical length is reached, when signalling pathways are activated which remove the 
cell from the replicating population by either apoptosis or senescence. The end replication 
problem arises due to the uni-directional nature of DNA replication and the 5’ to 3’ 
function of DNA polymerase. This means that synthesis of the lagging strand must occur 
discontinuously with small RNA primers added a short distance ahead to elongate the 
DNA sequence via the formation of Okazaki fragments. However, when the replication 
fork reaches the end of the lagging strand a gap is left in the sequence once the RNA 
primer has been removed. This means DNA polymerase is unable to replicate the 
sequence, therefore a section of telomeric DNA is lost with subsequent replications (Levy 
et al, 1992). The concept of the number of repetitive sequences at the chromosome end 
determining the replicative capacity of somatic cells, as well as the telomeric repeat 
sequences acting as a protective buffer to upstream genes was put forward by Olovnikov 
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(1973). In addition, Olovnikov also suggested that cells from continually dividing tissues 
and organs required a mechanism by which to overcome the end replication problem. The 
discovery of telomerase and its ability to elongate telomeric DNA repeats solved the 
mystery of the end replication problem (Olovnikov 1973).  
1.3.2.3 Role of Telomerase 
Telomerase is considered prerequisite for any cell type which has the need to undergo 
continual division. Thus telomerase is expressed in over ninety percent of human tumours 
and is also constitutively expressed in germ-line cells and many types of human stem cells 
(Kim et al, 1994). Modest amounts of telomerase activity have been discovered in 
progenitor cells of skin, gut epithelium and bone marrow, reflecting the potential for 
renewal in these cell compartments (Artandi & DePinho 2010). Introduction of telomerase 
into telomerase null cells confers a survival advantage with telomerase expressing cells 
displaying longer TL, increased replicative capacity and reduced evidence of cellular 
senescence (Bodnar et al, 1998).  
In vitro reconstitution experiments with single amino acid modified hTERT confirms it to 
be the catalytic component of the telomerase enzyme, and essential for telomerase function 
(Weinrich et al, 1997). Immortality of normal prostate cells in culture is achieved by c-myc 
mediated up-regulation of hTERT expression and results in stabilisation of TL (Gil et al, 
2005). Factors essential for normal cell cycle checkpoints and maintenance of senescence 
such as p53 and p16INK4A can down-regulate hTERT expression (Kanaya et al, 2000, 
Bazarov et al, 2010). Conversely, growth factors known to stimulate cellular proliferation 
such as the viral oncogenes human papilloma virus and cytomegalovirus can up-regulate 
hTERT expression (Horikawa & Barrett 2003, Straat et al, 2009). Variation at the TERC 
gene has also been shown to influence TL. Genome wide association analyses have 
revealed a locus at 3q26 which correlates with mean leucocyte TL, a locus which includes 
the TERC gene (Codd et al, 2010).  
1.3.2.4 Components of Shelterin Influence Telomere Length 
The shelterin complex as a whole and its constituents influence TL in a number of ways. 
TRF1 and TRF2 are negative regulators of TL acting indirectly to control the access of 
telomerase to the telomere. This is performed by facilitation of an isometric change in the 
telomere to cis configuration, by doing so the telomere changes from an open to a closed 
state preventing the access of telomerase and an inability to elongate TL if required (De 
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Boeck et al, 2009). It is postulated that TRF1 and TRF2 effectively sense TL, as the longer 
the telomere the more abundant the levels of TRF1 and TRF2, with very short telomeres 
unable to bind enough TRF1 and TRF2 to generate the closed state (van Steensel & de 
Lange 1997, Smogorzewska et al, 2000).  TRF2 makes a further contribution to the control 
of TL by its role in the maintenance of the t-loop (Stansel et al, 2001).  
Pot1 can also play a role in the maintenance of telomeric DNA content. This occurs as a 
function of the interaction between Pot1, TRF1 and the single stranded 3’ overhang section 
of the telomere. It is the presence of Pot1 at the 3’ overhang which directly inhibits the 
interaction between the RNA template and DNA primer. Thus in the most simple terms 
Pot1 acts as a negative regulator of TL by inhibiting telomerase (Loayza & De Lange 
2003, Kelleher et al, 2005).  
1.3.2.5 Epigenetic Regulation 
Epigenetic regulation of telomeric heterochromatin signatures by methylation of 
subtelomeric DNA, in addition to the epigenetic regulation of the expression of telomerase 
subunits is an important mechanism in the maintenance of TL. Alteration of the 
methylation status of telomeric chromatin by knockout of the SUV39H1 and SUV39H2 
methyltransferases resulted in hypomethylated telomeres which showed an impaired ability 
to elongate (Garcia-Cao et al, 2004). This effect may be linked to alteration in the ability of 
components of the shelterin complex to regulate telomerase activity (Benetti et al, 2007).   
Delineating the effect epigenetic modulation of the hTERT gene on TL has proved 
troubling with both hypo- and hypermethylation of the hTERT promoter and associated 
histones shown to impact on hTERT expression and TL (Devereux et al, 1999, Guilleret & 
Benhattar 2003, Atkinson et al, 2005). The discovery of methylation status contributing to 
TL control is significant. Methylation can be intrinsically controlled but nutrition may also 
play a role hence both of these factors could impact on TL (Paul 2011).  
1.3.2.6 Alternative Lengthening of Telomeres 
Telomerase is responsible for the maintenance of TL in approximately 85-90% of human 
cancers, a process known as alternative lengthening of telomeres (ALT) is responsible for 
the remainder. ALT is thought to occur by a homologous recombination mechanism which 
elongates telomeres independent of telomerase. This confers a number of phenotypic 
changes in cells that have undergone this process and a number of controlling factors have 
been identified. However, the reason why some cell types utilise this method of telomere 
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maintenance as opposed to telomerase dependent mechanisms is not clearly understood 
(Cesare & Reddel 2010).  
Homologous recombination (HR) is thought to represent the most conserved method of 
ALT. ALT was first reported in mammalian cells by Murnane et al (1994) and confirmed 
by Bryan et al (1995) when it was noted that in cells without telomerase, telomeres were 
highly heterogenous, with rapid changes occurring on longer telomeres (Murnane et al, 
1994, Bryan et al, 1995).  The current thoughts are that the telomere replicates itself via the 
t-loop or copying of a sister chromatid (Cesare & Reddel 2010). Master control of the ALT 
process resides with the telomere associated proteins, in particular the MRN complex 
(Zhong et al, 2007). One of the key phenotypic changes seen in cells that have undergone 
ALT is the generation of t-circles. These are thought to form during the resolution of the 
telomere-loop junction and were first identified by electron microscopy of telomere 
enriched nuclear extracts (Cesare & Griffith 2004). They may contribute to the ALT 
process by providing a template for telomeric extension.  
 
1.3.3 Determinants of Telomere Length 
1.3.3.1 Age 
The relationship between ageing and TL is one that despite being first recognised over 
twenty years ago still has not been fully delineated. It is clear that TL declines with age as 
predicted by the end replication problem, but it is not clear whether a cause and effect 
relationship exists.  
Cooke and Smith first linked telomeres to the ageing process with the observation that 
germ cells had much longer telomeres than adult cells of the non-germ line variety, and 
that this might be due to the fact somatic cells lacked the recently discovered telomerase 
(Cooke & Smith 1986). Cooke and Smith thus provided a framework to explain the end 
replication problem and its relationship with the Hayflick limit. This theory was 
corroborated with the observation that the TL of fibroblasts in culture reduced with serial 
passage and that initial TL determined the replicative capacity of similarly cultured 
fibroblasts (Allsopp et al, 1992, Harley et al, 1990, Allsopp et al, 1995, Vaziri et al, 1994). 
These observations then lead to the theory that TL could act as a mitotic clock in human 
cells given the dependent relationship of TL with replication (Vaziri et al, 1994, Allsopp et 
al, 1995). If the initial observations of Cooke and Smith were true and that telomere 
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attrition stimulated cells to enter senescence then the consequences of this mitotic clock 
‘running down’ should be entry into senescence. This was confirmed by Allsop & Harley 
(1995) who demonstrated that a critical TL was responsible for the entry into senescence 
(Allsopp & Harley 1995). Senescence was by-passed by the introduction of telomerase into 
human cells which had longer telomeres and reduced markers of senescence (Bodnar et al, 
1998).  
Since these initial in vitro observations, efforts have been made to extrapolate them to the 
organismal level, particularly in human lifespan. Numerous studies have established that as 
expected human TL falls with increasing chronological age similar to cells in vitro. This 
has been confirmed in various human cell types including peripheral blood leucocytes 
(Hastie et al, 1990, Vaziri et al, 1994), colorectal tissue (Nakamura et al, 2000), liver 
(Takubo et al, 2002) and pancreas (Ishii et al, 2006). TL in post-mitotic tissues such as 
neurons from the cerebral cortex and cardiac myocytes has been shown to be maintained in 
relation to chronological age, on a consistent basis (Takubo et al, 2002). Results 
quantifying the annual rate of telomere loss have been variable but the rate of loss usually 
lies between 20-60bp per year (Takubo et al, 2010). However on a population level 
differences in attrition rates are impacted on by a number of different factors which are 
potentially modifiable (Shiels et al, 2011).  
Further refinement of the hypothesis of telomere biology in the ageing process has been 
possible due to the development of telomerase deficient mouse models. Through deletion 
of the TERC gene mice with phenotypic changes consistent with accelerated ageing are 
obtained. These include infertility, heart failure, immune deficiencies, tissue atrophy and 
reduced regenerative capacity. Molecular analysis of these animals revealed critically short 
telomeres in comparison with control animals, with gross evidence of multiple 
chromosomal abnormalities indicative of telomere dysfunction (Blasco et al, 1997).  
In a reverse of the process which produced the original TERC deficient model, late 
generation TERC-/- mice were crossed with TERC+/- producing offspring in which 
telomerase was re-activated. These mice had telomeres which were restored to normal 
length and, moreover, the premature ageing phenotype was rescued (Samper et al, 2001). 
The effect of over-expressing telomerase on lifespan has also been investigated. Initial 
models of TERT over-expression did have overall longer survival but this was complicated 
by an increase in sporadic malignancies in some generations (Gonzalez-Suarez et al, 
2005). In order to circumvent this predicted issue, a mouse model, known as SUPER-M 
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has been constructed. In addition to over-expression of TERT; p53, p16 and p19ARF tumour 
suppressors are also constitutively over-expressed. By doing so the incidence of cancer is 
reduced and therefore dissociated from the ageing process. SUPER-M mice have a delayed 
onset of age related pathologies, improved overall survival, and longer telomeres in both 
stem and differentiated cells compared with wild type controls (Tomas-Loba et al, 2008). 
Jaskelioff et al (2011) have reversed degenerative phenotypes in multiple organs including 
testes, spleen and intestines as well as reversing markers of neurodegeneration, in a mouse 
model in which telomerase activity is induced and TL extended in late generations 
(Jaskelioff et al, 2011).  
1.3.3.2 Genetic Determinants  
TL is known to be determined in part by intrinsic genetic factors inherited by the 
individual, and is thought to explain some of the inter-individual variability of TL. Indeed 
Slagboom et al (1994) used 123 human mono- and di-zygotic twin pairs, and calculated 
78% heritability in TL (Slagboom et al, 1994). Further investigation has revealed that TL 
is predominantly inherited from the paternal lineage. Paternal age at birth was positively 
associated with offspring TL, with no relationship demonstrated between maternal age and 
TL (De Meyer et al, 2007). Variability in TL as a result of inherited factors could result 
from different mechanisms. The finding of paternal age significantly impacting on TL 
could indicate that TL is not fully re-set after fertilisation and that if paternal TL is short 
this is inherited by the offspring (De Meyer et al, 2007). This is a scenario similar to that 
seen in animals created by nuclear transfer, in particular when the donor nucleus is 
harvested from a somatic cell of an older animal (Shiels et al, 1999). However, under 
normal reproductive mechanisms germ cells are the source of parental DNA, which retain 
the ability to maintain TL using telomerase.  This is consistent with the fact that TL at birth 
is similar between organs of individuals and between sexes, but a wide inter-individual 
variability remains and further highlights the fact that adult TL is determined in part by 
intrinsic genetic and in-utero factors (Okuda et al, 2002).  
 1.3.3.3 Sex 
Male sex confers a lower mean age of mortality compared with females in a number of 
different populations. Consistent with this, a number of studies have established that males 
have shorter overall TL and faster rates of telomere attrition (Njajou et al, 2009). However, 
at birth there is no sex difference in TL indicating that factors which contribute to telomere 
maintenance, or accelerate attrition, accumulate throughout an individual’s lifetime (Okuda 
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et al, 2002). An obvious mediator of this sex difference later in life is the effect of 
oestrogen exposure and the menopausal state. Lin et al (2011) have recently reported that 
increased endogenous oestrogen exposure was associated with greater TL suggesting 
oestrogens may be associated with decelerated cellular ageing (Lin et al, 2011). Exogenous 
hormone replacement of oestrogen and progesterone has also been associated with greater 
TL in post-menopausal women (Lee et al, 2005). In a molecular context oestrogen has 
been shown to increase telomerase expression by up-regulation of hTERT activity with a 
concomitant increase in TL (Bayne et al, 2011). 
1.3.3.4 Oxidative stress 
Damage induced by ROS has emerged as a key player in the determination of TL by virtue 
of accumulating evidence from a number of different experimental systems. The 
heterogeneity of TL both in vitro in cultures cells and in vivo is partly explained by the 
balance of oxidant load and antioxidant defence mechanisms. The intimate relationship 
between TL and oxidative stress has stimulated some investigators to theorise TL as a 
biomarker of oxidative damage. 
Investigators focusing on the capacity of telomere attrition rates to affect the replicative 
potential of cells in culture discovered that manipulation of the culture conditions could 
have a profound effect. Culture of human fibroblasts under mild hyperoxia (oxygen partial 
pressure 40%) irreversibly blocks proliferation, induces a state indistinct from senescence 
and is signalled by increased telomere attrition rates with a cut-off of 4Kb (von Zglinicki et 
al, 1995). Treatment of cells cultured under stressful conditions with free radical 
scavengers abrogates the induced accelerated telomere attrition and can even prolong 
replicative lifespan (von Zglinicki et al, 2000). Whilst cells with an inherent augmented 
antioxidant capacity such as human foreskin BJ fibroblasts are protected against telomere 
damaging effects of oxidative stress (Lorenz et al, 2001). 
A number of diseases in which oxidative stress plays a critical role have been shown to be 
associated with short telomeres in peripheral blood leucocytes (PBLs) namely, vascular 
dementia (von Zglinicki et al, 2000), atherosclerosis (Brouilette et al, 2008) and COPD 
(Savale et al, 2009). Patients with chronic kidney disease (CKD) on dialysis suffer from 
increased mortality due to an excess of a number of pathologies related to oxidative stress. 
In these patients this excess risk of mortality is mediated by telomere attrition with a 
dependant relationship between fetuin-A a circulating inhibitor of calcification and 
mediator of oxidative stress, and short TL (Carrero et al, 2008).  
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Variation in endogenous antioxidant mechanisms could explain some of the variability in 
TL at the in vivo level. Starr et al (2008) correlated a panel of 384 SNPs from 141 
oxidative stress genes with TL, with two genes in particular displaying a significant 
association (Starr et al, 2008). Furthermore, increased consumption of antioxidant vitamins 
has also been confirmed as an independent correlate of longer TL in a female population 
(Xu et al, 2009).  
Telomeres exhibit a number of features which makes them particularly susceptible to 
oxidative damage. The base guanine is particularly sensitive to oxidative damage which is 
reflected in the level of modified guanine bases particularly 8-oxodG, in senescent cells 
exposed to oxidative damage (Kawanishi & Oikawa 2004). Oxidative damage induces 
single strand DNA breaks in telomeric repeats causing interference with the replication 
fork at telomere ends leading to enlargement of unreplicated ends (von Zglinicki 2002). 
Moreover, telomeres are less proficient at repair of single-strand breaks than the remainder 
of the genome, as indicated by the enhanced level of repair in minisateillites compared 
with telomeres in cells exposed to oxidative damage (Petersen et al, 1998). This 
impairment of damage repair at the telomere may in part be explained by the positioning of 
TRF2 at the telomere end and has been shown to block the access of DNA repair enzymes 
to telomeric strand breaks (Richter et al, 2007).  
Endogenous ROS is mainly derived from mitochondria as an inevitable by-product of 
oxidative metabolism, with damage occurring due to an imbalance between ROS 
generation and scavenging pathways (Shiels & Davies 2004, Muller et al, 2007). A pro-
inflammatory state is a well recognised stimulator of excess ROS production mainly from 
immune cells such as macrophages and neutrophils. Hence, patients suffering from 
conditions typified by a chronic inflammatory response have been shown to display 
evidence of telomere attrition, which is postulated to be as a result of excess ROS 
generation. Typical conditions include inflammatory bowel disease (Risques et al, 2008b), 
chronic pancreatitis (Hashimoto et al, 2008) and type II diabetes mellitus (Sampson et al, 
2006).  
Exogenous or environmental sources of ROS include cigarette smoke. Cigarette smoke 
contains ROS but can also stimulate endogenous generation by virtue of its pro-
inflammatory effects. Several studies have determined a link between cigarette smoke and 
TL. Indeed, Valdes et al (2005) estimated that a 40 pack year smoking history corresponds 
to 7.4 years of ageing related telomere attrition (Valdes et al, 2005).  
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1.3.4  Telomere Function & Molecular Basis of Dysfunction 
As outlined above the maintenance of TL is a stochastic and heterogeneous process 
whereby a variety of endogenous and external factors co-operate to determine TL. The 
importance of maintaining an adequate TL is fundamental to the functionality of the 
telomere, as short telomeres are almost universally dysfunctional.  
1.3.4.1 Protection of the Genome & Role in Senescence 
Telomeric suppression of DNA damage signalling 
The unique nucleo-protein structure of the telomere is essential for its ability to suppress 
the DDR that would otherwise be initiated if the ends of chromosomes were not protected 
by the telomere. The most important of these components is the shelterin complex, 
particularly TRF2 and Pot1. TRF2 has been shown to play a clear role in DDR suppression 
as exemplified by the fact that deletion of TRF2 leads to accumulation of γH2Ax (a 
modified histone indicative of DNA damage) and frequent telomere fusions both 
suggesting de-protection of telomeres (Lazzerini Denchi et al, 2006). TRF2 is thought to 
suppress the initiation of a DDR through direct interaction with ATM the major 
intermediary in the response to double strand DNA breaks (DSBs). Deletion of TRF2 leads 
to ATM activation and formation of DNA damage foci at telomeres, which are identical to 
those formed at sites of DSBs (Karlseder et al, 1999, Lazzerini Denchi et al, 2006). TRF2 
may also suppress the DDR through its ability to create the t-loop configuration of the 
telomere end thereby preventing the apparatus for detecting DSBs access to the telomere 
end which would otherwise be recognised as a DNA break (Stansel et al, 2001).  
A further contribution to the suppression of a DDR is the ability of Pot1 to suppress the 
ATR pathway. Inhibition of Pot1 triggers the accumulation of DNA damage foci at 
telomeres, leading to the accumulation of γH2Ax and other factors signifying a damage 
response (Hockemeyer et al, 2005). The ability of Pot1 to repress ATR signalling lies in its 
interaction with another shelterin component, TPP1. TPP1 recruits Pot1 to the telomere 
and improves its ability to bind to the G-overhang. Moreover, deletion of TPP1 results in 
damage foci at telomeres indistinct from those caused by Pot1 deletion (Denchi & de 
Lange 2007, Hockemeyer et al, 2007).   
Whether telomere attrition occurs through replicative means as determined by the end 
replication problem or is accelerated by oxidative damage the end result is indistinct, 
namely uncapping of the telomere and loss of its key function in suppressing the DDR. 
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This mainly results from the reduced ability to recruit shelterin complexes in sufficient 
numbers to maintain TL and, the inability of TRF2 and Pot1 to suppress the DDR as 
outlined above (Smogorzewska et al, 2000, de Lange 2005).  
The exact length at which telomeres become uncapped and lose their protective function is 
a matter for debate and appears to be organism dependent (O'Sullivan & Karlseder 2010). 
In human fibroblasts in senescence the bulk of telomeres as determined by southern 
analysis appeared to be around 4kb (Karlseder et al, 2002). However, ultra-short telomeres 
of seven canonical telomeric repeats termed t-stumps have been identified in cancer cells 
(Xu & Blackburn 2007), whereas in telomerase negative cells repeats of 12.8bp have been 
noted (Capper et al, 2007). It has also been shown that it is the shortest telomere and not 
average TL that is the main stimulus for senescence (Abdallah et al, 2009). 
Uncapped telomeres stimulate senescence via initiation of a DNA damage 
response 
The molecular response of the cell to critical telomere attrition and uncapping is a complex 
interplay between DDR effectors many of which play a dual role in the maintenance of TL. 
In basic terms, when DDR signalling cascades are initiated in response to telomere attrition 
cell cycle checkpoints are elicited resulting in either; i) removal of the cell at the G1/S 
transition by either induction of senescence or apoptosis, or ii) sensing and repair of the 
damage. Some of the key pathways involved in this process are described below. 
Loss of telomeric sequences including bound shelterin complexes results in the activation 
of the ATM pathway. The exposed DNA is sensed as a DSB by the MRN complex (Table 
1.2) and activates ATM, which has been de-repressed by the loss of TRF2 from the 
telomere complex. A series of reactions then ensues which culminates in the activation of 
p21 via p53 phosphorylation (Figure 1.7). p21 inhibits cell cycle progression by 
inactivating pRB and is prerequisite for the induction and maintenance of senescence 
(d'Adda di Fagagna et al, 2003, Herbig et al, 2004). As opposed to senescence and 
depending on the cell type, apoptosis may be triggered in a p53 dependent manner 
(Karlseder et al, 1999). Alternatively, if telomeric damage results in exposure of single 
stranded DNA then the ATR response pathway is invoked by the de-repression of ATR by 
Pot1 (Denchi & de Lange 2007) (Figure 1.7). The DDR is actively maintained in senescent 
cells to prevent future re-entry into the cell cycle, thus telomere initiated senescence 
reflects a direct DNA damage response checkpoint reliant on dysfunctional telomeres 
(d'Adda di Fagagna et al, 2003). 
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Figure 1.7: Schematic representation of the response elicited by telomere uncapping, modified from 
Deng et al 2008. 
 
Similar to p21, p16INK4A (CDKN2A) is a cyclin dependent kinase inhibitor which prevents 
pRB phosphorylation, maintaining it in an activated state and preventing cell proliferation 
by inhibition of E2F (a growth factor which increases the transcription of a plethora of 
genes required for progress through the cell cycle).  Both telomeric and non-telomeric 
DNA damage can engage the p16INK4A pathway but do so with slower kinetics to that of 
the p53/p21 pathway, and in this setting is seen as secondary to the p53/p21 pathway 
(Jacobs & de Lange 2005). Cells that senesce solely due to p53/p21 activation can resume 
growth after inactivation of p53 whereas those fully engaging the p16INK4A /pRB pathway 
cannot, even after inactivation of p53, p16INK4A and pRB (Beausejour et al, 2003). Clearly 
this finding is relevant in the presence of inactivating mutations of p53 when senescence 
checkpoints can be bypassed leading to uncontrolled proliferation. 
Uncapped telomeres result in chromosomal instability 
Short dysfunctional telomeres not only initiate a DDR and senescence, but also allow 
deleterious repair reactions to occur, namely NHEJ and HR. NHEJ in particular results in 
‘end to end’ chromosome fusions, which are dicentric and therefore cannot be segregated 
in mitosis. The consequence of this is bridge breakage fusion events, translocations, 
karyotypic instability and aneuploidy (Riboni et al, 1997) (Figure 1.8).  
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Figure 1.8: Slide to the left indicates normal chromosomal arrangement. Slide to the right shows 
karyotype after NHEJ induced by dysfunctional telomeres (indicated by circle). 
 
 1.3.4.2 DNA Replication 
Facilitation of DNA replication is an integral function of the telomere, which is performed 
by permanent and dynamic telomere associated proteins. As mentioned previously 
complete telomere (and hence complete chromosome) replication is only possible through 
the unique action of telomerase. However, even in the absence of telomerase (when 
telomeric sequences will be lost due to the end replication problem) a functional 
relationship is required between DNA replication machinery and the telomere associated 
proteins. For example, telomere replication requires the RecQ helicase WRN in a TRF2 
dependent relationship (Crabbe et al, 2004). Verdun et al (2005) showed that telomeres 
recruit elements of the MRN complex and ATM in the G2 phase of the cell cycle. This led 
the authors to conclude that a localised DDR at telomeres is essential for recruiting the 
processing machinery that promotes formation of the chromosome end complex (Verdun et 
al, 2005). This relationship highlights the intricate nature of the interplay between proteins 
which have a seemingly paradoxical relationship by promoting efficient telomeric 
replication, but also sensing and signalling telomere damage and initiating cell cycle 
checkpoints.  
1.3.4.3 Telomeres are required for Efficient Meiosis 
Attachment of telomeres to the nuclear envelope in meiosis is required to promote accurate 
chromosome pairing, by reducing the freedom of movement of sequences near telomeres 
and limiting chromosomal attachment sites (Gilson et al, 1993). This gives rise to the 
‘bouquet’ arrangement of chromosomes in meiotic prophase and is dependent on 
interaction between the telomere and the nuclear membrane protein SUN1 (Ding et al, 
2007). The consequences of inadequate chromosomal pairing and bouquet formation is 
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apparent in SUN1 knockout mice where massive apoptotic events are induced leading to 
the abolition of gametogenesis (Ding et al, 2007).  
 
 
1.3.5 Epidemiological Aspects of Telomere Research 
 
Maintenance of TL is clearly a complex process and determining the exact relationship 
between telomere dynamics with both ageing and cancer proving similarly difficult. Some 
of the reasons for this are methodological and explained by variation in the means used to 
determine TL in index studies. These methodological differences may preclude TL use as a 
true biomarker of ageing, as was first proposed by the discovery of TL attrition with 
increasing chronological age.  
 
1.3.5.1 Methods of Telomere Length Measurement 
The main methods used to determine TL are southern blot analysis, quantitative 
fluorescence in-situ hybridisation (q-FISH) and quantitative-PCR (q-PCR). Each of these 
techniques harbours a number of advantages and disadvantages, which could potentially 
determine the significance of results gained through their use. The techniques and related 
comments are outlined in the table below (Table 1.4).  
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Table 1.4: Table displaying summary of the main mechanistic details of the commonly used 
techniques to determine telomere length including the advantages and disadvantages of 
each (Aubert et al, 2011).  
 
Technique Method Advantages Disadvantages 
Southern Blotting • Restriction enzyme cut 
DNA, separated by 
electrophoresis and 
transferred to membrane. 
• Hybridisation with specific 
telomere probe. 
• ‘Smear’ signal converted to 
Kb TL by various 
algorithms. 
• Thought to be most 
accurate method and 
‘gold standard’. 
• Reproducible 
• Time consuming 
• Large quantity of 
DNA required. 
• Relative 
insensitivity for very 
short telomeres. 
Q-FISH • Uses image cytometry and 
metaphase spreads. 
• Uses high affinity peptide 
nucleic acid probes which 
hybridise to denatured 
telomere DNA repeats. 
• Fluorescent signal detected 
and measured relative to 
known telomere length. 
• Allows 
simultaneous 
karyotyping. 
• Microscopically 
identified cells can 
be selected for 
analysis. 
• Single telomere 
analysis possible. 
 
• Difficult to achieve 
semi- quantification 
of TL due to 
hybridisation 
factors.  
• Unable to measure 
TL in terminally 
senescent or highly 
aberrant cells. 
Q-PCR • Based on the method fist 
reported by Cawthon 
(2002). 
• Uses primers which anneal 
to C- and G-rich strands of 
the telomere but have 
mismatches across their 
length leading to less 
primer dimer formation.  
• Amplification measured 
quantitatively and 
compared with that of a 
single copy gene (S).  
• Generates a ratio between 
telomere (T) and single 
copy amplification termed 
T/S ratio.  
• Recently modified as 
monochrome multiplex 
technique (Cawthon 2009). 
• High throughput 
possible as less 
labour intensive.  
• Large numbers of 
samples analysed in 
short space of time.  
• If performed with 
required precision 
and controls 
accurate 
comparisons with 
southern blots 
achievable. 
• Concerns over 
reproducibility. 
• Small errors can 
result in significant 
alterations in T/S 
(improved with 
introduction of 
monochrome 
technique).  
 
 
The convenience of the q-PCR methodology to determine TL has lead to its widespread 
use as the method of choice in the majority of experimental, clinical and epidemiological 
studies. However, as outlined in Table 1.4 this methodology is fraught with technical 
considerations, which may confound results and lead to misleading conclusions. The main 
problem associated with the technique is the variability in data leading to equivocal results 
and poor correlation between data derived from southern blotting, the so-called ‘gold 
standard’ method (Aviv 2004, Aviv 2008, Aviv 2009). These differences have stimulated 
leaders in the field to call for uniformity of methodology in an attempt to reduce variability 
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and prevent confounding factors skewing results. Potential ways in which variability could 
be reduced includes; double blind analysis of samples, standardisation of DNA 
preparation, inclusion of suitable controls and introduction of a worldwide laboratory 
standard operating procedure (Shiels 2010, Martin-Ruiz et al, 2011). Despite potential 
issues with the technique q-PCR is a useful tool for researchers in the field of telomere 
biology and its relation to ageing and disease. However, it is imperative that conclusions 
drawn from studies using the technique are done so in the context of the potential 
limitations.  
 
1.3.5.2 Telomere length as a Biomarker of Ageing 
 
The initial observations of a decline in TL with chronological age lead to the introduction 
of the concept of TL as a biomarker of aging. However, as it became clear that telomere 
dynamics were subject to manipulation by numerous intrinsic and extrinsic forces the 
emphasis was shifted more towards using TL as a marker of cellular bio-ageing.  
 
Baker and Sprott (1988) outlined the criteria considered prerequisite for any marker to be 
classified as a biomarker of ageing. They defined such a marker as:  
 
“a biological parameter of an organism that either alone or in some multivariate composite 
will, in the absence of disease better predict functional capability at some late age, than 
will chronological age” (Baker & Sprott 1988). 
 
 
Although the change in TL with chronological age is incontrovertible the use of TL as a 
marker of ageing has recently been questioned. Mather et al (2011) have recently reviewed 
the literature pertinent to the utilisation of TL as a biomarker of ageing and suggest that 
whilst there is clear evidence that telomeres are involved in ageing and diseases of 
premature ageing, the data supporting TL as a biomarker of ageing is inconclusive (Mather 
et al, 2011). There are a number of potential reasons highlighted, the high degree of inter-
individual variability at similar chronological ages, the lack of definitive association 
between TL and functional capacity, and the methodological reasons outlined above. To be 
a useful biomarker TL should predict lifespan better than chronological age. Studies 
investigating this specific issue are inconclusive. Cawthon et al (2003) first reported an 
overall increase in mortality with reduction in TL. This excess mortality was attributed to 
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higher mortality from cardiovascular and infectious disease (Cawthon et al, 2003). A 
recent report has also confirmed a weak association between short TL and mortality in an 
elderly population (Fitzpatrick et al, 2011). However, several studies have failed to 
conclusively demonstrate that short TL predicts mortality (Bischoff et al, 2005, Harris et 
al, 2006).  
 
 
1.3.6 Telomere Dysfunction & Cancer 
As outlined above, telomeres not only act as a cellular marker of replicative potential but 
they also function to maintain genomic integrity and facilitate accurate chromosomal 
replication. Integral to the ability to maintain genomic integrity is the capacity to induce 
cell cycle checkpoints, allowing repair of sensed damage, or if the damage is deemed 
irreparable removal of the cell from the proliferating population by apoptosis or 
senescence. It is therefore no surprise that acceleration of telomere attrition, or aberration 
of any of the elements maintaining optimal telomere dynamics leads to the development of 
chromosomal abnormalities which are not just typical of transformed cells, but essential 
for the initiation of neoplasia. The body of evidence implicating altered telomere biology 
in the cancer process is increasing rapidly. Some of the postulated mechanisms and in vivo 
studies providing the rationale for this indelible relationship will be discussed below. 
 
1.3.6.1 Mechanisms of Tumourigenesis 
 
Dysfunctional Telomeres & p53 
In an attempt to characterise the relationship between telomere attrition, p53 and malignant 
transformation a number of mouse models have been developed. These have used the 
aforementioned TERC-/- mouse crossed with mouse models designed to reflect aberrancy 
of different components of the telomere complex and DDR mechanism. In the context of 
the relationship between human cancer and ageing perhaps the most important observation 
results from the TERC-/-,Trp53-/- (p53 null) mouse. In these animals progressive telomere 
attrition corresponded with increased tumour incidence and decreased survival. Moreover, 
late generation mice succumbed to a range of tumours strikingly similar to those seen in 
elderly humans, namely breast, skin and intestinal. Cytogenetic analysis also revealed 
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chromosomal aberrations typical of these tumour types (Artandi et al, 2000, O'Hagan et al, 
2002). This model emphasises the importance of mutated p53 in the initiation of 
tumourigenesis in the setting of critically short telomeres (Chin et al, 1999).  
Models of specific tumour types have also yielded valuable information. The APCmin 
mouse model has been designed to develop benign micro and macroadenomas throughout 
the gastrointestinal tract. When crossed with the TERC-/- mouse, early generation offspring 
develop microadenomas, which progress onto more aggressive and detrimental 
macroadenomas. However, in later generation animals which have short and dysfunctional 
telomeres only microadenomas develop (Rudolph et al, 2001). This finding of protection 
against cancer in later generation in animals with short telomeres is observed in a 
CDKN2A-/- mouse deficient in p16INK4A and ARF who develop increased incidence of 
lymphoma and sarcoma (Greenberg et al, 1999). These findings suggest that in the 
presence of competent tumour suppressive pathways in particular p53, short telomeres 
elicit a protective function against neoplasia, presumably through initiation of senescence.  
Telomere dysfunction drives chromosomal instability 
Human tumours particularly of an epithelial origin display large numbers of focal 
amplifications and deletions. These copy number alterations are thought to drive the 
process of carcinogenesis by causing activation of proto-oncogenes or inactivation of 
tumour suppressor genes (Pinkel & Albertson 2005). Spectral karyotype analysis of cancer 
cells from tumours in mouse models driven by telomere dysfunction reveal similar copy 
number alterations. These show chromosome end fusions and numerous non-reciprocal 
translocations leading to aberrant copy number. Furthermore, these have been shown to be 
a major driver of amplication/deletion events at genes relevant to the initiation and 
maintenance of neoplasia (O'Hagan et al, 2002). These hallmarks are evident not only in 
the TERC-/- mouse model of telomere attrition, but also in the TPP1acd/acd mouse which 
models telomere uncapping by disrupting the shelterin complex. These mice display 
increased epithelial cancers particularly of the skin, in a p53 deficient setting with hallmark 
copy number aberrations (Else et al, 2009).  
 
 
1.4.6.2 Senescence & Cancer 
The irreversible growth arrest initiated by senescence makes it an ideal candidate for a role 
in the prevention of neoplastic transformation and tumour suppression. Indeed senescent 
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cells have been shown in abundance in a variety of pre-malignant lesions. For example, 
pre-malignant lesions from the lungs of an oncogenic k-Ras mouse model contained 
abundant senescent cells, when compared with invasive lung adenocarcinomas (Collado et 
al, 2005). These findings have been corroborated in a mouse model of prostate cancer 
lacking the tumour suppressor PTEN and importantly, from benign lesions of human skin 
carrying oncogenic mutant BRAF (Michaloglou et al, 2005, Chen et al, 2005b). These 
findings implicate senescence as a barrier of transformation from benign non-invasive 
lesions to malignancy.  
 
Both oncogene induced and replicative senescence have been shown to exert a tumour 
suppressive role. Analysis of benign naevi showed high levels of senescence but no 
discernible reduction in TL, indicating that oncogene-induced senescence rather than 
replicative senescence may confer the limitation of proliferation in these lesions 
(Michaloglou et al, 2005). Meanwhile, complex inter-generational crossing of the 
telomerase knockout mouse with the Eμ-Myc transgenic model of Burkitts lymphoma 
revealed hallmarks of chromosomal instability due to telomere dysfunction in tumour cells 
of late generation animals. Furthermore, over-expression of the anti-apoptotic gene Bcl2 in 
cells from late generation crossed animals with subsequent re-implantation resulted in 
lymph node tumours which were small and proved positive for markers of senescence such 
as p16INK4A. These results suggest that dysfunctional telomeres can induce senescence in 
the absence of apoptosis to exert a tumour suppressive effect (Feldser & Greider 2007). 
Similarly, telomerase null mice in which the pro-apoptotic effect of p53 was ameliorated 
but p53-dependant senescence pathways maintained, displayed near universal reduction in 
tumour formation (Cosme-Blanco et al, 2007).   
 
Whilst the studies mentioned above provide evidence of senescence acting as a barrier to 
malignant transformation, some of the characteristics of senescent cells confer tumour 
promoting properties. The development of the secretory associated senescence phenotype 
(SASP) can alter the behaviour of neighbouring cells via the secretion of mostly pro-
inflammatory cytokines and growth factors known to stimulate various characteristics of 
neoplasia (Rodier & Campisi 2011). Human cells subjected to DNA damage adopt the 
senescence phenotype and secrete IL-6 in a manner dependent on the DDR proteins ATM, 
NBS1 and Chk2. Furthermore, IL-6 promoted human cancer cell invasiveness in a 
dependent relationship with ATM (Rodier et al, 2009) and stimulated both pre-malignant 
and weakly malignant cells to penetrate the basement membrane (Coppe et al, 2008). In 
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addition, vascular endothelial growth factor (VEGF) released by senescent cells can 
stimulate endothelial cell migration and invasion, both key steps in the process of 
neoangiogenesis (Coppe et al, 2006). Senescent cells also harbour the ability to secrete 
matrix metalloproteinases (MMPs) particularly MMP-1, -3 and -10. These proteases 
contribute to the tissue remodelling required for tumour cell invasion (Davalos et al, 2010). 
It is therefore plausible that senescent cells could play a role in the progression and 
development of neoplasia via paracrine signalling to neighbouring cells (Campisi & 
d'Adda di Fagagna 2007). In support of this paradigm Krtolica et al (2001) reported that 
co-injection of senescent cells into xenograft models of malignancy stimulated pre-
malignant lesions to become malignant and accelerated the rate of tumour formation when 
co-injected with malignant cells (Krtolica et al, 2001). The seemingly dichotomous 
relationship between senescence and cancer can be explained in evolutionary terms as a 
further example of antagonistic pleiotropy. Whereby tumour suppression by senescence is 
a protective mechanism in younger individuals but, as an individual ages and deleterious 
mutations accumulate its effect becomes pro-tumourigenic (Coppe et al, 2010).   
 
 
1.3.6.3 Telomere Length and Human Cancer Risk 
 
Numerous studies have now been published with the aim of delineating the relationship 
between human TL and cancer risk. The methodologies used to measure TL, the source of 
telomeric DNA and the cancer populations studied have been diverse. On the whole the 
results have indicated that short TL is associated with increased cancer risk. However, 
some studies have produced conflicting results with both short and long TL associated with 
increased cancer risk in some histological subtypes. These differences are difficult to 
rationalise however inherent differences in the methodologies used and the natural history 
of the cancer type under investigation could explain some of the heterogeneity.   
 
Leucocyte Telomere Length & Cancer Risk 
 
The rationale behind using peripheral blood leucocytes (PBLs) as a source of telomeric 
DNA is one borne of convenience. Evidently it is easier to obtain a patient blood sample 
than a sample of tumour cells, particularly of solid tumours. The use of PBLs may also 
give a more general indication of telomere dynamics as opposed to the tumour level where 
the reactivation of telomerase will stabilise TL to enable enhanced proliferation. TL in 
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different cell compartments have been shown to be comparable, indicating PBL TL could 
serve as a surrogate parameter of the tissue under investigation (Friedrich et al, 2000).  
 
Over the last ten years the number of studies documenting an association between PBL TL 
and cancer risk has steadily increased. The first study to investigate any potential link was 
published by Wu et al (2003) using a retrospective case-control study design and southern 
blot analysis to determine TL. The authors reported a significant association between short 
TL and bladder, lung, head and neck and renal cell cancer (Wu et al, 2003). Since these 
initial findings numerous cancer types have been investigated producing similar results. 
Short TL has been associated with an increased risk of breast (Shen et al, 2009), bladder 
(McGrath et al, 2007), ovarian (Mirabello et al, 2010), gastric (Hou et al, 2009), colorectal 
(Pooley et al, 2010) and oesophageal cancer (Xing et al, 2009). Conversely some studies 
have reported an equivocal risk of colorectal (Zee et al, 2009, Lee et al, 2010), prostate 
(Mirabello et al, 2009) and breast (Kim et al, 2011) cancer with short TL. Whilst, some 
studies have even reported an association between long telomeres and an  increased risk of 
colorectal (Jones et al, 2011), breast cancer (Svenson et al, 2008) and clear cell renal 
cancer (Svenson et al, 2009). These conflicting results clearly indicate a degree of 
heterogeneity between studies. Such sources could relate to the method used to determine 
TL or the study population under investigation. The natural history of the cancer type 
under investigation could also potentially confound results, as could the retrospective 
design of most of the studies. Willeit et al (2010) therefore employed a prospective 
longitudinal study design to investigate cancer risk in 787 healthy participants followed-up 
over a period of 10 years. They reported that both cancer risk and mortality from cancer 
was increased in patients in the shortest telomere group when compared with the longest 
(Willeit et al, 2010).   
 
Overall cancer risk has been shown to be affected by genetic variation in expression of 
telomere-associated proteins. Four SNPs in the TERT and Pot1 genes were associated with 
increased breast cancer risk (Shen et al, 2010). Similarly variation in the TERT and TRF1 
gene was associated with skin cancer risk (Nan et al, 2011), with TERT and TNKS 
variability associated with susceptibility to lung cancer (Choi et al, 2009). Whilst it is clear 
genetic variability influences cancer risk the direct relationship with TL can only be 
speculated on as concomitant measurement of TL was not performed in these studies. 
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Tissue telomere length & Cancer Risk 
 
Measurement of cancer tissue TL has the added advantage over PBL TL that direct 
correlation of TL from pathological specimens with outcome measurements could provide 
a novel addition to routine biomarkers of risk stratification. Several studies in a number of 
tumour subtypes have attempted to provide prognostic information (Bisoffi et al, 2006). 
Short TL has been shown to be associated with adverse pathological features, metastasis 
and poor prognosis in breast cancer (Griffith et al, 1999b, Fordyce et al, 2006). Similarly 
TL in prostate cancer sample specimens predicts time to recurrence independent of age, 
Gleason score and pelvic node involvement (Fordyce et al, 2005). However, this 
correlation between TL and adverse outcomes was not replicated in colorectal cancer 
where longer TL was associated with poor outcome and more advanced disease. Although, 
as in the previous studies mentioned in different tumour subtypes TL in cancer specimens 
was significantly shorter than adjacent normal tissue (Gertler et al, 2004, Garcia-Aranda et 
al, 2006). These differences may result from the behavioural characteristics of colorectal 
cancers relating to the natural history of the progression through the adenoma-carcinoma 
sequence of events leading to cancer development in this tissue (Kim et al, 2002, Plentz et 
al, 2003). 
  
Clearly a number of aspects of telomeric function are altered in the development and 
progression of oncogenesis. In order to provide a molecular context for this a number of 
pathways which intricately link ageing and cancer were considered. For example, the 
ability of a cell to optimally respond to stressful stimuli is dependent on its ability to sense 
the damage and respond accordingly, in the face of the metabolic and oxidative conditions 
at that time. It has been postulated that one way in which this critical cellular response can 
be rationalised is via the concept of the MTR trinity (Mitochondrion Telomere and 
Ribosome biogenesis). Through this triad critical DNA damage is sensed by the telomere 
nucleo-protein complex which also plays a role in effector mechanisms such as 
senescence. Energy production and apoptosis are facilitated by the mitochondria and 
energy utilisation, as well as the requisite protein synthetic pathways are controlled via 
rDNA (Shiels & Davies 2004). A potential linking factor of these individual elements of 
the MTR are a group of nutrient sensing proteins termed the sirtuins. These proteins 
control a number of critical cellular functions fundamental to both the ageing and cancer 
with aberrancy of their expression linked to both processes. A full description of this 
interesting group of proteins will now follow. 
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1.4 Sirtuins 
 
1.4.1 Silent Information Regulator 2 (Sir2) 
 
The term Silent information regulator 2 (Sir2) was coined to describe the product of a 
unique class of genes first discovered in the budding yeast Saccharomyces cerevisiae, 
which function to silence gene transcription at the silent mating type loci. This contributes 
to a number of different mechanisms which control gene expression at the level of 
transcription at specific chromosomal domains. Transcriptional silencing involves 
induction of a specialised chromatin structure that physically impedes transcription as well 
as a number of other processes, including epigenetic modification by methylation 
(Guarente 1999, Gartenberg 2000). Following intensive investigation it has become clear 
that Sir2 is part of a family of genes phylogenetically conserved from bacteria to man more 
broadly termed the sirtuins. However, it was not until Sir2 was implicated in the control of 
yeast longevity and latterly the ageing process in general that interest increased, giving rise 
to the prospect that manipulation of these genes or their products could affect human 
longevity or even reverse the ageing process (Kaeberlein et al, 2007, Kaeberlein 2008).  
 
1.4.2 MAMMALIAN SIRTUINS 
The field of ageing research was fundamentally changed with the discovery that Sir2 and 
its homologues not only controlled key cellular processes but also longevity in model 
organisms (Kaeberlein et al, 1999). Work was therefore initiated to determine whether the 
same effects were evident in higher organisms including humans. To date seven 
homologues of Sir2 termed sirtuin 1-7 have been discovered in mammals, these have 
varying sub-cellular localisations and functions compatible with critical regulators of 
cellular function. Some of the key aspects of the molecular biology and physiology of the 
sirtuins are discussed below.  
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1.4.2.1 Homology with Sir2   
Genetic Homology 
In mammals there are seven orthologues of the Sir2 gene termed sirtuin (SIRT) 1-7. SIRT1 
shares the closest homology with the yeast Sir2, whilst SIRT4 and SIRT5 resemble 
prokaryotic sirtuin sequences. SIRT6 and SIRT7 more closely resemble each other than the 
Sir2 gene (Frye 1999, Frye 2000). Analysis of over sixty conserved sirtuin sequences from 
a varying range of organisms has identified five groups into which the sirtuins can be 
classified, termed class I-IV and U. Yeast Sir2, SIRT1, SIRT2 and SIRT3 lie within class I. 
SIRT4 and SIRT5 are class II and class III sirtuins respectively with class IV containing 
mammalian SIRT6 and SIRT7. Neither class I nor class IV are found in prokaryotes. Class 
U contains sirtuins from some gram positive bacteria and Thermotoga maritima in which 
the sequence motifs are intermediate between class I to IV (Frye 2000).  
Structural & Enzymatic Homology 
The basic structure of the mammalian sirtuins resembles that described previously in yeast, 
consisting of a large domain of a classical open α/β, Rossman fold structure and a smaller 
domain.  The main enzymatic function of yeast Sir2 is as a histone deacetylase requiring 
NAD+ as a dependant cofactor, which is conserved by the mammalian sirtuins (Imai et al, 
2000). The NAD+ binding site was discovered to be situated within a pocket in which the 
large domain forms the floor and the small domain the ceiling. The conserved domain 
contains a motif of Cys-X-X-Cys-(X)15-20-Cys-X-X-Cys which is thought to bind a Zn+ 
ion (Min et al, 2001).  
The utilisation of NAD+ as a cofactor for the deacteylase activity of the mammalian 
sirtuins is maintained by SIRT1, SIRT2, SIRT3, SIRT5 and SIRT6 (Schwer et al, 2002, 
Michishita et al, 2005, Michishita et al, 2009, Nakagawa et al, 2009). In addition SIRT4 
and SIRT6 have been shown to possess robust ADP-ribosyl-transferase activity, a reaction 
which also requires NAD+ as a fundamental cofactor ( Liszt et al, 2005, Haigis et al, 2006, 
Michishita et al, 2009). The control of the deacetylase activity is dependent on the 
NAD+/NADH ratio within the cell. This requirement of NAD+ as a cofactor for the 
catalytic activity of Sir2 and the sirtuins in general raises the intriguing possibility of 
altering key cellular processes implicated in organismal ageing through varying availability 
of metabolic intermediates, potentially by dietary manipulation (Guarente 2000).  
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1.4.2.2 Sirtuin Sub-Cellular Localisation  
The most extensive study investigating the cellular localisation of the sirtuins was 
undertaken by Michishita and colleagues (2005). SIRT1, SIRT6 and SIRT7 were found 
mainly in the nucleus, however there was some sub-nuclear variation in that SIRT1 
appeared to be excluded from the nucleoli and SIRT6 was found overlapped with 
heterochromatic regions (Michishita et al, 2005). SIRT3 was already known to reside in 
mitochondria (Schwer et al, 2002).This was confirmed and expanded upon by data 
demonstrating that SIRT4 and SIRT5 co-localised with a mitochondrial marker confirming 
SIRT3, SIRT4 and SIRT5 as mitochondrial sirtuins (Michishita et al, 2005).   Consistent 
with its role as a tubulin deacteylase SIRT2 is predominantly found in the cytoplasm, 
however during mitosis resides in the nucleus (North et al, 2003).  
Some of the major features of the mammalian sirtuins including genetics, activity and 
localisation are summarised in Table 1.5.  
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Table 1.5: Table displaying some of the common characteristics of SIRT1-7. 
Sirtuin Class Chromososme Cellular 
Localisation 
Enzymatic 
Function 
Targets Cellular Function 
SIRT1 I 10q21.3 Nucleus, 
cytoplasm 
Deacetylase H1, H3, H4 
p53, NF-κB, 
ku70, FOXO, 
PGC-1α,  
Cell survival, glucose 
metabolism, 
inflammation, 
neurodegeneration 
SIRT2 I 19q13.2 Cytoplasm Deacetylase H4, α-tubulin Cell cycle control 
SIRT3 I 11p15.5 Mitochondria Deacetylase Acetyl CoA 
synthetase 2, 
long chain acyl 
CoA 
dehydrogenase 
Thermogenesis, 
metabolic response 
SIRT4 II 12q24.23 Mitochondria ADP-
ribosyl 
transferase 
Glutamate 
dehydrogenase 
Insulin 
secretion/metabolic 
control 
SIRT5 III 6p23 Mitochondria Deacetylase Carbamoyl 
phosphate 
synthetase-1 
Control of urea cycle 
SIRT6 IV 19p13.3 Nucleus Deacetylase
ADP-
ribosyl 
transferase 
Telomere 
histone H3, 
HIF-1α, DNA-
dependent 
protein kinase 
Maintenance of 
genomic integrity, 
DNA repair, insulin 
secretion 
SIRT7 IV 17q25 Nucleus Deacetylase RNA 
polymerase I 
rDNA transcription, 
cell proliferation 
 
This variability in the sub-cellular localisation and targets with which they interact is 
reflected in the diverse fundamental cellular processes under the control of the sirtuins.  
The sirtuins, in particular SIRT1 have been demonstrated to regulate not only histones but 
a multitude of other non-histone proteins which control a number of key processes such as 
cell survival, stress resistance, metabolism and protection of genomic integrity. Clearly, 
these processes need to be controlled with fine precision as they are intricately linked not 
only to normal and premature ageing but also to some of the deleterious pathological 
outcomes associated with ageing, in particular neoplasia. The key features and functions of 
each of the sirtuins will now be discussed.  
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1.4.3 SIRTUIN 1 
Cloning studies have determined that the human Sirt1 gene spans 33,660 bp over one 
genomic locus. FISH analysis defined the position of the Sirt1 gene to chromosome 
10q21.3. Whilst, phylogenetic analysis revealed the human Sirt1 gene shared 56% pair 
wise homology with yeast Sir2, the highest of any the human sirtuins (Voelter-Mahlknecht 
& Mahlknecht 2006). Consistent with its place in the group of histone deacetylases SIRT1 
exerts a controlling influence on chromatin and hence epigenetic phenomena. SIRT1 
displays strong deacetylase activity towards lysine 26 on histone H1 (H1K26), H4K16 and 
H3K9. RNA interference to knockdown SIRT1 expression reveals hypoacetylation at these 
and other key sites suggesting a key involvement of SIRT1 in heterochromatin regulation 
(Vaquero et al, 2004). SIRT1 can further modify chromatin via its ability to deacetylase 
and regulate key methyltransferases, namely SUV39H1. The acetylation of H4K16 is 
thought to be particularly important for optimal chromatin function and is evolutionarily 
conserved (Vaquero et al, 2004, Vaquero et al, 2007).  
1.4.3.1 SIRT1 Controls Key Homeostatic Processes 
Cell Survival & Response to Stress 
The main feature of SIRT1 which distinguishes it from the remainder of the sirtuins and its 
yeast homolog Sir2 is its ability to deacetylate a multitude of non-histone targets including 
p53, FOXO, NF-κB and Ku70 (Yang et al, 2005, Jeong et al, 2007, Ghosh et al, 2007, Yi 
& Luo 2010) (Figure 1.9). This confers SIRT1 with the capacity to regulate a number of 
key cellular processes and adaptive mechanisms, allowing the tailoring of stress response 
to the level of any external insult such as CR or genotoxic stress, and dictating cellular fate 
by modulating apoptotic pathways and intermediaries (Milner 2009). 
60 
 
 
Figure 1.9: Some of the processes and downstream targets through which SIRT1 acts to regulate cell 
survival and response to stress. Taken from (Haigis & Sinclair 2010).  
 
SIRT1 Interaction with p53- Apoptosis & Senescence 
Two separate studies identified p53 to be the first SIRT1 non-histone target.  These studies 
demonstrated that p53 was a SIRT1 target and that the p53 pro-apoptotic response to stress 
was repressed by SIRT1 induced deacetylation of p53. Whilst expression of dominant 
negative SIRT1 potentiated the p53 controlled cellular stress response (Luo et al, 2001, 
Vaziri et al, 2001).  
SIRT1 mediates an effect over the two known pathways of p53 induced apoptosis. 
Transcription independent apoptosis is modulated via SIRT1 control over p53 sub-cellular 
localisation. This was demonstrated by Han et al (2008) in mouse embryonic stem cells 
(mES) cells where SIRT1 blocked nuclear translocation of cytoplasmic p53 in response to 
endogenous ROS (Han et al, 2008a). Transcription dependant apoptosis is a finely 
balanced process involving p53 mediated upregulation of pro-apoptotic genes such as Bax, 
PUMA and NOXA (Yu & Zhang 2008). SIRT1 has the ability to influence this pro-
apoptotic pathway by deacetylating members of this intricately controlled process. For 
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example, deacetylation of Ku70 alters the Ku70/Bax interaction resulting in an altered 
apoptotic response (Cohen et al, 2004a). 
The effect of SIRT1 on p53 mediated senescence is complex with the results of studies 
seemingly at odds. SIRT1 represses p53 activation by deacetylation thereby antagonising 
premature senescence in MEFs (Langley et al, 2002). However, in contrast with these 
findings SIRT1 deficient MEFs displayed an enhanced resistance to replicative senescence 
under conditions of chronic sublethal genotoxic stress induced by H2O2, an effect which is 
mediated by p19ARF and its ability to positively regulate p53 (Chua et al, 2005). Thus 
SIRT1 has two distinct mechanisms of influencing p53 function, by direct deacetylation 
and through regulation of p19ARF. These have opposite affects on net p53, thus highlighting 
the complexity of the role SIRT1 plays in the control of senescence. It is likely that the 
overall effect is dependent on the trigger of cellular stress and the apoptotic signalling 
mechanism induced. 
SIRT1 and other Non—Histone Targets 
FOXO transcription factors have been shown to up-regulate the transcription of genes 
controlling apoptosis, cell cycle arrest and differentiation. Integrated responses to stressful 
stimuli are achieved by a number of mechanisms including modification of acetylation 
status by SIRT1. SIRT1 has been shown to deacetylate FOXO1, FOXO3 and FOXO4 but 
the overall effect of deacetylation is complex (Brunet et al, 2004, Daitoku et al, 2004, 
Motta et al, 2004, van der Horst et al, 2004). Deacetylation can result in activation of 
FOXO1 and FOXO4 with subsequent upregulation of target genes involves in stress 
resistance, or inhibition of FOXO3 dependant apoptosis and promotion of DNA repair 
(Brunet et al, 2004, Daitoku et al, 2004, Kobayashi et al, 2005, Yang et al, 2005). The 
overall effect appears to be one of shifting FOXO-dependant responses towards cell 
survival by stress resistance and inhibition of apoptosis, leading to cell cycle arrest.  
NF-κB controls key processes involved in cell cycle control, cell fate and is paramount for 
both adaptive and innate immune responses.  Once activated it translocates to the nucleus 
where it enhances transcription by tethering histone acetyl transferases (HATs). SIRT1 
physically interacts with the RelA/p65 subunit of NF-κB resulting in its deacetylation and 
inactivation, thus SIRT1 activity augments TNF-α induced apoptosis (Yeung et al, 2004). 
Thus the effect of the interaction between SIRT1 and NF-κB is to positively regulate 
apoptosis whereas interaction of SIRT1 with p53, Ku-70 and FOXO results in the 
62 
 
attenuation of apoptosis, promoting cell survival. It is therefore clear that the overall effect 
of SIRT1 on cell survival is varied and complex. Some of the reported variations can be 
explained by the response induced by the different types of experimental stimuli utilised. 
For example induction of the DNA damage response by γ-irradiation stimulates ATM 
dependant accumulation of p53 and ultimately upregulation of pro-apoptotic gene products 
whilst TNF-α induces p53-independant apoptosis which is repressed by NF-κB (Yi & Luo 
2010). Further variation in response depending on the cell type used is almost certainly 
inevitable. It stands to reason that aberrancy of expression of SIRT1 or any of the 
mediators involved in the signalling pathways controlling cell survival leading to altered 
longevity and cell turnover with the obvious implications for ageing and cancer. 
Metabolic Regulation 
SIRT1 plays a role in glucose homeostasis by two main mechanisms, regulation of insulin 
secretion and stimulation of hepatic gluconeogensis. Moynihan et al (2005) using β-cell-
specific SIRT1-overexpressing mice and Bordone et al (2006) using SIRT1-/- mice 
independently demonstrated that SIRT1 positively regulates glucose stimulated insulin 
secretion in pancreatic β-cells (Moynihan et al, 2005, Bordone et al, 2006). Modulation of 
hepatic gluconeogenesis occurs via SIRT1 mediated activation of PGC-1α. Activation of 
PGC-1α in the liver stimulates gluconeogenesis and inhibits glycolytic pathways via a 
nutrient signalling response mediated by pyruvate (Rodgers et al, 2005).  
In addition to its role in glucose homeostasis SIRT1 can regulate adipogenesis and 
lipolysis via its interaction with PPARγ. Repression of PPARγ by SIRT1 results in 
attenuation of adipogenesis and upregulation of lipolysis in response to food withdrawal 
(Picard et al, 2004).  
Vascular Biology 
There is increasing evidence that SIRT1 plays a key role in vascular function and 
lipoprotein metabolism, translating to a protective effect against cardiovascular disease. 
SIRT1 activates transcription of liver X receptors (LXR) target gene encoding the ATP-
binding cassette transporter A1. This has the effect of increasing high density lipoprotein 
synthesis with the concomitant benefits on atherosclerotic plaque formation via altered 
cholesterol transport (Li et al, 2007). In addition, SIRT1 has been shown to regulate 
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vascular tone by deacetylating and stimulating endothelial nitric oxide synthase (eNOS) 
thereby increasing nitric oxide (NO) levels (Mattagajasingh et al, 2007).  
Neuronal Function 
SIRT1 has been shown in a number of model systems to play a key role in neuronal 
survival, in particular axonal degeneration. The wallerian degeneration slow (Wlds) mouse 
line exhibits delayed axonal degeneration in response to injury, an effect which is mediated 
by the increased expression of an enzyme (Nmnat1) required for the de novo synthesis and 
salvage of NAD+ with SIRT1 as a downstream effector (Araki et al, 2004). In a more 
clinical context SIRT1 has been shown to modulate disease activity in Alzheimer’s disease 
(AD) by ameliorating the damage induced by Aβ peptides through an effect on NF-κB 
signalling (Albani et al, 2010).  
Differentiation 
Terminal cellular differentiation of a number of different histological subtypes provides 
another mechanism by which SIRT1 can alter tissue dynamics in response to changes in 
the metabolic micro-environment. SIRT1 can modulate neuronal differentiation by 
becoming transiently translocated to the nucleus of neural precursor cells (stem-like cells) 
and repressing the Notch1/Hes1 signalling pathway. However, the functional role of 
SIRT1 on neuronal development remains to be fully elucidated (Hisahara et al, 2008). 
Skeletal muscle differentiation and gene expression is also subject to regulation by SIRT1 
due to dynamic fluctuations in [NAD+]:[NADH] and overexpression of SIRT1 results in 
immature myotubes with reduced expression of myosin heavy chain and myogenin. Thus 
gene expression and muscle differentiation is regulated by metabolic demands of muscle 
that occur in response to food intake, fasting and exercise (Fulco et al, 2003). 
 
1.5.4 SIRTUIN 2 
FISH analysis of the human SIRT2 gene localises it to chromosome 19q13.1 (Voelter-
Mahlknecht et al, 2005). SIRT2 is predominantly located in the cytoplasm and expression 
profiling reveals high levels in foetal brain, adult brain and kidney (Michishita et al, 2005). 
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The bulk of evidence investigating the cellular function of SIRT2 points to its role as a 
mediator of the cell cycle via its ability to deacetylate tubulin (North et al, 2003). 
1.4.4.1 Functions of SIRT2   
Cell Cycle Control 
Functional studies of human SIRT2 have revealed that its expression is abundantly 
increased during mitosis and in particular at the G2/M transition of the cell cycle when it is 
also phosphorylated. Cells overexpressing SIRT2 display a marked prolongation of the 
mitotic phase of the cell cycle (Dryden et al, 2003). Further analysis by North and 
colleagues (2003) revealed the predominant intra-cellular target of SIRT2 to be α-tubulin 
(North et al, 2003). SIRT2 has also been shown to deacetylate lysine 16 on H4 again 
specifically during the G2/M transition when SIRT2 can be localised on Chromatin 
(Vaquero et al, 2006). The ability of SIRT2 to control mitotic exit from the cell cycle is 
dependent on its phosphorylation levels. Dephosphorylation of SIRT2 by the phosphatase 
CDC14B also has the effect of destabilising the SIRT2 protein promoting mitotic exit 
(Dryden et al, 2003). Phosphorylation of SIRT2 has since been demonstrated to be 
achieved by the cell cycle regulator cyclin-dependent kinase 1 at serine 368 (North & 
Verdin 2007b).  Failure of SIRT2 to control cell cycle exit and act as a checkpoint could 
allow abnormal chromosomal condensation and therefore chromosomal aberrancy. SIRT2 
has therefore been identified as a potential contributor to the chromosomal abnormalities 
evident in some tumour types.  
 Tubulin-Independent targets 
Pertinent to its potential role in cell turnover and accurate chromosomal replication SIRT2 
has recently been demonstrated to interact with the ubiquitous transcription factor NF-κB. 
SIRT2 can deacetylate the p65 subunit both in vitro and in vivo at Lys 310. Furthermore 
p65 is hyperacetylated in SIRT2(-/-) cells stimulated by TNF-α, leading to the increased 
expression of NF-κB dependant genes (Rothgiesser et al, 2010).  
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1.4.5 SIRTUIN 3, 4 & 5 
Collectively SIRT3, 4 & 5 are termed the mitochondrial sirtuins. Localisation of these 
sirtuins to the mitochondria stimulated great intrigue in the ageing research community 
given the importance of these organelles in regulating nutrient utilisation, energy 
production and in apoptosis. Furthermore, as a by-product of the reactions involved in 
energy production, mitochondria are the primary site of reactive oxygen species generation 
in the cell (Huang et al, 2010). 
1.4.5.1 Sirtuin 3 
The human SIRT3 gene is located on the short arm of chromosome 11 at position 15.5. It 
possesses robust NAD+ deacetylase activity and is localised to the mitochondrial matrix 
(Onyango et al, 2002, Schwer et al, 2002, Michishita et al, 2005). Some controversy exists 
as to whether SIRT3 is truly mitochondrial. Upon translation it translocates from the 
cytoplasm into mitochondria where it is cleaved and activated by matrix processing 
peptidase (Scher et al, 2007). Other studies, however, have confirmed SIRT3 as a purely 
mitochondrial deacetylase (Hallows et al, 2006). 
SIRT3 and Metabolic Regulation  
Although SIRT3 targets a wide range of mitochondrial proteins for deacetylation the most 
widely characterised substrate is acetyl-CoA synthetase 2 (AceCS2). AceCS2 converts 
acetate to acetyl-CoA in the presence of ATP and its transcription is upregulated during 
ketogenic states such as starvation or diabetes. SIRT3 deacetylates and hence activates 
AceCS2 at lysine 642 providing a potential mechanism whereby SIRT3 could play a 
regulatory role in energy production and utilisation under certain conditions (Hallows et al, 
2006, Schwer et al, 2006). Generation of a transgenic SIRT3 knockout mouse confirmed 
that a variety of mitochondrial proteins exhibit marked hyperacetylation. However, despite 
this profound alteration in enzymatic structure no demonstrable effect on physiological 
phenotype was noted under normal and short-term fasting conditions (Lombard et al, 
2007). SIRT3 has also been implicated in the evolution of the ketogenic response to fasting 
by its ability to deacetylate mitochondrial 3-hydroxy 3-methylglutaryl CoA synthase 2 
(HMGCS2) the rate limiting step in β-hydroxybutyrate synthesis (Shimazu et al, 2010). 
Hirschey et al (2010) report SIRT3 levels in liver and brown adipose tissue are increased 
in response to fasting. Furthermore, SIRT3 null mice exhibit hallmarks of fatty acid 
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oxidation disorders during fasting including reduced ATP levels and intolerance to cold 
exposure (Hirschey et al, 2010). It therefore, appears that SIRT3 may be involved in 
response to states of energy limitation when it can control the rate of ketosis and 
incorporate acetate into central metabolism where it can be used as an energy source.   
1.4.5.2 Sirtuin 4 
SIRT4 is found in mitochondria and unlike the sirtuin proteins already discussed it 
possesses ADP-ribosyltransferase activity, as demonstrated by the fact that mice lacking 
SIRT4 show no significant change in mitochondrial protein acetylation levels (Michishita 
et al, 2005, Lombard et al, 2007). SIRT4 has been implicated in amino acid-stimulated 
insulin secretion from pancreatic β-cells due to its ability to ADP-ribosylate and inhibit 
glutamate dehydrogenase (GDH). This enzyme controls the conversion of glutamate into 
α-ketoglutarate, a component of the citric acid cycle. By doing so it increases the 
ATP:ADP ratio a key stimulant of insulin secretion. Knockdown of SIRT4 results in 
upregulated amino-acid stimulated insulin secretion by increasing GDH activity (Haigis et 
al, 2006, Ahuja et al, 2007). SIRT4 may also play a role in the response to CR. Levels of 
SIRT4 are noted to decrease during CR corresponding with an increased GDH activity and 
hence insulin secretion from β-cells isolated from CR mice. Thus SIRT4 may play a role in 
changing the main stimulus to insulin secretion from carbohydrate to amino acids during 
CR (Haigis et al, 2006). A further recently identified function of SIRT4 is the capacity to 
oxidise fatty acids in liver and muscle cells. SIRT4 was knocked down both in vivo and in 
vitro resulting in an increase in hepatic mitochondrial and fatty acid oxidation gene 
expression (Nasrin et al, 2010). These findings again correlate with the potential that 
inhibition of SIRT4 during CR or periods of fasting controls entry into alternative means of 
energy production.  
1.4.5.3 Sirtuin 5  
Initial studies mapped the human SIRT5 gene to chromosome 6p.23 and found that it was 
particularly well expressed in cardiac myocytes and lymphoblasts, however further studies 
have demonstrated high expression levels in brain, liver, kidney, skeletal muscle and testis 
(Mahlknecht et al, 2006a). The first target of SIRT5 described was cytochrome C, a 
protein found in the mitochondrial inter-membrane space with a role in oxidative 
metabolism and apoptosis (Schlicker et al, 2008). The first in vivo target identified was 
recently uncovered as carbamoyl phosphate synthetase I (CPS I). This enzyme plays a key 
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role in the in the urea cycle which is responsible for the detoxification and excretion of the 
ammonia produced during the breakdown of amino acids. SIRT5 deacetylates and 
increases activity of CPS I, a response which is seen during conditions of fasting when the 
levels of NAD+ increase in isolated mouse hepatocytes. Thus an adaptive mechanism by 
which nitrogenous waste, which is particularly abundant when amino acids are utilised as 
an energy source is induced. This was confirmed by the fact high levels of ammonia were 
recorded in fasted SIRT5 KO mice. These findings were also evident in mice chronically 
calorie restricted and fed high protein diets (Nakagawa et al, 2009, Nakagawa & Guarente 
2009). It is therefore tempting to speculate that SIRT5 may contribute to the control of life 
span due to its ability to aid in the adaptation to alternative energy sources.  
 
1.4.6 SIRTUIN 6 
Intensive investigations into the function of SIRT6 have elucidated that its main function 
concerns DNA repair and maintenance of genomic integrity. It is located on chromosome 
19 at position 13.3 and seems to possess both NAD+ dependent deacetylase as well as 
ADP-ribosyl transferase activity. Expression levels are noted to be highest in thymus, 
skeletal muscle and brain (Liszt et al, 2005, Mahlknecht et al, 2006b, Pan et al, 2011). 
Initial clues regarding SIRT6 function came from knockout studies. SIRT6-/- mice were 
small, displayed profound abnormalities including lymphopenia, loss of subcutaneous fat, 
lordokyphosis, and severe metabolic defects including hypoglycaemia eventually dying at 
around four weeks (Mostoslavsky et al, 2006). These features are consistent with a 
premature ageing phenotype.   
1.4.6.1 SIRT6 Maintains Genomic Integrity 
SIRT6 plays an important role in the maintenance of genomic integrity and more 
specifically DNA damage repair. Analysis of MEFs isolated from SIRT6-/- mice revealed 
striking chromosomal aberrations and increased sensitivity to radiation damage. 
Furthermore they exhibited reduced capacity for BER when exposed to agents known to 
elicit DNA damage repaired by this pathway (Mostoslavsky et al, 2006). Recent evidence 
has also implicated SIRT6 in promoting DSB repair by promoting DNA-dependant protein 
kinase (DNA-PK) (McCord et al, 2009, Kaidi et al, 2010). Further work has also defined a 
role for SIRT6 in the maintenance of telomeric function. Cells deficient in SIRT6 
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displayed a senescence phenotype with increased markers of senescence and DNA damage 
response at telomeres. In addition there was evidence of increased chromosome end-to-end 
fusions indicating defective telomere function. The mechanism of telomere dysfunction is 
thought to be mediated through alteration in acetylation at H3K9 (Michishita et al, 2008b). 
It is, therefore clear from the results of these studies that SIRT6 is firmly established as a 
key mediator of genomic integrity with the ability to repair DNA damage of different 
types. As is evident from the original knockout mouse model this has fundamental 
implications for the ageing process.  
1.4.6.2 SIRT6 & Metabolic Response 
The potential role of SIRT6 in glucose homeostasis became apparent from examination of 
the SIRT6 knockout mice. These animals are hypoglycaemic from day 12 onwards to the 
extent that by day 24 glucose levels are undetectable with serum IGF-1 levels 
concomitantly reduced (Mostoslavsky et al, 2006). The mechanism behind this profound 
hypoglycaemia has recently been elucidated by Zhong and colleagues (2010). SIRT6 
deficiency causes an upregulation of glucose uptake and switch in glucose metabolism to 
glycolysis from mitochondrial respiration, an effect caused by the SIRT6 mediated co-
repression of HIF-1α, which is a key factor of the cellular adaptation to nutrient and 
hypoxic stress (Zhong et al, 2010, Zhong& Mostoslavsky 2010). This model predicts that 
in times of nutrient stress, for example CR, that SIRT6 would be inactivated triggering a 
HIF-1α dependant metabolic switch favouring glycolysis. This contradicts evidence 
produced by Kanfi et al (2008) suggesting that SIRT6 levels increase during CR (Kanfi et 
al, 2008b). This response is more in keeping with that expected for SIRT1 where it is seen 
to increase in response to nutrient deprivation (Cohen et al, 2004b). It may be that different 
sirtuins have evolved to function in contrasting scenarios.  
1.4.6.3 SIRT6 & NF-κB 
An intriguing discovery was that of Kawahara et al (2009), who show that SIRT6 
functions at chromatin to attenuate NF-κB signalling. This is achieved by two main 
mechanisms firstly; SIRT6 interacts directly with the NF-κB RelA subunit and secondly by 
deacetylating H3K9 at NF-κB target gene promoters. Interaction between NF-κB and 
SIRT6 is implicated in normal and premature ageing as haploinsufficiency of the NF-κB 
subunit RelA rescues the premature ageing phenotype of SIRT6 deficient mice (Kawahara 
et al, 2009).  
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1.4.7 SIRTUIN 7 
There is a relative paucity of information regarding the physiological function of SIRT7 in 
comparison with the other human SIRT proteins. The genomic locus has been shown to 
reside at 17q25.3. Expression levels of SIRT7 appear to be highest in blood and CD33+ 
bone marrow precursor cells as well as other rapidly dividing tissues such as liver, spleen 
and testis (Voelter-Mahlknecht et al, 2006).  
Initial studies investigating the potential function of SIRT7 demonstrated that it co-
localises to the nucleolus where it interacts with RNA polymerase Pol I, increasing its 
transcription and activity. Cells expressing SIRT7-shRNAs were significantly reduced in 
number, with further assays indicating cellular depletion of SIRT7 leads to apoptosis (Ford 
et al, 2006). Thus SIRT7 is implicated in the regulation of cell growth by driving ribosome 
biogenesis in response to fluctuating metabolic conditions. Grob et al, have also reported a 
role for SIRT7 in the resumption of rDNA transcription during telophase (Grob et al, 
2009). Contrary to these findings studies using a SIRT7 knockout mouse model and 
harvested cells, have demonstrated anti-proliferative effects of SIRT7. MEFs derived from 
the SIRT7 knockout mouse model demonstrated increased viability under both normal and 
pro-oxidative conditions. (Vakhrusheva et al, 2008a). SIRT7 knockout mice display 
reduced mortality with evidence of myocardial hypertrophy and inflammatory 
cardiomyopathy. In addition, SIRT7 interacts with p53 resulting in its deacetylation 
corresponding to hyperacetylation of p53 and increased apoptosis in the myocardium of 
mutant mice (Vakhrusheva et al, 2008b). 
 
1.4.8 Sirtuins in Mammalian Ageing, Calorie Restriction & the MTR  
As outlined in the previous section there is an ever expanding body of evidence linking 
sirtuin expression to a complex array of biochemical and ultimately physiological 
processes, progressive dysfunction of which typify normal and abnormal organismal 
ageing. 
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1.4.8.1 Ageing & Lifespan Regulation 
SIRT1 has been implicated in a number of different facets of the ageing process. For 
example, Chua et al (2005) reported that SIRT1 deficient MEFs have a dramatically 
increased resistance to replicative senescence, essentially becoming immortalised (Chua et 
al, 2005). Sasaki et al (2006) analysed SIRT1 levels from human lung fibroblasts and 
MEFs with normal, accelerated and delayed ageing. SIRT1 decreased with serial passage 
of cells and decreased rapidly in prematurely senescent cells. Furthermore at the animal 
level, SIRT1 decreased in the tissues in which mitotic activity decreases with age. This loss 
was accelerated in mice with an accelerated ageing phenotype (Sasaki et al, 2006). 
When overall survival is taken into consideration results are variable. With both normal 
and prolonged lifespan reported in SIRT1 under-expressing transgenic mouse models 
under both normal and CR conditions (Boily et al, 2008, Li et al, 2008). The importance of 
SIRT1 in overall cellular function is underlined by the fact that mice in which the SIRT1 
gene is completely knocked out rarely survive past the post-natal period, a response 
associated with p53 hyperacetylation (Cheng et al, 2003) 
Evidence implicating sirtuins expression in human lifespan is sparse. However, it has been 
demonstrated that under-expression of human SIRT3 seems to be detrimental for 
longevity. Bellizi et al (2003) analysed the allele frequency of a VNTR polymorphism, 
which was shown to exhibit enhancer activity at the SIRT3 gene. The specific allele 
lacking enhancer activity was almost completely lacking in male study participants over 
the age of 90 (Rose et al, 2003, Bellizzi et al, 2005). Put together, the results of all these 
studies implicate the sirtuins in the control of longevity. This effect is likely to result from 
the ability of the sirtuins to maintain a fine balance between cellular resistance to stress, 
apoptosis and the promotion of efficient DNA repair.      
1.4.8.2 Calorie Restriction 
CR has been shown to extend lifespan in a number of different model systems (Imai & 
Guarente 2010). The adaptive responses induced by calorie restriction in mammalian 
models includes improved insulin sensitivity, reduced levels of glucose, cholesterol and 
free fatty acids along with reduced fat mass and increased levels of activity (Anderson & 
Weindruch 2010). A number of avenues of investigation have been followed leading to the 
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assumption that the responses induced by CR are mediated in part by the sirtuins and in 
particular SIRT1.  
1. Expression of SIRT1 is induced in calorie restricted rats, an effect dependent on 
SIRT1 deacetylation of Ku70, inhibiting stress-induced apoptosis (Cohen et al, 
2004b, Kanfi et al, 2008a). 
2. Increased activity induced by CR is dependent on adequate SIRT1 expression 
(Chen et al, 2008). 
3. Transgenic mice over-expressing SIRT1 display a number of phenotypic responses 
similar to those seen in CR mice (Bordone et al, 2007). 
4. Treatment of regular chow fed mice with the SIRT1 activator resveratrol induces a 
transcription profiles similar to that of CR (Pearson et al, 2008).  
5. Under-expression of SIRT1 specifically in the brain results in mutant mice who 
display defects in the endocrine and behavioural responses to CR (Cohen et al, 
2009). 
Clearly there exists a role for SIRT1 in the response to CR however both SIRT3 and 
SIRT6 have similarly been implicated. SIRT6 levels are increased in cultured cells, fasted 
mice and calorie restricted rats, an effect mediated by protein stabilisation as opposed to 
increased mRNA expression (Kanfi et al, 2008a). Two recent studies have implicated 
SIRT3 in the response to CR. Qui et al (2010) have demonstrated that SIRT3 is required 
for the protective effect of CR on levels of oxidative stress. Furthermore, reduction of 
cellular ROS levels is dependent on SIRT3 mediated deacetylation and hence 
augmentation of the activity of SOD2 (Qiu et al, 2010). Complementing these findings 
Someya and colleagues (2010) report that SIRT3 is required for the CR mediated 
prevention of age related hearing loss in transgenic mice. Again, this effect is mediated by 
SIRT3 dependent enhancement of the mitochondrial anti-oxidant defence system through 
regulation of isocitrate dehydrogenase 2 (Idh2) (Someya et al, 2010).   
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1.4.8.3 Sirtuins & the MTR 
As mentioned previously the MTR trinity (Mitochondrion Telomere and Ribosome 
biogenesis) could provide a rationale paradigm whereby DNA damage is sensed and 
repaired. When the sub-cellular localisation and cellular function of the sirtuins are 
considered it is no surprise that they are considered the linchpin of the MTR hypothesis 
Each of the sirtuins could conceivably play a role in the MTR controlled stress response 
and it may be that there is interaction between sirtuins. As mentioned previously one of the 
defining features of sirtuin kinetics is the fact that NAD+ is an essential cofactor for the 
activity of the majority of the sirtuins. This provides a plausible link between the metabolic 
state of the cell and the response to stress. SIRT1 is likely to be a key player in the overall 
response given its wide ranging function. Its ability to deacetylate p53 is likely to be 
crucial in the response mechanism. Via p53 SIRT1 has been shown to modulate cellular 
senescence and apoptosis in a number of models (Langley et al, 2002, Chua et al, 2005).  
SIRT1 has also recently been shown to attenuate ageing associated telomere attrition; 
hence SIRT1 could also play a role in determining the telomere associated DNA damage 
response (Palacios et al, 2010). Whilst SIRT6 plays a crucial role in the propagation of a 
specialised telomeric chromatin state essential for normal telomere function (Michishita et 
al, 2008b). The key roles of the mitochondrial sirtuins in metabolism and hence energy 
production are essential to fuel the damage response. However, this could be a double-
edged sword as increase fuel utilisation with concomitantly increased generation of ROS 
could accelerate telomere attrition and initiate the DNA damage response. The interaction 
of the mitochondrial sirtuins, in particular SIRT3, with intermediaries of metabolism and 
anti-oxidant mechanisms is likely to be crucial in balancing the response (Schwer et al, 
2002, Qiu et al, 2010). Ribosome biogenesis is one of the most energy consuming cellular 
processes, hence a balancing act where adaptation to cellular energy status is essential. 
SIRT1 has been shown to be essential for this response as part of the eNoSC (energy 
dependant nucleolar silencing complex) in combination with nucleomethylin and 
SUV39H1. This complex senses energy status, controls rRNA transcription and establishes 
silent chromatin at the rDNA locus (Murayama et al, 2008). Further control over ribosomal 
gene transcription is elicited by SIRT7,  
Aberrancy of any of the components of the MTR could lead to dysregulation of any of the 
effector pathways resulting in a reduced capacity to sense and repair genotoxic damage, 
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with the ensuing potential of accelerated biological ageing and concomitantly associated 
condition such as cancer.  
 
1.4.9 Sirtuins & Cancer 
When the myriad of cellular processes in which the sirtuins have been implicated are 
considered it is no surprise that aberrancy of their expression is implicated in the process of 
cancer development and progression. This is particularly important in the case of SIRT1 
which has an intimate relationship with p53, FOXO and many other factors not only 
fundamental in regulating the DNA damage response and the fate of a cell in stress, but 
ultimately protecting the cell from neoplastic transformation i.e. tumour suppressors. 
Rationalising the relationship between the sirtuins and tumourigenesis is complex. 
Currently the literature attempting to delineate the relationship between the sirtuins, and in 
particular SIRT1 and the cancer process is divergent with some studies claiming a tumour 
suppressor and some a tumour promoter role.  
1.4.9.1 SIRT1 & Cancer 
SIRT1 as a Tumour Promoter 
It has been purported that SIRT1 could promote cancer formation and increase cancer risk 
by virtue of its ability to negatively regulate mediators known to act as tumour suppressors 
such as p53. However the relationship is not straightforward with complex interacting 
feedback loops regulating SIRT1, and its effect over a number of pro- and anti-oncogenic 
transcription factors and non-histone proteins. In order to be classed as a positive regulator 
of neoplastic transformation over-expression of SIRT1 in transgenic mice should increase 
the rate of detection of spontaneous cancers. However, although such mouse models show 
improvements in metabolic parameters consistent with the role of SIRT1 in metabolic 
pathways no increase in tumour development has been detected as yet (Banks et al, 2008, 
Pfluger et al, 2008). 
In order to be recognised as a potential tumour promoter expression levels in isolated and 
cultured cells would have to be reflective of this hypothesis. Consistent with this SIRT1 
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has been shown to be upregulated in human cancer specimens and cells of different 
histological subtype (Table 1.6). 
Table 1.6: Table summarising SIRT1 in cancer tissue expression studies. 
Cancer Type Specimen Method of 
Analysis 
Comments Reference 
Acute myeloid 
Leukaemia (AML) 
Isolated and 
cultured  primary 
AML blasts  
RTq-PCR Comparison with 
control cells 
(CD34+ 
progenitors, 
peripheral blood 
mononuclear cells) 
 
(Bradbury et al, 
2005) 
Human prostate  
 
 
Human prostate  
 
Tumour specimen 
 
 
Tumour specimen 
 
IHC 
 
 
IHC 
 
Comparison with 
uninvolved cells.  
 
Comparison with 
normal adjacent 
prostate tissue. 
 
(Huffman et al, 
2007) 
 
(Jung-Hynes et al, 
2009) 
Skin Squamous cell, 
basal cell, Bowens 
disease, actinic 
keratosis biopsies 
 
IHC Comparison with 
20 normal skin 
biopsies 
(Hida et al, 2007) 
Colorectal Surgical specimens 
& CRC cell lines 
IHC Comparison with 
adjacent normal 
mucosa 
 
(Stunkel et al, 
2007) 
Gastric Surgical specimens 
post-gastrectomy 
IHC No direct 
comparison made 
but low expression 
in normal samples 
 
(Cha et al, 2009) 
Ovarian Tumour samples IHC Increased 
expression in 
malignant 
compared with 
benign tumours. 
(Jang et al, 2009) 
 
SIRT1, p53 & Cancer 
The ability of SIRT1 to deacetylate and therefore inhibit p53 activity lead investigators to 
assume SIRT1 expression would increase the risk of neoplastic transformation. Indeed 
overexpression of SIRT1 has been demonstrated to repress p53-dependant cell cycle arrest 
and apoptosis in response to DNA damage and oxidative stress, with the overall effect of 
promoting tumour growth (Luo et al, 2001, Vaziri et al, 2001, Cheng et al, 2003, Brunet et 
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al, 2004).  Fine control of the p53-SIRT1 axis is essential for normal response to stress and 
the ageing process. A variety of control mechanisms have evolved to regulate the level of 
SIRT1 controlled acetylation level of p53 and hence its activity. One such strategy is the 
interaction between p53 and microRNA 34a (miR34a). The miR34a family regulates cell 
cycle progression, senescence and apoptosis and, importantly its transcription can be 
activated by p53. Moreover, it is suggested it functions as tumour suppressor in vivo 
(Yamakuchi & Lowenstein 2009). miR34a can also bind to the 3’-UTR of SIRT1 mRNA 
to repress its translation. Consistent with this finding over-expression of miR34a reduced 
SIRT1 activity in human colon cancer cells and enhanced p53-dependent apoptosis, an 
effect not observed in cells lacking p53. Importantly, over-expression of SIRT1 rescued 
colon cancer cells from miR34a induced apoptosis (Yamakuchi et al, 2008). Thus in a 
cellular environment where SIRT1 is over-expressed the tumour suppressor effect of p53 
and miR34a is abrogated by disruption of the SIRT1-p53-miR34a axis. 
SIRT1, HIC1 & p53 
Hypermethylated in cancer-1 (HIC1) is a commonly mutated tumour suppressor gene. This 
is particularly important when the interaction between HIC1, SIRT1 and p53 is considered. 
HIC1 and SIRT1 form a transcriptional repression complex which binds directly to the 
SIRT1 promoter, repressing its transcription. In cancer cells mutated and hence inactivated 
HIC1 results in up-regulated SIRT1 expression, leading to augmented deacetylation and 
inactivation of p53, thus allowing cells to bypass apoptosis and survive DNA damage 
(Chen et al, 2005a). The authors propose a HIC1-SIRT1-p53 regulatory loop that in 
normal circumstances controls growth arrest and apoptosis in response to DNA damage. 
This regulatory loop gains particular importance during organismal aging when the HIC1 
promoter becomes progressively hypermethylated, promoting survival of aging cells but 
increasing cancer risk (Chen et al, 2005a).  
SIRT1, DBC1 & p53 
Deleted in Breast Cancer-1 (DBC1) is a protein with purported tumour suppressor function 
resulting from its effect on cell proliferation, apoptosis and histone modification (Kim et 
al, 2009). DBC1 is a negative regulator of SIRT1 which forms a stable complex with 
SIRT1 inhibiting its activity, as expected this leads to increased p53 acetylation and up-
regulation of p53 function. Knockdown of DBC1 by RNAi promoted SIRT1 mediated 
deacetylation of p53 and inhibited apoptosis induced by genotoxic stress (Kim et al, 2008, 
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Zhao et al, 2008). These data indicate that increased SIRT1 expression or reduced DBC1 
activity increase cancer risk by inhibiting p53.  
SIRT1, FOXO & Cancer 
The ability of the FOXO factors to induce cell cycle arrest, DNA repair and apoptosis 
makes them attractive candidates as tumour suppressors. Inactivation of FOXO could lead 
to dysfunctional cell cycle checkpoints leading to neoplastic transformation. Consistent 
with this over-expression of FOXO reduces tumourigenicity in a number of experimental 
models (Greer & Brunet 2005, Greer & Brunet 2008). Ford et al (2005) used RNAi to 
determine if either FOXO3 or FOXO4 can influence the apoptotic consequences of SIRT1 
inhibition in human colorectal cancer cells. Co-silencing experiments revealed that 
FOXO4 but not FOXO3 rescues SIRT1 siRNA-treated cells from apoptosis, inferring that 
FOXO4 is essential for apoptosis in these cancer cells (Ford et al, 2005). Thus the overall 
effect of the interaction between the FOXO transcription factors and SIRT1 may be to 
promote tumourigenesis by a shift from pro- to anti-apoptotic pathways with promotion of 
cell cycle progression.  
SIRT1 as a Tumour Suppressor 
For a gene product to be considered a tumour suppressor a number of key criteria have to 
be met. Firstly, over-expression in cell culture should induce cell growth arrest. Secondly, 
there should be evidence of deleterious point mutations or gene deletions in human cancer 
subtypes and finally there should be evidence of under-expression or hypo-activity in 
isolated cancer cells (Brooks & Gu 2009). There is accumulating evidence from expression 
studies and in vitro work in specific cancer types that SIRT1 can act in a tumour 
suppressive fashion. 
Wang et al (2008) have extensively investigated the expression of SIRT1 in a number of 
tumour types. They report that levels of SIRT1 were lower than normal control tissue in 
glioblastoma, bladder, prostate and ovarian carcinoma. These results were validated using 
western blot analysis, where there was reduced expression in breast and hepatocellular 
carcinoma with equivalent expression levels between lung, colon, stomach, bladder and 
skin cancer specimens, and their respective control tissue samples (Wang et al, 2008a).   
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Stimulation of SIRT1 deficient MEFs by chronic oxidative stress resulted in diminished 
upregulation of the senescence mediator p19ARF and its downstream target p53, with a 
concomitant extension of replicative lifespan. These results raise the possibility that SIRT1 
may exert a negative regulatory role on oncogenesis by inducing the expression of tumour 
suppressor genes and senescence. However, the same study failed to show any change in 
p19ARF expression or progress through the cell cycle in SIRT1 deficient MEFs subjected to 
viral oncogene expression (Chua et al, 2005).  
 
Two main studies have utilised transgenic models to provide evidence that it is the ability 
of SIRT1 to promote genomic integrity that may explain in part its tumour suppressive 
effect. Wang et al (2008) developed double heterozygotic SIRT1+/-; p53+/- mice, which 
developed a high incidence of tumours with evidence of aneuploidy and chromosomal 
aberrations consistent with severe genetic instability. (Wang et al, 2008a). Oberdoerffer et 
al (2008) developed a transgenic murine p53+/- model in which SIRT1 was over-expressed. 
This combination resulted in decreased incidence of thymic lymphoma and increased 
survival following exposure to γ-irradiation. Further investigation using isolated MEFs 
showed that SIRT1 dissociates from its original loci to DSBs. Again this was shown to be 
dependent on H2γX, but also on intact ATM signalling pathways (Oberdoerffer et al, 
2008). These studies provide further evidence of a tumour suppressive function of SIRT1 
via its role in the maintenance of genomic integrity and prevention of potentially 
oncogenic chromosomal aberrations.    
 
SIRT1 as a Pro-apoptotic Tumour Suppressor 
An interaction exists between SIRT1 and survivin in BRCA1 association breast cancers 
whereby, SIRT1 suppresses survivin. Survivin is an inhibitor of apoptosis and is over-
expressed in many tumour types, making it an attractive chemotherapeutic target. BRCA1 
associated cancers have low SIRT1 expression levels with high levels of survivin. BRCA1 
is found at the SIRT1 promoter in cells expressing wild type BRCA1 and increases SIRT1 
expression which in turn inhibits survivin by deacetylation. Furthermore, treatment with 
resveratrol inhibits the growth of BRCA1 deficient tumours both in vitro and in vivo 
(Wang et al, 2008b). 
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As mentioned previously NF-κB is a ubiquitous mediator of the cell, cycle, growth, 
angiogenesis and apoptosis. Yeung et al (2004) demonstrated that SIRT1 over-expression 
or treatment with resveratrol sensitised non-small cell lung cancer (NSCLC) cells to 
apoptosis when stimulated by TNF-α, by deacetylating the RelA/p65 subunit of NF-κB 
(Yeung et al, 2004).  
 
SIRT1 Activation by Resveratrol  
Resveratrol (3,5,40-trihydroxystilbene) is a naturally occurring phytoalexin found in 
grapes, peanuts and various berries. It has gained popular attention due to its purported 
health benefits stemming from its anti-oxidative capacity. It is thought to some degree to 
explain the French paradox whereby rates of coronary artery disease are lower in France 
compared many other western countries despite high levels of saturated fat intake. This 
effect is thought in part to be mitigated by higher levels of red wine and hence resveratrol 
consumption (Lippi et al, 2010). However, a number of other potential health benefits have 
been attributed to resveratrol, particularly pertinent is its beneficial effect in cancer. The 
mechanism by which resveratrol imparts its beneficial effects is matter of great debate, 
however there are well defined effects on sirtuin expression, particularly an up-regulation 
of SIRT1 levels (Howitz et al, 2003). 
The anti-proliferative effect of SIRT1 activation by resveratrol has been investigated in a 
number of experimental contexts. It was first demonstrated to possess anti-carcinogenic 
effects in 1997, on a murine model of skin carcinogenesis (Jang et al, 1997). However, it 
also has beneficial effects on tumour growth in a mouse model of colorectal carcinogenesis 
(Firestein et al, 2008), in BRCA1 mutated breast cancer models (Wang et al, 2008b) and is 
pro-apoptotic in non-small cell lung cancer cells (Yeung et al, 2004). The beneficial effect 
of resveratrol on a murine model of skin cancer is partly SIRT1 dependent (Boily et al, 
2009).  
1.4.9.2 SIRT2 & Cancer 
SIRT2 is a tubulin deacetylase required for normal mitotic progression and control of 
mitotic checkpoint function to ensure chromosomal fidelity (North et al, 2003, Inoue et al, 
2007, Inoue et al, 2009). Hence is reported to be a negative regulator of cellular 
proliferation. Consistent with this SIRT2 expression is found to be reduced in human 
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glioma tissue samples and cell lines, indicating a potential tumour suppressor effect 
(Hiratsuka et al, 2003).  
 
1.4.9.3 SIRT3, SIRT4, SIRT5 & Cancer 
It is becoming more apparent that the ‘mitochondrial’ sirtuins have complex cellular 
functions not just limited to their original description as regulators of metabolism. The first 
supportive evidence demonstrated a link between SIRT3 expression and node positive 
breast cancer (Ashraf et al, 2006). More recently Kim et al (2010) provided evidence 
supporting a tumour suppressor role for SIRT3. SIRT3-/- mice develop ER/PR-positive 
mammary tumours, whilst in vitro transformation of SIRT3-/- MEFs by oncogene 
expression is reversed by superoxide dismutase (Kim et al, 2010).  
There are as yet no studies directly linking either SIRT4 or SIRT5 to cancer initiation, 
progression or metastasis. This situation will almost certainly change in the future as the 
knowledge base surrounding these sirtuins expands. 
1.4.9.4 SIRT6 & Cancer  
SIRT6 is responsible for maintenance of genomic integrity, an effect mediated by its 
ability to control BER via its ability to complex with DNA-PK and modulate telomeric 
chromatin (Mostoslavsky et al, 2006, McCord et al, 2009, Michishita et al, 2009). Clearly 
aberration of SIRT6 expression could therefore lead to genomic instability, a hallmark of a 
number of cancer subtypes. In contrast, lack of SIRT6 might provide a growth advantage 
for tumour cells as SIRT6 deficient cells are more resistant to apoptosis when exposed to 
hypoxia, an effect mediated by HIF-1α, which is up-regulated in many primary cancers 
(Zhong et al, 2010).  
 
1.4.9.5 SIRT7 & Cancer 
Potential for the role of SIRT7 in cancer comes from different lines of research. The region 
of the genome in which SIRT7 resides is frequently implicated in acute leukaemia and 
lymphoma. (Voelter-Mahlknecht et al, 2006). Meanwhile SIRT7 expression is reported to 
be increased in human papillary thyroid cancer, and also in breast cancer tissue when 
compared with control and non-malignant tissue (Ashraf et al, 2006, de Nigris et al, 2002, 
Frye 2002).  
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1.5 Statement of Research Aims 
With the advancing age of the general population and the strong risk elicited by 
chronological age on cancer risk, the incidence of cancer is only likely to increase in the 
next few decades. It is therefore intuitive that delineating the molecular mechanisms which 
influence each of the processes could lead to the development of novel targets for 
intervention. As presented above accelerated telomere attrition and aberrant sirtuin 
expression have shown a clear and consistent link with the cancer process in published 
studies. However, some controversies and dichotomies exist. Some studies have presented 
counter-intuitive evidence of long telomeres associated with cancer risk. Whilst, studies 
have still have not reconciled the role of the sirtuins as either tumour promoters or 
suppressors. In addition studies have mainly focused on the molecular biology of the 
sirtuins in the neoplastic as opposed to the clinical significance of their expression. The 
overall aim of this study, therefore, is to determine the role and significance of telomere 
attrition and sirtuin relative expression in colorectal cancer. This will be achieved through 
a number of research questions: 
1. Do patients with colorectal cancer display evidence of accelerated biological ageing 
in the form of telomere attrition? 
 
2. Are peripheral blood leucocyte (PBL) telomere lengths reflected in associations 
with,  pro-inflammatory cytokines (IL-6/IL-10), CRP and levels of circulating 
factors involved in redox control (fetuin-A, antioxidant vitamins, trace elements) 
inthe CRC  patient cohort? 
 
3. Does PBL telomere length predict adverse pathological or prognostic factors? 
 
4. Is there a difference in telomere length between colorectal tumour and normal 
adjacent tissue, does tissue telomere length correlate with pathological features? 
 
5. Is aberrancy of sirtuin expression evident in colorectal cancer, as indicated by 
differential relative expression between tumour and adjacent normal tissue? 
6. Do sirtuin expression levels predict adverse pathological or prognostic tumour 
features? 
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7. Is there any relationship between sirtuin expression and cellular ageing indicated by 
telomere length at the tumour level? 
8. Finally, does sirtuin expression correlate with a variety of commonly recorded 
biochemical and haematological variables, particularly those involved in systemic 
inflammation? 
The work carried out in this thesis therefore aims to place the biology of ageing and 
CRC in a clinical context, and by doing so provide robust information that may prove 
useful in the hunt for genuine new targets for anti-mitotic agents or markers of disease 
severity. 
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CHAPTER 2:  MATERIALS & METHODS 
As outlined in the aims section of this thesis there are two main components to this study: 
determination of differences in the biological age of colorectal cancer patients compared 
with controls using PBL TL and comparison of the relative transcriptional expression 
levels of SIRT1-7 between colorectal tumour and normal tissue. This therefore required 
two sources of study material from colorectal cancer patients, blood samples to harvest 
PBLs and extract DNA and tumour tissue to extract RNA.  
 
2.1 Patient Recruitment & Sample Collection 
2.1.1 PBL Group 
This group was comprised of patients recruited prospectively from the Department of 
Colorectal Surgery, Glasgow Royal Infirmary. All patients were admitted for assessment 
and management of histologically proven colorectal adenocarcinoma. Blood samples 
(n=64) were collected for analysis during diagnostic workup. 10mls of whole blood was 
collected in EDTA tubes and immediately centrifuged. The resulting cellular component 
and buffy coat was stored at 4oC until use in the telomere assay.  The plasma was stored at 
-80oC and used in the experiments to determine potential correlates of TL including redox 
control factors, markers of systemic inflammation and fetuin-A. Table 2.1 presents details 
of the patient clinical and pathological variables for this group (this group will be referred 
to as the CRC PBL group). Full ethical approval from the local NHS ethics committee was 
gained prior to the commencement of any sample collection (COREC 08/S0704/22). 
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Table 2.1: Table displaying baseline demographic and clinico-pathological variables for the CRC PBL 
telomere group. 
 
 CRC PBL Group 
Characteristic Number/Total % 
Sex Male 33/64 51.56 
 Female 31/64 48.44 
Age 45-55 9/64 14.06 
56-65 17/64 26.66 
66-75 24/64 37.5 
76-85 14/64 21.88 
Tumour 
Site 
Colon 42/64 65.63 
Rectum 22/64 34.37 
Duke’s 
Stage 
A 6/64 9.38 
B 23/64 35.94 
C 16/64 25.00 
D 18/64† 28.13 
Unknown 1/64 1.67 
Tumour T1 2/52 3.85 
T2 8/52 15.38 
T3 30/52 57.69 
T4 12/52 23.08 
   
Nodes N0 30/52 57.69 
N1 15/52 28.85 
N2 7/52 13.46 
Metastasis M0 47/52 90.38 
M1 5/52¶ 9.62 
‡Peterson 
Index 
High Risk 13/48 27.18 
Low Risk 35/48 72.92 
mGPS 0 42/64 65.63 
1 13/64 20.31 
2 9/64 14.06 
Unknown   
Smoker Never 23/64 43.40 
Ever 20/64 37.74§ 
Unknown 11/64 18.86 
Carstairs  
Index 
2 2/64 3.13 
3 8/64 12.5 
4 11/64 17.2 
5 7/64 11.0 
6 5/64 7.81 
7 28/64 43.75 
 Unknown 3/64  
    
† Includes patients with in-operable disease and patients who underwent synchronous resection of their primary cancer and liver 
metastasis. 
¶ Synchronous resection of liver metastasis. 
‡ Pathological scoring system where score of 2 or more indicates high risk pathological features. Points awarded for vascular 
invasion (1), margin positivity (1), peritoneal breach (1) & tumour perforation (2) 
§This compares with 58% of the control population who had ‘ever’ smoked. 
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2.1.2 Tissue Group 
 
The second group utilised colorectal cancer tissue (tumour and normal) collected under the 
auspices of the local Biobank (NHS Greater Glasgow & Clyde), this group was used to 
determine relative transcriptional expression levels of SIRT1-7 and in addition, cancer 
tissue TL (Table 2.2). All measurements were performed in paired samples (tumour and 
adjacent normal tissue) to allow direct comparison. Colorectal cancer patients who were 
admitted for potentially curative surgery were approached pre-operatively by Biobank staff 
and full informed consent obtained for the collection and use of excess tissue for research 
purposes. A total of fifty five paired samples were available for RNA extraction. All 
samples were snap frozen in liquid nitrogen and stored at -80oC until use. All tissue 
samples were validated by a consultant pathologist and deemed representative of the 
pathological specimen. Of the 55 samples, 32 paired tissue samples were available for 
additional DNA extraction and subsequent TL analysis (this group will be referred to as the 
CRC tissue group). Full ethical approval was gained for use of surplus Biobank tissue for 
use in research (COREC 08/S0704/42) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
85 
 
 
Table 2.2: Table displaying the patient characteristics of the full group of patients from tissue samples 
were collected and RNA extracted for use in the RT-PCR assay to determine SIRT1-7 
relative expression and the 32 samples from which DNA was extracted to determine tissue 
telomere length. 
 
 
 
 CRC Tissue Group 
 Sirtuin Experiment Telomere Experiment  
Characteristic Number/Total % Number/Total % 
Sex Male 27/55 49.1 15/32 46.88 
 Female 28/55 50.9 17/32 53.13 
Age <65 9/55 16.4 4/32 12.5 
65-75 24/55 43.6 15/32 46.9 
>75 22/55 40 13/32 40.6 
     
Tumour 
Site 
Colon 39/55 70.9 26/32 81.25 
Rectum 16/55 29.1 6/32 18.75 
Duke’s 
Stage 
A 10/55 18.2 4/32 12.5 
B 27/55 49.1 16/32 50.0 
C 12/55 21.8 8/32 25.0 
D 6/55† 10.9 4/32† 12.5 
     
Tumour T1 0/55  0/32  
T2 10/55 18.2 4/32 12.5 
T3 28/55 50.9 19/32 59.38 
T4 17/55 30.9 9/32 28.13 
     
Nodes N0 39/55 70.9 21/32 65.63 
N1 13/55 23.6 9/32 28.13 
N2 3/55 5.5 2/32 6.25 
Metastasis M0 49/55 89.1 28/32 87.5 
M1 6/55† 10.9 4/32† 12.5 
Peterson 
Index‡ 
 
Low Risk 
High Risk 
40/55 
15/55 
72.7 
27.3 
26/32 
6/32 
81.25 
18.75 
mGPS 0 31/55 56.4 18/32 56.25 
1 10/55 18.2 3/32 9.38 
2 6/55 14.5 6/32 18.75 
Unknown 6    
Smoker No 28/55 50.9 5/32 15.63 
Yes 23/55 41.8 18/32 56.25 
Unknown 4  11/32 34.38 
 † synchronous resection of their primary cancer and liver metastasis. 
‡ Pathological scoring system where score of 2 or more indicates high risk pathological features. Points awarded for vascular 
invasion (1), margin positivity (1), peritoneal breach (1) & tumour perforation (2) 
 
 
2.1.3 Correlation with Patient Clinico-Pathological Factors 
 
An attempt was made to correlate both PBL TL and sirtuin expression data with routinely 
available clinico-pathological parameters. Where possible biochemical, haematological 
and pathological data were extracted from a prospective database maintained by the 
Department of Surgery (details in individual results chapters). The Peterson Index (PI) was 
used as an additional measure to identify patients with pathologically more aggressive 
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disease and hence poorer outcome. Pathologically determined vascular invasion, margin 
involvement or serosal breach was allocated a score of 1, with tumour perforation scoring 
2. A cumulative score of 0-1 indicates a low risk and 2-5 a high risk PI. A high risk PI 
suggests aggressive disease and has been shown to correlate with a poorer outcome from 
CRC in lymph node negative patients (Petersen et al, 2002).   
 
2.1.4 Control Group 
 
The control population used in the comparative study with CRC patients was comprised of 
subjects from the MRC West of Scotland Twenty-07 Cohort. Subjects used to form this 
cohort comprised of 1348 individuals aged either 57 (n=847) or 76 (n=501).  This is a 
community-based cohort study designed to longitudinally investigate the social processes 
that produce or maintain inequalities in health and has been described in detail previously 
(Benzeval et al, 2009). The two age groups were specifically chosen to demonstrate that 
both the chronologically older group and an age adjusted combined group had longer 
telomeres than CRC patients. In addition to age, sex and smoking status was available for 
this cohort. None of the subjects in this group had been diagnosed with cancer at any stage.  
 
 
2.2 Quantitative Real-Time PCR 
 
Quantitative real-time PCR was utilised as the assay of choice in the analysis of PBL TL 
and also SIRT1-7 relative expression. Although the same basic technique was used in each 
of the assays different methods of quantification were used to give an estimation of TL and 
relative quantification of sirtuin gene transcription. These modifications along with the 
specifics of the reaction will be outlined in the relevant methods section. The essential 
steps of the reaction are however are now discussed.  
 
Real-time PCR (RT-PCR) has a number of advantages over more rudimentary PCR 
techniques. The main advantage is the ability to detect PCR amplification during the early 
phases of the reaction. Basic end-point PCR techniques rely on agarose gels to detect the 
amplification product towards the end of the reaction leading to results which are 
imprecise, of low sensitivity and resolution. Accuracy is greatly increased by 
quantification at the earlier exponential phase of the PCR reaction.  
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The RT-PCR reaction assumes that there is a quantitative relationship between the amount 
of starting target sample and the amount of PCR product at any given cycle number. The 
reaction relies on a DNA polymerase with 5’ exo-nuclease activity of which there are 
several commercially available systems such as AmpliTaq Gold® TaqMan® system. The 
other key component to this reaction is a specific oligonucleotide probe which is specific 
for a DNA sequence between the forward and reverse primers. These probes are designed 
with a high energy dye at the 5’ end termed a reporter and lower energy dye at the 3’ end 
termed a quencher. When the probe is intact the reporter dye emission is suppressed by the 
quencher. However, when the probe is cleaved by the 5’ exo-nuclease the energy from the 
reporter molecule is released and sensed by a fluorescence sequence detection system 
(again a number of these are commercially available such as the ABI Prism Detection 
System).  Thus with each cycle of the PCR reaction there is an increase in the fluorescence 
emission detected by the reporter dye, furthermore the reaction is specific at three levels, 
the complementary probe cleaved during the amplification reaction along with the forward 
and reverse primers.  
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Figure 2.1: Schematic representation of the RT-PCR reaction involving the specific Taqman® probe 
and primer set with attached quencher and reporter (fluorophore) dyes. Taken from 
(Stratagene 2004) 
 
 
Quantification of gene expression using RT-PCR requires normalisation of the reporter dye 
emission signal using a passive reference dye. This is incorporated into the PCR mastermix 
and is required to correct for fluctuations in fluorescence as a result of alterations in 
concentration or volume. The Rn (normalised reporter) value is the emission of the reporter 
dye divided by the emission of the normalised reporter. The ΔRn is the change in Rn 
between an untreated or early cycle sample (Rn-, no template control) and a sample 
containing a full complement of reaction components including the target (Rn+). The ΔRn 
reflects the initial level of target DNA, as the signal increases this indicates the amount of 
hybridised probe that has been degraded by the exo-nuclease. The Rn is used by the 
software of the detection system to define a baseline of fluorescence (usually determined 
from the initial cycles of the reaction) and a threshold which is the average standard 
deviation of Rn for the early PCR cycles and is set in the exponential phase of the reaction 
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when it is at its most efficient. Finally, the threshold cycle (Ct) is the cycle number at 
which fluorescence passes the fixed threshold. The Ct value is used in the final calculation 
of gene expression. Different methods of relative quantification were used in this study to 
determine PBL TL and sirtuin gene relative expression which will be detailed in due 
course.     
 
 
Figure 2.2: Schematic representation of the ideal RT-PCR reaction.  
 
 
 
 
2.3 PBL and Tissue Telomere Length Determination and 
Correlation in Colorectal Cancer 
 
 
2.3.1 Tissue Processing & DNA extraction  
 
DNA was extracted from both blood and tissue using the Maxwell® automated 
purification system according to the manufacturer’s instructions (Promega, WI, USA). 
Briefly, whole blood samples were spun down into cellular and plasma components. The 
erythrocytic component and buffy coat were thoroughly mixed and 300µl aliquoted into 
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the predispensed reagent cartridges.  Cancer and normal tissue samples were thawed and 
50mg added to the reagent cartridge. The DNA concentration and purity were quantified 
using the Nanodrop spectrophotometer (Thermo Fisher Scientific, MA, USA). All DNA 
samples were validated on 0.5% agarose gel (Figure 2.3). 
 
 
 
Figure 2.3: 0.5% TBE agarose gel demonstrating validation of the extracted DNA for use in the 
telomere length determination assay (300ng DNA used). 
 
 
2.3.2 Telomere length Determination Using Real-Time PCR 
 
Telomere lengths were determined from DNA extracted as outlined above from the PBLs 
of both the control and CRC group and from the CRC tissue (tumour and normal). This 
was achieved by Q-PCR using the method first described by Cawthon (Cawthon 2002). 
This method aims to determine sample DNA relative TL (relative T/S) by determining the 
ratio of telomere repeat copy number to single gene copy number and comparing this with 
a reference DNA sample of known relative TL. The telomere repeat to single copy gene 
ratio (T/S ratio) is proportional to the average TL. The quantity of telomere and single 
copy repeats are determined using the standard curve method where successive dilutions of 
the reference DNA are used to construct a standard curve which is then used to determine 
copy number. The gene used to determine single copy number was the ribosomal protein 
36B4 gene. 
 
2.3.2.1 Plate Construction 
All samples were assayed in triplicate on 96-well plates. In order to determine the telomere 
copy number to single gene copy number pairs of plates were used to run each sample 
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using the telomere primer mix and the single gene primer mix, in this case the acidic 
ribosomal phosphate 36B4 was utilised.  Telomere and 36B4 plates were constructed 
identically to include; a five point standard curve created from the stock solution of 
reference DNA (standards range from 100ng-3.13ng), reference DNA sample (positive 
control/calibrator 10ng/µl), no template negative control and sample DNA (7ng/µl) (Table 
2.3 & Figure 2.4).  
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A SD1 SD1 SD1 Sample Sample Sample Sample Sample Sample Sample Sample Sample 
B SD2 SD2 SD2 Sample Sample Sample Sample Sample Sample Sample Sample Sample 
C SD3 SD3 SD3 Sample Sample Sample Sample Sample Sample Sample Sample Sample 
D SD4 SD4 SD4 Sample Sample Sample Sample Sample Sample Sample Sample Sample 
E SD5 SD5 SD5 Sample Sample Sample Sample Sample Sample Sample Sample Sample 
F SD6 SD6 SD6 Sample Sample Sample Sample Sample Sample Sample Sample Sample 
G SC SC SC Sample Sample Sample Sample Sample Sample Sample Sample Sample 
H Sample Sample Sample Sample Sample Sample Sample Sample Sample Sample Sample Sample 
Figure 2.4: 96 well plate layout for both telomere and 36B4 plates. SD1-6 = serial dilutions for 
standard curve construction. SC = control reference sample. 
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Table 2.3:  Table displaying the reaction constituents for the telomere and 36B4 plates. Sample DNA 
was used at a concentration of 7ng/µl. (Primer sequences displayed in Figure 2.5) 
 
Telomere Master Mix 
 
Volume (µl) 36B4 Master Mix Volume (µl) 
SYBER green 2X master 
mix (Roche, Switzerland) 
10 SYBER green 2X master 
mix (Roche, Switzerland) 
10 
Telo 1 primer 0.75 36B4 Fwd primer 0.4 
Telo 2 primer 0.75 36B4 Rev primer 0.4 
PCR grade H20 3.5 PCR grade H20 4.2 
Sample DNA  5 Sample DNA  5 
Total 20 Total 20 
 
 
Analysis was performed on the Roche Light Cycler LC480 (Roche, Switzerland). The 
telomere-specific amplicon primer set was previously validated and the optimum 
concentration determined (Koppelstaetter et al, 2005) (Figure 2.5).   
 
 
Tel 1, CGGTTTGTTTGGGTTTGGGTTTGGGTTTGGGTTTGGGTT 
Tel 2, GGCTTGCCTTACCCTTACCCTTACCCTTACCCTTACCCT 
 
36B4 for, CAGCAAGTGGGAAGGTGTAATCC 
36B4 rev, CCCATTCTATCATCAACGGGTACAA 
 
Figure 2.5: Primer sequences for telomere and 36B4 genes. 
 
 
All samples were heated to 95oC for 5 minutes prior to plate construction and then 
subsequently run under the following conditions: 
 
Telomere plates: 95oC for 10 minutes (polymerase activation) 
   30 cycles of  95oC for 5 seconds  
     59oC for 10 seconds 
     72oC for 2 minutes 
   
Melt Sequence (1 cycle) 95oC for 30 seconds  
     65oC for 30 seconds 
     95oC for 2 minutes 
 
 Cool Sequence (1 cycle) 40oC for 10 minutes 
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36B4 plates:  95oC for 10 minutes (polymerase activation) 
   35 cycles of  95oC for 5 seconds  
     59oC for 15 seconds 
     72oC for 15 seconds 
 
Melt Sequence (1 cycle) 95oC for 30 seconds  
     65oC for 30 seconds 
     95oC for 2 minutes 
 
 Cool Sequence (1 cycle) 40oC for 10 minutes 
 
 
 
 
2.3.2.2 Data Analysis 
 
The LightCycler LC480 software version 1.5 was used to generate standard curves and for 
subsequent quantification of the telomere and single gene copy number. This relative T/S 
value is the estimate of the relative TL of the sample in question. In order to make 
meaningful comparisons between the two plates (telomere and single copy) the efficiency 
of the PCR reaction of the two plates should be as similar as possible. This is determined 
by the slope of the standard curve, which was deemed acceptable if the slope was between 
-3.1 and -3.8 with a perfect slope = -3.2. An example of a typical generated standard curve 
is shown in Figure 2.6. The computer software then compares the sample quantities on the 
telomere plate with their counterparts on the 36B4 plate to give a T/S ratio, which is then 
normalised to the T/S of the reference DNA sample to give a relative T/S or telomere 
length for each DNA sample under investigation.  
 
The intra-assay co-efficient of variation (CV) for the telomere plates was 0.43% and 0.15% 
for the 36B4 plates. The intra-assay CV was 17%. 
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Figure 2.6: Shows the software generated standard curve. x-axis displays the logarithmic 
transformation of the individual standard concentrations. y-axis displays the crossing point 
which is analogous to the Ct and is the threshold cycle at which amplification products are 
first detected. The slope for this curve is -3.147. 
 
  
 
2.3.3 Correlates of PBL Telomere Length 
 
2.3.3.1 Measurement of Plasma Fetuin-A 
Fetuin-A concentrations were measured from the plasma of blood samples of CRC PBL 
patients using a commercial Human Fetuin-A ELISA Kit (BioVendor R&D, Czech 
Republic). Fetuin-A was not measured in either the CRC tissue group or the control 
population. Samples were measured in triplicate. Absorbance of each sample was read by a 
microplate reader at dual wavelengths 405nm and 650nm, and sample concentrations were 
then calculated using the standard curve. All methodologies were carried out according to 
the manufacturer’s instructions. The minimum detectable concentration was 0.35ng/ml. 
 
2.3.3.2 Measurement of Markers of Systemic Inflammation 
Systemic inflammation is known to predict poor outcome from colorectal cancer and is 
also intricately linked with aspects of biological ageing, in particular telomere attrition. For 
the CRC PBL and tumour patients, routinely available indices of inflammation (CRP, 
albumin, white cell, neutrophil and lymphocyte count) were measured using routine 
methods in the Departments of Haematology and Biochemistry, Glasgow Royal Infirmary. 
For the CRC PBL patients only plasma concentrations of interleukin (IL)-6, IL-10 and 
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vascular endothelial growth factor (VEGF) were measured using enzyme linked 
immunosorbent assay (ELISA) kits (Quantikine ELISA, R&D Systems, Huntingdon, UK). 
The minimum detectable concentrations were 2 pg/ml for IL-6, 4pg/ml for IL-10 and 
5pg/ml for VEGF (these analyses were performed by Fiona Breckenridge, Dept of 
Biochemistry, Glasgow Royal Infirmary). The neutrophil to lymphocyte ratio (NLR) and 
modified Glasgow Prognostic Score (mGPS) was calculated for each patient thereby 
giving an estimation of systemic inflammation. mGPS is calculated by awarding a point for 
plasma albumin level under 35 mg/dl and C- Reactive Protein (CRP) under 10 mg/l 
thereby giving a score of 0,1 or 2. A score of 1 or 2 indicates higher levels of systemic 
inflammation and has been shown in numerous cancer types to correlate with poor cancer 
specific survival (Roxburgh& McMillan 2010).  
2.3.3.3 Measurement of Redox Control Factors  
The separated plasma from each blood sample was used to create a redox profile for each 
CRC PBL patient. Concentrations of antioxidant vitamins A (retinol) and E (α-tocopherol) 
and the carotenoids (lutein, lycopene, α- and β-carotene) were determined using a high 
performance liquid chromatography (HPLC) based assay as previously described (Talwar 
et al, 1998). Plasma was de-proteinised with alcohol containing internal standards and 
extraction of the analytes was performed using hexane. Analysis was carried out using 
reversed phase–HPLC (5 µm microbore, Phenomenex, Macclesfield, UK) and dual 
wavelength monitoring (Waters, MA). The 95% normal reference intervals for the above 
assays as established in our laboratory were as follows: retinol (1.0-2.8 µmol/l), α-
tocopherol (14-39 µmol/l), lutein (82-202 µg/l), lycopene (100-300 µg/l), α-carotene (14-
60 µg/l) and β-carotene (92-312 µg/l). These analyses were performed in the laboratory of 
Dr Dhinesh Talwar, Department of Biochemistry, Glasgow Royal Infirmary.  
2.3.3.4 Measurement of Vitamin D 
Plasma Vitamin D (25-OHD) concentration was measured from collected and separated 
samples using an automated solid phase extraction procedure with subsequent HPLC- mass 
spectrometry technique. The lower limit of sensitivity was 4 nmol/L (assay performed in 
the laboratory of Dr Dhinesh Talwar, Department of Biochemistry, Glasgow Royal 
Infirmary.   
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2.3.4 Statistical Analysis 
All clinical, pathological and biochemical data were displayed either categorically or as 
median with inter-quartile range (IQR). TL was analysed as both a continuous and 
categorical variable by sub-division into quartiles. Pearsons correlations were performed to 
establish any relationships between the various parameters. Comparison between groups of 
continuous variables was achieved using the Mann-Whitney or Wilcoxon Signed Rank test 
and categorical variables by chi-square analysis. TL was corrected for age and sex using 
analysis of covariance analysis. All analyses were performed using SPSS version 15 (SPSS 
Inc, Chicago, Illinois).   
 
 
 
2.4 Sirtuin Relative Expression in Colorectal Cancer Tumour & 
Normal Tissue 
 
2.4.1 Tissue Processing & RNA Extraction 
Specimens were crushed using a mortar and pestle under liquid nitrogen. The resulting 
tissue powder was then used for RNA extraction which was performed using TRIzol® (Life 
Technologies) following the manufacturers guidelines; briefly, 50mg of tissue was 
homogenised in 1ml of TRIzol then incubated for 5 minutes at room temperature. Phase 
separation was achieved using 200µl of chloroform per 1ml of TRIzol and incubation for 
2-3 minutes at room temperature. Samples were then centrifuged (12000g) for 15 minutes 
at 4oC. The resulting RNA containing aqueous phase was transferred to a fresh tube and 
the RNA precipitated with 500µl of isopropanol. The samples were then rested for 15 
minutes at room temperature and subsequently centrifuged for 10 minutes at 4oC and 
12000g. The supernatant was then removed and the RNA pellet suspended in 1ml of 75% 
ethanol, this was then further centrifuged for 5 minutes at 40C and 7500g.  The supernatant 
was removed and the resulting RNA pellet air dried. The RNA pellet was dissolved in 30-
100µl of RNA/DNA free H20 and incubated for 10 minutes in a heatblock at 57oC.  The 
RNA concentration and purity of the resulting solution were estimated using the Nanodrop 
spectrophotometer (Thermo Fisher Scientific, MA, USA). Validation of the RNA was 
achieved by 1% TBE containing agarose gel electrophoresis. Ethidium bromide 0.5µg/ml 
and a UV lightbox were used to achieve visualisation (Figure 2.7). 
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Figure 2.7: Extracted RNA (500ng) from tumour and adjacent colorectal cancer sample run on 1% 
agarose gel (100V for 90 minutes). Prominent and intact 18S and 28S bands represent 
ribosomal RNA the presence of which validates the RNA extraction process and sample 
integrity. 
 
2.4.2 DNAse Treatment 
All traces of contaminating DNA was removed from the RNA samples using a 
commercially available DNA-Free Kit (Ambion, UK) performed following the 
manufacturer’s instructions.  
 
2.4.3 cDNA Synthesis 
cDNA for use in the q-PCR assay was synthesised from the extracted RNA by reverse 
transcription using 2µg of DNase treated RNA. The Superscript First-strand Synthesis 
System for reverse transcriptase PCR (Invitrogen, UK) was utilised to achieve full length 
cDNA. Briefly, an RNA/primer mix containing hexamer 50ng/µl, 10mM dNTP, RNA 2µg 
was made up to a total volume of 12µl with H2O. This was then incubated at 65oC for 5 
minutes followed by 1 minute on ice. 5X first strand buffer, 0.1M DTT and 1µl RNAase 
out were then added and incubated at 25oC for 2 minutes. The SuperScript II reverse 
18S 
28S 
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transcriptase enzyme was then added and incubated at 25oC for 10 minutes, 42oC for 50 
minutes and the reaction finally terminated at 75oC for 15 minutes. A parallel reaction 
without the reverse transcriptase enzyme was used as a negative control. The reaction was 
completed with RNase H (1µl) and incubated at 37oC for 20 minutes. These samples were 
then stored at -20oC if not used immediately. 
2.4.3.1 Validation of the cDNA Product 
A validation reaction was performed to ensure cDNA of sufficient quality had been 
synthesised during the previous step. This was achieved using a non-quantitative reverse 
transcriptase PCR reaction using the β-actin housekeeping gene (Appendix 1), this step 
was performed on both the tissue sample under investigation and corresponding negative 
control. The reaction mixture was composed of:  
• cDNA (12.5ng), forward and reverse primers (400nm), magnesium poor 10X PCR 
buffer, 10mM dNTP, 50mM MgCl2, Taq DNA polymerase (5U/μl) and nuclease 
free water to a total volume of 50μl.  
The reaction was run using the DNA Engine thermocycler PTC-200 (BioRad) under the 
following conditions:   
• 94oC for 3mins, followed by 30 cycles of 94oC for 45 seconds (denaturing), 61oC 
for 30 seconds (annealing), 72oC for 1 minute 30 seconds (extension) and a final 
extension step of 10 minutes at 72oC. 
The resulting reaction products were then analysed using 1% agarose gel electrophoresis 
with samples taken on for use in the RT-PCR step if they displayed the β-actin band at 
350bp and the corresponding negative control did not show any amplification which would 
otherwise indicate contamination of the samples (Figure 2.8).  
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Figure 2.8: 1% TBE agarose gel showing the product of the cDNA synthesis step and subsequent 
validation by β-actin reverse transcriptase PCR. Each lane represents a tissue sample with 
corresponding negative control. 
 
2.4.4 Real-time polymerase chain reaction (PCR) 
Quantitative RT-PCR was performed to estimate the mRNA expression patterns for 
SIRT1-7 using the Applied Biosystems 7500 Fast RealTime PCR System (Life 
Technologies Corporation, CA).  
2.4.4.1 Endogenous Reference Gene & Quantification of Gene Expression 
Quantification of the sirtuin relative expression in the tumour and normal samples was 
performed using the 2-∆∆Ct method, otherwise known as the comparative Ct method (as 
opposed to the standard curve method used for TL determination). This uses an 
endogenous reference or housekeeping gene in comparison with the target gene, with a 
final comparison with a normal sample or no template control. In this study the enzyme 
hypoxanthine ribosyltransferase (HPRT) was used as the endogenous reference gene. This 
gene had been validated as the reference gene in previous work from our laboratory. 
Briefly, to be utilised in the experiment the amplification efficiencies between the 
housekeeping gene and target gene must be approximately equal. This is investigated 
experimentally by serially diluting the target sample and recording the ΔCtsample, the ΔCt is 
plotted against the log of the template concentration with a slope of 0 indicating equal 
efficiency (Zino 2010). HPRT has been further validated in an independent study aiming to 
100 
 
determine the best candidate for use as the endogenous control in RT-PCR experiments 
using CRC tissue (de Kok et al, 2005).  
2.4.4.2 Taqman Primer & Probe Validation  
As mentioned in the description of the main steps involved in the real-time PCR reaction, a 
specific TaqMan® primer-probe set which contain the conjugated quencher and reporter 
tags are required to allow fluorescence detection and subsequent quantification. The 
sequence of each of the seven SIRT gene forward primer, reverse primer and TaqMan® 
probe are outlined in Appendix 1. The SIRT4, SIRT5 and SIRT6 primer-probe sets used in 
the RT-PCR experiment were pre-designed and validated by the company of purchase 
(Applied Biosystems, UK. Manufacturers code- SIRT4 HS00202033_m1, SIRT5 
HS00229729_m1 & SIRT6 HS00213036_m1). The SIRT1, SIRT2, SIRT3. SIRT7 and 
HPRT primer-probe sets were designed and validated by Mr Samer Zino during the course 
of previous sirtuin research performed in the host laboratory. These were designed using 
the Primer Express software programme (Applied Biosystems, UK). From these 
experiments concentrations of 900nM forward and 900nM reverse were deemed optimal 
for SIRT1, SIRT2, SIRT3 and HPRT with 300nM forward and 900nM reverse for SIRT7. 
A probe concentration of 225nM was the most efficient for all five genes (Zino 2010). 
2.4.4.3 Reaction Conditions 
Real time PCR was performed in 96-well plates using a 25µl reaction. An individual 
master mix solution was prepared for each gene and to reduce error samples were analysed 
in batches (Table 2.4).  
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Table 2.4: Table displaying the constituents for the individual master mix used for each sirtuin and 
endogenous reference gene analysis experiment. 
 
Master mix for SIRT1-SIRT3, 
SIRT7 and HPRT 
Volume 
(µl) 
Master mix for SIRT4, SIRT5 & 
SIRT6 
Volume 
(µl) 
ABI 2X TaqMan® master mix 12.5 ABI 2X TaqMan® master mix 12.5 
Forward primer 1.5 Primer mix 1.25 
Reverse primer 1.5 Template (6.25ng/µl) 8 
Probe 1 PCR grade water 3.25 
Template (6.25ng/µl) 8   
PCR grade water 0.5   
Total 25 Total 25 
 
Primer-probe concentrations for SIRT1-3, SIRT7 and HPRT used were as outlined above. 
The volume of pre-manufactured primer mix (SIRT4-6) was used to give a final 
concentration of forward 900nM and reverse 900nM. 
Cycle conditions for real-time quantitative PCR were 50oC for 2min, 95oC for 10min 
followed by 50 cycles of 95oC for 15s and 60oC for 1min.  
Configuration of the software on the ABI Fast 7500 thermocycler allowed relative 
quantification calculations to be performed for each gene in comparison with the HPRT 
endogenous reference with a normal sample as control. No template and no amplitude 
controls were also included in batch sample runs for validation purposes. Relative 
quantification values were the taken forward for analyses with patient variables. 
2.4.5 Statistical Analysis 
Relative expression levels are expressed as median and IQR or 95% confidence interval 
where appropriate. Differences in expression between the tissue groups were determined 
using the Mann-Whitney or Wilcoxon Signed Rank test where appropriate. Sirtuin 
expression levels were correlated with clinico-pathological characteristics as a continuous 
variable using Pearsons correlation analysis and categorical variable using chi-square, 
Mann-Whitney or Kruskal-Wallis where appropriate. Bonferroni correction was used in 
the analysis of inter-relationships between individual sirtuins. Determination of a 
relationship with survival was performed using Kaplan-Meier and log rank analysis. All 
analyses were performed using SPSS version 15.0 (Chicago, Illinois, USA).  
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CHAPTER 3:  TELOMERE LENGTH AND COLORECTAL CANCER 
3.1 Introduction 
Colorectal cancer (CRC) is the third most common cancer in the UK and is responsible for 
approximately 16,000 deaths every year. Increasing chronological age is a risk factor for 
many types of cancer including colorectal, with eighty percent of CRC cases occurring in 
patients over the age of sixty (Cancer Research UK 2010). Consequently, an understanding 
of the biology of ageing may provide insight into cancer pathogenesis (Lamb & Shiels 
2009). Biological ageing comprises ageing at the cellular and organ level and is affected by 
genetic, metabolic and environmental factors. Fully delineating the key molecular 
mechanisms underpinning both the biological ageing and cancer processes could improve 
the understanding of the disease process and lead to the discovery of novel biomarkers or 
targets for therapeutic intervention, further improving survival rates. 
A key manifestation of ageing at the cellular level is telomere attrition. Telomeres are 
nucleoprotein structures located at the ends of all eukaryotic chromosomes and are 
composed of a repetitive guanine-rich DNA sequence (TTAGGG)n (Moyzis et al, 1988). 
They possess a number of critical functions including maintenance of genomic integrity by 
protecting chromosomes from fusion events, repair of DNA damage and maintenance of 
cellular stability (Lamb & Shiels 2009). Telomere attrition is associated with increasing 
chronological age and furthermore may act as a biomarker of replicative ageing, or mitotic 
clock (Harley et al, 1990). Once this progressive loss of telomeric DNA content reaches a 
critical level, cells are stimulated to either apoptose, or enter replicative senescence 
(Hayflick & Moorhead 1961).  
Evidence is accumulating that telomere attrition and senescence are contributory factors in 
a range of age related disease processes including cancer (Blasco 2005), cardiovascular 
disease (Brouilette et al, 2007), chronic kidney disease (Carrero et al, 2008) and 
pulmonary disease (Savale et al, 2009). Furthermore, critically short telomeres have been 
linked with life stress (Epel et al, 2004, Shiels et al, 2011) and an overall increased 
likelihood of mortality (Cawthon et al, 2003). In essence, telomere attrition in PBLs 
reflects ‘miles on the clock’ and a corresponding increased likelihood of disease and 
mortality. The body of work aimed at delineating the relationship between critical telomere 
attrition and the cancer process is rapidly expanding. Short telomeres in peripheral blood 
leucocytes (PBL) have been shown to be associated with an increased risk in a variety of 
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solid tumours (Wu et al, 2003, Jang et al, 2008, Hou et al, 2009, Mirabello et al, 2010). 
However, results of recent studies from the same laboratory have indicated an increased 
risk of breast and renal cell carcinoma with increased and not decreased TL (Svenson et al, 
2008, Svenson et al, 2009, Svenson& Roos 2009). These results are counter-intuitive and 
are divergent from the majority of pertinent work in the area.  
Chapter Aims 
• To test the hypothesis that patients with colorectal cancer display evidence of 
accelerated biological ageing in the form of telomere attrition when compared with 
healthy controls.  
• By determining telomere length in PBL, tumour tissue and normal colonic tissue 
we aim to provide key information on telomere dynamics in each of these 
important cell compartments.  
• Correlate PBL and tissue telomere length with clinical and pathological outcomes 
to determine whether telomere length could prove useful as a prognostic tool. 
 
3.2 Results 
3.2.1 Analysis of telomere lengths in PBLs of CRC patients and healthy                
controls 
 
Sixty-four (64) patients were available for analysis in the CRC PBL patient group (mean 
age = 68 ± 10.8). These were compared with one thousand three hundred and forty eight 
(1348) West of Scotland control subjects (no diagnosed cancer), aged approximately 57 
(n=847, male 46%, female 54%) and 76 (n=501, male 42%, female 58%) years old (mean 
age = 64 ± 9.24). As expected there was a significant negative association between 
chronological age and TL in the healthy controls (Pearson r=-0.215, p<0.001). Likewise a 
significant negative relationship was observed between chronological age and PBL 
telomere length in the CRC group (Pearson r=-0.257, p=0.04, Figure 3.1A), indicating that 
as patient age increased, TL decreased. Although this negative association was maintained 
when the CRC PBL group was split according to sex (Figure 3.1B), the relationship did not 
104 
 
reach significance in either males (Pearson r=-2.43, p=0.123) or females (Pearson r=-2.47, 
p=0.187). This age-related telomere attrition demonstrates the association between 
chronological and biological ageing. 
 
 
 
 
 
 
Figure 3.1: (A) Scatter plot displaying the significant negative correlation between relative T/S and 
chronological age in the CRC PBL group (Pearson r=-0.257, p=0.04). (B) Similar scatter 
plot with CRC PBL group split according to sex, relationship not significant. Trend line 
identical for male and female. 
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Patients had consistently shorter telomeres than the control population (p<0.001) (Figure 
3.2), indicating that the CRC patients were of increased biological age. Since the median 
age of the control population was greater than that of the CRC group, analyses were 
performed correcting for both age and gender. After correction of TL for age and gender, 
colorectal cancer patients still had consistently shorter telomeres (adjusted mean 
RelT/S=0.66±0.02(se)) compared with those in the control group (adjusted mean 
RelT/S=0.75±0.005(se), p<0.001), indicating that the colorectal cancer patients were of 
increased biological age. To further validate that the cancer patients were more 
biologically aged, we compared them to a sub-group of the control population, those 
individuals aged 76yrs.  Analysis of covariance revealed that despite being on average 
chronologically younger, the cancer group had significantly shorter telomeres (adjusted 
mean RelT/S=0.61±0.03(se)) than the control population (adjusted mean 
RelT/S=0.70±0.01(se)) and hence were more biologically aged (p=0.004). The median 
duration of diagnosis in the CRC PBL group (defined as the date of positive tissue 
diagnosis until date of sample collection) was 42 (6-185) days. Analysis did not reveal any 
association between duration of diagnosis and TL.  
 
 
 
Figure 3.2: Measurement of PBL telomeres from a control and colorectal cancer (CRC) population 
revealed that the CRC patients had significantly shorter telomeres (Mean telomere length ± 
standard error (Rel T/S 0.66 ± 0.02) than the control population ((0.75 ± 0.05) p<0.001). 
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3.2.2 Clinico-pathological Correlation with CRC PBL Telomere Length  
 
No associations, other than chronological age were observed between PBL telomere length 
and the various clinico-pathological parameters when analysed using the continuous 
variable. Consequently, patients were categorised into those with short telomeres (Relative 
T/S < 0.55, shortest quartile) and those with long telomeres (Relative T/S > 0.55). Short 
TL was significantly positively associated with high risk pathological features indicated by 
a high risk Peterson Index (chi square, P=0.035). However, no significant relationship was 
identified between tumour site, Dukes stage, and any other clinico-pathological 
characteristic measured.  
 
3.1.2.3 Socio-Economic Correlation with Telomere Length 
 
The Carstairs index was used to stratify the patients in the CRC PBL group according to 
levels of socio-economic deprivation. This system uses four variables; overcrowding, male 
unemployment, low social class and lack of motor vehicle to compose an overall score for 
a postcode sector. Every postcode sector in Scotland is therefore assigned a score ranging 
from 1 (least deprived) to 7 (most deprived) (Carstairs& Morris 1989). The distribution of 
Carstairs index scores in this group of patients is outlined in (Table 2.1). There is a clear 
preponderance of patients from areas of socio-economic deprivation with 43.75% residing 
in areas with a Carstairs Index of 7. There was no apparent significant relationship 
demonstrated between levels of socio-economic deprivation and TL, in this group of 
patients (Figure 3.3). However, this study is not correctly designed or powered to tease out 
relationships between TL and population variables such as deprivation, this will be 
addressed in due course. 
 
 
107 
 
 
Figure 3.3: Bar chart displaying telomere length stratified according to the Carstairs Index of 
deprivation. There was no significant relationship between telomere length and the 
different levels of deprivation score (error bars ± 95% confidence interval) 
 
 
 
3.1.2.4 Comparison of telomere length in colorectal tumour tissue and 
normal adjacent tissue 
 
The relative T/S ratio of 32 matched colorectal tumour tissue and adjacent normal mucosa 
samples was compared to determine whether a difference in biological age was apparent 
between tissue types. Telomere length in the tumour tissue (median=0.43, IQR=0.40) was 
found to be significantly shorter than in the adjacent normal tissue (median=0.65, 
IQR=0.28) (p=0.004, Figure 3.4). Additionally, a comparison was made between the TL 
from the three tissue sources. There was no significant difference in TL between the CRC 
PBL group and that from the normal CRC tissue group (Figure 3.5).  
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Figure 3.4: Box plot highlighting the difference in telomere lengths between thirty two matched 
tumour and adjacent normal tissue samples of colorectal cancer patients. Tumour tissue 
(median Rel T/S = 0.43) displayed significantly shorter telomeres than normal tissue 
samples (median Rel T/S = 0.65, Wilcoxon signed rank test, p=0.004).  
 
 
 
Figure 3.5: Box plot displaying the difference between the difference telomere length between the PBL 
and tissue group. No significant difference between the TL in PBL and normal tissue. TL 
in CRC tumour tissue significantly shorter than TL in CRC PBL (Mann-Whitney, 
p=0.003). 
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3.1.2.5 Clinico-pathological Correlation with Tissue Telomere Length  
Analysis of TL from both CRC tissue and normal adjacent mucosa as a continuous or 
categorical variable did not reveal any significant associations with the clinic-pathological 
variables outlined in Table 2.1. Of particular note and in contrary to the relationship seen 
in the CRC PBL group there was no association between CRC tissue TL with 
chronological age, nor any sex difference. Although there was no significant association 
with any pathological variables there was an interesting trend in TL with Dukes stage 
where TL decreased progressively from Dukes’ A to C then increased in Dukes D patients 
(Figure 3.6A). There was no significant difference between CRC tissue TL according to 
tumour site, with median rectal relative T/S 0.33 (±0.79) compared with colonic relative 
T/S 0.42 (±0.93), p = 0.412 (Figure 3.6B).  
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Figure 3.6: (A) Box plot displaying TL in CRC tissue samples in relation to Dukes stage. No 
significant relationship demonstrated. Dukes A- Tumour limited to muscularis propria, 
Dukes B- local spread beyond muscularis propria, Dukes C- nodal spread, Dukes D- 
Distant metastasis (B) Box plot displaying non-significant difference between colonic and 
rectal tissue telomere length (p=.412) 
 
3.3 Discussion 
 
3.3.1 Patients with CRC display evidence of accelerated biological ageing 
 
This study demonstrates that patients with colorectal cancer display clear evidence of 
accelerated biological ageing in the form of telomere attrition when compared with healthy 
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control subjects (Maxwell et al, 2011). The relationship between TL and CRC risk is 
proving to be a difficult one to fully delineate but highlights the inter-individual variation 
in both biological ageing and the effect of potential confounders. Demonstration of 
telomere attrition in the PBLs of CRC cancer patients is similar to that reported by Pooley 
et al (2010) in both retro- and prospectively recruited patients (Pooley et al, 2010). These 
data contradict two studies of both male and female CRC patients where no relationship 
between CRC and TL was identified (Lee et al, 2010, Zee et al, 2009).  
 
The intricacies of the relationship between TL and CRC are highlighted in a recent study 
by Jones et al (2011). The authors report a significant association between a SNP at the 
TERC locus, long telomeres and increased CRC risk. The supposition from this data is that 
longer telomeres predispose to CRC cancer, potentially resulting from an increased 
replicative capacity of cells with longer telomeres and hence more chance of acquiring 
tumour-causing mutations.  However, in the same study the authors report that TL in PBLs 
from CRC patients is shorter than control subjects. This relationship was determined using 
DNA from patients enrolled in three different trials involving varying aspects of CRC 
management. The authors use these differences in populations as an explanation of the 
seemingly paradoxical results within this study (Jones et al, 2011). Prevalent studies 
investigating a number of other cancer entities including gastric (Hou et al, 2009), bladder 
(Wu et al, 2003), ovarian (Mirabello et al, 2010) and lung (Jang et al, 2008) are, however, 
in concordance with our observations.   
 
Clearly some heterogeneity exists between studies attempting to determine the relationship 
between TL and varying types of cancer. In order to eliminate some of this heterogeneity 
between studies and increase the sample size under investigation Ma et al (2011) have 
recently reported a meta-analysis, which provides perhaps the most compelling evidence 
for an association between cancer risk and shortened PBL TL. The authors amalgamated 
previously published data thereby producing a study population for investigation which 
contained 11,255 cases and 13,101 controls. They report that shorter telomeres were 
significantly associated with some individual cancers for example bladder and lung, and 
also grouped cancers such as those of the gastrointestinal tract and urogenital system (Ma 
et al, 2011). Another recent meta-analysis has confirmed this association of short TL with 
overall cancer risk in retrospective analyses (Wentzensen et al, 2011). Prospective as 
opposed to retrospective studies have the advantage that they are less open to observer bias 
and other potentially confounding factors. The results of these studies are again 
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heterogeneous. Most recently Willeit et al (2011) have reported long-term follow up of a 
random sample of 1000 persons aged 40-79 years. TL was measured at two time points and 
cancer incidence recorded over a 15 year period. The authors report a change in TL over 
time with short telomeres associated with an increased cancer risk and mortality from 
cancer. This study corroborates previously reported 10 year follow up data from the same 
authors (Willeit et al, 2010, Willeit et al, 2011). However, meta-analysis of prospective 
studies has not revealed any significant association between short TL and over-all cancer 
risk (Wentzensen et al, 2011).  Analysis of prospective longitudinal studies must be done 
with caution as they, depending on the design, cannot look at the relative rate of change 
compared with a baseline (birth) TL. Thus any change may be a regression to the mean and 
not a true reflection of TL change over a lifetime.   
 
The original hypothesis of this study was to determine if patients with CRC display 
evidence of accelerated biological ageing. The significant difference in TL between the 
PBL CRC and control group indicates advanced biological age in the CRC group and 
supports the original hypothesis. This is exemplified by the fact that when the analyses 
were corrected for age the significant difference in TL remained, meaning that although the 
two groups were similar in chronological age the cancer patients displayed evidence of 
accelerated biological ageing. The possibility exists that accelerated ageing arises as a 
consequence of the disease process (Svenson & Roos 2009). Possible reasons for this 
include the fact that the cancer process is well known to induce a pro-oxidative and 
systemic inflammatory state (Leung et al, 2008). If this were the case then it would be 
expected that TL would continue to shorten the longer the disease progressed. Longer 
telomeres closer to diagnosis have been demonstrated in CRC patients previously (Jones et 
al, 2011). However, our analysis refutes this, as there was no relationship between TL and 
the duration of the disease prior to sample collection. It may be that our median duration of 
42 days between diagnosis and sample collection is not sufficient to observe any effect 
elicited by the disease process. This could only be resolved by making serial measurements 
of TL throughout the course of the disease, but this is almost certainly an impossible aim 
as treatment of the tumour either with palliative or curative intent could confound results. 
It would also be of interest to monitor the effect of curative resection of the tumour, if the 
disease process is the driver of telomere attrition then this should be attenuated when the 
tumour is removed.   
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Although analysis did not reveal any association between socio-economic deprivation and 
TL in our group, recent evidence has suggested such a link exists in a population with 
similar demographics and spectrum of socio-economic deprivation (Shiels et al, 2011). In 
this study lower socio-economic class and poor diet contributed to accelerated biological 
ageing, represented by telomere attrition. Furthermore, there was a potential association 
with the pro-inflammatory cytokine IL-6. This study provides evidence supporting the link 
between social deprivation and a biological explanation of the excess disease burden, 
including cancer seen in this population. It is likely that the number of participants in the 
current study prohibited determination of any association between socio-economic 
deprivation and altered telomere dynamics.  
 
Our analysis suggests that the cancer patients with the shortest PBL telomeres have 
pathologically more severe disease as indicated by a higher Peterson Index. This is an 
intriguing observation as it indicates that systemic telomere biology could not only affect 
the risk of CRC but also the pathological outcome. It is, therefore relevant that there is no 
significant difference in TL between PBL and normal colonic tissue comparing our two 
sample groups (Figure 3.2). It should be borne in mind that this comparison is not direct 
i.e. the blood sample and colonic tissue sample were not from the same patient. The groups 
are, however, comparable in terms of demographics and pathology. No study has ever 
reported on the compartmental telomere dynamics in cancer patients. Clearly, direct 
comparison would need to be made before firm conclusions could be drawn but PBL TL 
could prove useful as a surrogate marker of pathological aggressiveness and could allow 
risk stratification prior to commencement of specific treatment algorithms.   
 
As outlined in the introduction to this thesis telomeres have been shown to be critical 
mediators of genomic integrity with telomere attrition associated with major chromosomal 
abnormalities. One of the key concepts in the process of genomic instability induced by 
dysfunctional telomeres is that of crisis. This is a period of rampant genomic instability 
and cell death which is driven by continued telomere erosion and uncapping in cells 
deficient in p53/pRB. Mutation of p53 is critical, as up-regulation of wild type p53 would 
in normal circumstances facilitate senescence and prevent ongoing proliferation. It is 
therefore pertinent that 50-75% of colorectal cancers express some form of deleterious 
mutation of p53 (Pino & Chung 2010). Clearly this state of crisis is not compatible with 
the enhanced proliferative capacity of neoplastic cells. However, neoplastic cells almost 
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universally adopt telomere maintenance programmes (either re-activation of telomerase or 
ALT) which stabilise telomeres and allow continuing replication. Replication proceeds in 
the context of a permissive mutated genome which is reflected in the chromosomal 
aberrations typical of many human cancers including colorectal (Counter et al, 1992, 
Raynaud et al, 2008, Deng et al, 2008). This permissive mutated genome could explain the 
step-wise mutational model of colorectal carcinogenesis proposed by (Fearon& Vogelstein 
1990). Whereby, the process of carcinogenesis is initiated by mutation of the APC tumour 
suppressor gene, followed by activating mutation of KRAS and subsequent mutation of 
p53, TGF-β and PIK3CA. It is this sequence of mutations which drives the adenoma-
carcinoma sequence of events in colorectal carcinogenesis (Leslie et al, 2002).  
3.3.2 Tissue telomere dynamics in colorectal cancer 
 
In concordance with previous studies we have confirmed that TL in CRC tissue is 
significantly shorter than normal adjacent colorectal mucosa (Hastie et al, 1990, Rosenberg 
et al, 2003, Gertler et al, 2004, Rampazzo et al, 2010). One might expect that given 
telomerase activity in neoplastic cells, including those of a colorectal origin, TL would be 
elongated in representative neoplastic tissue. However, our data suggest the opposite, 
meaning telomerase must maintain telomeric DNA content at a level consistent with a high 
rate of cell proliferation. This avoids the initiation of senescence or apoptosis which would 
otherwise mean exit from the cell cycle, and prohibit the rapid proliferation of neoplastic 
cells. These cells can therefore continue to divide but do so with requisite maintenance of 
TL. Telomerase is reactivated in colorectal cancer. Activation has also been shown to 
reflect progression through the adenoma-carcinoma sequence. Yan et al (1999) have 
demonstrated that telomerase activity was significantly associated with the progression of 
adenomatous polyps from low to high grade, with activation universally demonstrated in 
all carcinoma specimens investigated (Yan et al, 1999). Studies have attempted to correlate 
TL with the various stages of adenoma-carcinoma sequence of CRC development. TL in 
epithelial cells at the earliest morphological definable stage of carcinoma (high grade 
dysplasia with minimal invasive growth) was shorter compared with surrounding adenoma, 
indicating that cancers arise from cells with critically short telomeres within the adenoma 
(Plentz et al, 2003).  
In this study there was no significant correlation of CRC tissue TL with any of the clinico-
pathological parameters in Table 2.1. However, as shown in Figure 3.6 TL appears to be 
longer in patients with more advanced disease (Dukes D). Although not statistically 
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significant this is pertinent as longer TL in more advanced disease is a recurring finding in 
analysis of tissue specimens of CRC. Both Gertler et al (2004) and Garcia-Aranda et al 
(2006) report that tissue TL is shorter in cancer specimens when compared with adjacent 
normal tissue. They also both report a significant association between longer carcinoma 
TL, more advanced disease (Dukes C and D) and poor prognosis (Gertler et al, 2004, 
Garcia-Aranda et al, 2006). Increased telomerase expression in CRC tissue samples has 
also been shown to correlate with poorer prognosis (Tatsumoto et al, 2000) and more 
aggressive disease (Simsek et al, 2010). It is therefore postulated that telomere attrition and 
subsequent chromosomal instability is required for the progression from dysplasia to 
neoplasia. But, upregulation of telomere maintenance mechanisms such as telomerase 
confers a proliferative advantage which is reflected in the association between longer TL, 
high telomerase expression levels and poor prognosis in CRC. Whilst we noted similar 
findings to those previously reported these were not significant and it may be that 
increasing the power of our study could replicate these significant recurring findings of 
increased TL with more advanced disease. 
As expected we have demonstrated that patients with CRC display evidence of accelerated 
biological ageing and that telomere dynamics in different tissue compartments in these 
patients are altered. As already mentioned the mechanisms controlling TL are only partly 
understood. We therefore attempted to correlate our TL measurements with factors 
involved in the control of the redox state and systemic inflammation, both known to impact 
on TL at a number of levels. 
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CHAPTER 4: CORRELATES OF TELOMERE LENGTH IN 
COLORECTAL CANCER 
4.1 Introduction 
 
Telomeres not only potentially serve as biomarkers of senescence and biological ageing, 
but also form part of a damage sensing and signalling system, facilitating DNA repair or 
apoptosis (Misri et al, 2008). Potential determinants of TL are varied. Telomere length is 
highly heritable therefore a proportion is genetically determined (Slagboom et al, 1994). 
Alteration in the expression of telomerase, can significantly affect telomere dynamics. In 
mice, knock out of the telomerase coding sequence resulted in progressive loss of 
telomeric DNA and progeria (Blasco et al, 1997). Reintroduction of telomerase reversed 
both these effects (Samper et al, 2001). A major influence on TL and hence telomere 
function is the control of redox state and potential damage induced by reactive oxygen 
species (Saretzki & Von Zglinicki 2002, von Zglinicki 2002). Correlation of TL with genes 
controlling redox state in a narrow age range cohort provides further evidence for a 
plausible mechanistic link between redox control and telomere biology (Starr et al, 2008). 
Pertinent in this respect, is the observation that fetuin-A, a mediator of redox homeostasis 
in the circulation, displays a dependent relationship with PBL TL in patients with chronic 
kidney disease. (Carrero et al, 2008). Fetuin-A is a ubiquitous serum protein which plays a 
role in extra-cellular calcium metabolism by virtue of its ability to inhibit calcium-
phosphate precipitation and is an important inhibitor of extra-skeletal calcification, an 
effect important in patients with chronic kidney disease on dialysis (Westenfeld et al, 
2007). Furthermore fetuin-levels are down-regulated according to the acute phase 
inflammatory response in a manner similar to serum albumin, corresponding to an inverse 
relationship with C-reactive protein (CRP) and inflammatory cytokines (Dervisoglu et al, 
2008). In clinical terms the effects of fetuin-A are complex with both high and low levels 
predicting risk and outcome of ischaemic heart disease and stroke. These differences could 
result from the differing effects of fetuin-A not only on inflammation but also on adhesion 
molecule interaction (Weikert et al, 2008, Bilgir et al, 2010).  
 
 
Other factors known to generate potentially damaging reactive oxygen species includes 
altered antioxidant ratio, disordered calcium and other divalent cation homeostasis, and 
alteration of micronutrient status. In addition to damage induced by reactive oxygen 
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species, inflammation has been shown to play a determining role in experimental and 
population based models of telomere attrition (Carrero et al, 2008, Shiels et al, 2011). The 
overall effect of oxidative damage and systemic inflammation is reflected in the correlation 
between PBL TL and solid organ biological age. Indeed in their work in vascular disease 
Wilson et al (2008) report that PBL TL is strongly correlated with vascular wall TL, thus 
indicating that PBL TL acts as a surrogate for vascular wall aging and supporting the 
notion that factors influencing TL do so at a systemic level (Wilson et al, 2008). 
Furthermore chronic systemic inflammation has a well characterised deleterious role in the 
development and progression of cancer, and in particular CRC (Roxburgh & McMillan 
2010).  
 
Chapter Aims 
 
• To assess whether PBL TL in CRC patients were reflected in markers of systemic 
inflammation including the mGPS, pro-inflammatory cytokines and common 
haematological indices of inflammation.  
 
• Delineate the relationship between PBL TL and factors known to exert control over 
redox state including antioxidant vitamins, factors involved in calcium homeostasis 
including circulating levels of fetuin-A and micronutrient status.  
 
• Further characterise the interplay between fetuin-A, inflammation and clinical 
parameters in our CRC patients. 
 
 
4.2 Results 
 
4.2.1 Correlation of CRC PBL telomere length and redox state 
 
4.1.2.1 No Association between Telomere Length and Antioxidant Vitamins 
or trace elements 
 
There was no significant association between TL as either a continuous or categorical 
variable, and anti-oxidant status as determined by correlation with serum levels of 
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antioxidant vitamins (retinol, α-tocopherol, lutein, lycopene, α-carotene and β-carotene)  
(Table 4.1). In addition, there was no correlation between TL and serum levels of the 
micronutrient trace elements; Mg2+, Fe2+, Cu2+, Zn2+ and Se2+ (Table 4.1). Furthermore, 
there was no correlation between any of the redox control factors and any clinico-
pathological parameters. 
 
 
Table 4.1: Table displaying relationship between CRC PBL telomere length with antioxidant vitamins 
and trace elements. 
 
Antioxidant Vitamins 
 Median (range)  Correlation with Telomere 
length‡ (p<0.05) 
 
Retinol 1.80 (0.7-3.70) µmol/L 1.67 (0.298) 
 α-tocopherol 26.5 (12.0-40.0) µmol/L 0.072 (0.652) 
Lutein  88.0 (21.0-607.0) µg/L 0.047 (0.772)  
Lycopene 83.0 (10.0-373.0) µg/L -0.006 (0.971) 
α-Carotene 15.5 (10.0-151.0) µg/L 0.178 (0.260) 
β-Carotene 65.5 (10.0-862.0) µg/L -0.174 (0.271) 
Micronutrient Trace Elements 
Magnesium (mmol/l) 0.82 (0.56-1.11) 0.009 (0.947) 
Iron (Fe2+, µmol/l) 20.2 (5.6-168.7) 0.067 (0.631) 
Copper (µmol/l) 19.4 (12.7-31.9) 0.132 (0.345) 
Zinc (µmol/l) 10.3 (6.6-14.1) 0.05 (0.721) 
Selenium (µmol/l) 0.84 (0.45-1.23) 0.143 (0.306) 
 
‡ Relationship displayed as Pearson correlation with telomere length as continuous variable (p<0.05). 
 
 
 
4.1.2.2 Relationship between CRC PBL telomere length and calcium 
homeostasis 
 
An attempt was made to determine any relationship between TL, plasma calcium 
concentration and factors involved in calcium homeostasis, namely vitamin D. When 
analysed as both categorical and continuous variables there was no relationship between 
TL and plasma calcium. Likewise there was no relationship between TL and vitamin D 
levels (n=26, Pearson r -0.75, p=0.715, Table 4.2).  
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Table 4.2: Table displaying the relationship between telomere length and elements associated with 
calcium homeostasis. Inter-relationship between Fetuin-A and elements of systemic 
inflammation. 
 
Calcium Homeostasis 
 Median (range) Correlation with telomere 
length (p<0.05) 
 
Fetuin-A 
 
*Age 
*Albumin 
*Calcium 
*IL-10 
*IL-6 
27.16 (14.71-67.27) ng/ml 
 
r= -0.32 
r= 0.28 
r= 0.30 
r= -0.21 
r= -0.483 
0.041† 
 
0.011 
0.03 
0.022 
0.061 
0.005 
Calcium 2.44 (2.31-2.61) mmol/L 0.072 (0.590)‡ 
Vitamin D 31.5 (11-111) nmol/L -0.75 (0.715)‡ 
 
†Patients with low fetuin-A (fetuin-A < log median=1.47/median=29.6) had significantly shorter telomeres (median T/S = 
0.6 Vs 0.72, Mann-Whitney).  
*Relationship with plasma log Fetuin-A concentration, displayed as Pearson correlation. 
‡ Relationship displayed as Pearson correlation with telomere length as continuous variable (p<0.05). 
 
 
 
 
4.2.2 Plasma levels of Fetuin-A are associated with chronological and 
biological age in colorectal cancer 
 
Fetuin-A concentration of plasma samples was measured to assess whether levels were 
associated with chronological and biological ageing within the CRC PBL group. A 
significant relationship was observed between fetuin-A concentration and the 
chronological age of subjects (Pearson r=-0.32, p=0.011, Figure 4.1A, Table 4.2), 
increasing chronological age was associated with decreasing fetuin-A concentration. There 
was no significant association between TL and fetuin-A. Therefore, further analysis of the 
relationship between fetuin-A concentration and TL was performed. Patients were 
categorised into two groups around the median plasma level giving a low fetuin-A level 
group (fetuin-A < log median=1.47/median=29.6) and a high fetuin-A level group (fetuin-
A > log median=1.47/median=29.6). Patients with low fetuin-A levels were shown to have 
significantly shorter telomeres (median RelT/S = 0.6) than those patients with high fetuin-
A levels (median RelT/S = 0.72) (Pearson r=0.3, p=0.019, Mann Whitney p=0.041, Table 
4.2), this relationship was maintained when the analysis was adjusted for age. Patients with 
low fetuin-A levels had significantly shorter telomeres (adjusted mean Rel T/S=0.59) in 
comparison to those patients with high fetuin-A levels (adjusted mean RelT/S =0.68, 
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p=0.047, Figure 4.1B). No difference in fetuin-A level was observed between males and 
females. 
 
 
 
 
Figure 4.1: Scatterplot (A) illustrating the significant negative correlation between patient 
chronological age and plasma fetuin-A level (pearson = -0.32, p=0.011). Boxplot (B) 
displaying  the association between plasma fetuin-A level and PBL telomere length in 
colorectal cancer patients. Patients with low levels of fetuin-A had significantly shorter 
telomeres when compared with those with higher Fetuin-A levels (Mann-Whitney, 
p=0.041). 
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4.2.2.1 Association between plasma Fetuin-A levels and patient clinico-
pathological parameters 
 
No association was apparent between fetuin-A concentration and tumour characteristics 
such as T-stage, lymph node involvement or Dukes stage, within the CRC PBL group. 
However, increasing concentrations of fetuin-A were significantly associated with 
increasing levels of albumin (Pearson r=0.28, p = 0.03) and calcium (Pearson r=0.30, 
p=0.022), but decreasing levels of IL-6 (Pearson r=-0.483, p=0.005) (Table 4.2, Figure 
4.2). A trend also existed between fetuin-A concentration and IL-10 (Pearson r=-0.21, 
p=0.061) (Table 4.2, Figure 4.2), whereby increasing concentrations of fetuin-A in patients 
was associated with decreasing levels of IL-10 (Figure 4.2).  
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Figure 4.2: Scatter plot displaying the relationship between  albumin (A), calcium (B), interleukin-10 
(C),  interleukin-6 (D) and log plasma fetuin-A concentration.  Both albumin 
(Pearson=0.28, p = 0.03) and calcium (Pearson=0.30, p=0.022) were significantly postively 
associated with fetuin-A concentration. Interleukin-6 displayed a significant negative 
association (Pearson=-0.483, p=0.005) and interleukin-10 a negative trend (Pearson=-0.21, 
p=0.061) . 
 
 
4.2.2.2 Tumour site is distinguishable by Fetuin-A and White Cell Count 
 
Patients in the CRC PBL group with rectal tumours (n=22) were associated with higher 
circulating concentrations of fetuin-A (log median=1.52/median=33.5), whereas those with 
colonic tumours (n=42) were associated with lower concentrations (log 
median=1.45/median=28.7) (p=0.045) (Figure 4.3a). Further comparison of the clinico-
pathological differences between colonic and rectal tumours showed that colonic tumours 
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were significantly associated with an increased white cell count (median=7.9) compared 
with rectal tumours (median=6.8) (p=0.011, Figure 4.3b). 
 
 
 
 
 
Figure 4.3: Differentiation of tumour site in the CRC PBL group using plasma fetuin-A (A) and white 
cell count (B). Patients with rectal cancers had significantly higher levels of fetuin-A 
(p=0.045) and a significantly lower white cell count (p=0.011) when compared with colon 
cancer patients. 
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4.2.3 Correlation of CRC PBL telomere length with markers of systemic 
inflammation 
 
TL was again analysed both as a continuous and categorical variable. Patients were 
categorised into those with short telomeres (RelT/S < 0.55, shortest quartile) and those 
with long telomeres (RelT/S > 0.55). No significant relationship was observed between TL 
and CRP, pro-inflammatory cytokines (IL-6, IL-10, VEGF) or mGPS as analysed as a 
continuous or categorical variable (Table 4.3).  
 
Table 4.3: Table displaying the relationship between CRC PBL telomere length and factors involved 
in systemic inflammation. 
 
Systemic Inflammation 
 Median (range)/ 
No Patients  
Correlation with Telomere 
Length (p<0.05) 
C-Reactive Protein 7.5 (0.40-95.0) mg/l 0.043 (0.743)‡ 
IL-6 6.5 (1.75-39.8) pg/ml -0.031 (0.814)‡ 
Il-10 11.2 (5.68-34.82) pg/ml -0.092 (0.490)‡ 
VEGF 84.75 (7.28-952.96) pg/ml 0.089 (0.503)‡ 
Neutrophil:Lymphocyte 
(NLR) 
 
0.32 (0.04-0.94) 
 
0.047¶ 
mGPS 
0 
1 
2 
 
42 (65.6%) 
13 (20.3%) 
9 (14.1%) 
 
NS 
NS 
NS 
 
 
‡ Relationship displayed as Pearson correlation with telomere length as continuous variable (p<0.05). 
¶Significant difference in NLR between short (Rel T/S <0.55, NLR 0.39 (IQR 0.90)) and long (Rel T/S >0.55, NLR 0.28 
(IQR 0.71)) telomere group (Mann-Whitney 0.047). 
 
 
 
However, there was a significant relationship between patients with short TL when 
analysed as a categorical variable and an elevated neutrophil:lymphocyte (NLR=0.39 (IQR 
0.90) Vs NLR=0.28 (IQR 0.71)) (Mann-Whitney, p=0.047, Figure 4.4, Table 4.3). Thus, 
indicating higher levels of systemic inflammation in CRC patients with shorter TL, hence a 
potential association between inflammation and accelerated biological ageing. 
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Figure 4.4: Box plot displaying the significant difference in NLR between the short (relative T/S 
<0.55) and long telomere (relative T/S > 0.55) group, Mann-Whitney p=0.047. 
 
 
 
4.3 Discussion 
 
As indicated in the previous chapter there is clear evidence of accelerated biological ageing 
in the form of telomere attrition in the CRC patients under investigation. As outlined in the 
introduction to this thesis (Introduction section 1.3.3) there are a number of factors which 
have been shown to play a role in the determination of TL. An attempt was therefore made 
to correlate TL with circulating factors involved in redox control and systemic markers of 
inflammation. Any potential association could indicate a mechanistic link in the 
determination of TL and hence a role in the pathogenesis of CRC.  
 
4.3.1 Correlation of telomere length with factors involved in redox control 
 
4.3.1.1 Antioxidant Vitamin Status 
 
Various investigators, using a number of experimental modalities, have identified damage 
induced by reactive oxygen species and oxidative stress as a key determinant of telomere 
erosion rates (von Zglinicki 2002, Serra et al, 2003). The relationship between redox state 
and telomere dynamics is likely to be a complex one involving interaction between a wide 
array of genetic and environmental factors.  The potential role of disordered redox state in 
this study was determined by measuring plasma levels of anti-oxidant vitamins, 
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micronutrient trace element status and factors involved in calcium homeostasis including, 
fetuin-A (a circulating calcium binding protein). Despite multi-modal analysis no 
significant relationship was demonstrated between TL and anti-oxidant status in this group 
of CRC patients. However, studies ranging from cell culture analysis to population based 
studies, have shown that anti-oxidants can protect against free radical induced telomere 
attrition. Alpha-tocopherol (vitamin E) can protect against H2O2 induced telomere damage 
in cultured fibroblasts, an effect dependent on telomerase activity (Makpol et al, 2010). 
Patients with type 2 diabetes mellitus, a condition associated with oxidative stress, display 
evidence of telomere attrition. This effect is mediated by plasma antioxidant status and 
genotypic variation in the expression of UCP-2, a gene involved in mitochondrial 
production of ROS (Salpea et al, 2010). In a group of healthy female study participants 
longer TL was associated with increased intake of multivitamins which included vitamin C 
and E (Xu et al, 2009). Specific to cancer patients, Shen et al (2009) report that breast 
cancer risk was significantly associated with shorter TL and that this risk was increased by 
reduced dietary intake of antioxidant vitamins (Shen et al, 2009). These studies indicate 
that the increased cancer risk associated with telomere attrition could in part be mediated 
by altered antioxidant status. However, it is unlikely that this current study is sufficiently 
powered to uncover any association between TL and plasma antioxidant status in this 
group of CRC patients. One advantage it does have is that determination of plasma 
antioxidant status is a potentially more objective assessment than dietary questionnaire. 
Hence studies using this methodology such as the one described above are potentially 
unreliable.  
 
4.3.1.2 Trace Element Status 
 
Similar to plasma antioxidant status, analysis of TL with regards to levels of trace element 
divalent cations namely; Mg2+, Fe2+, Cu2+, Zn2+ and Se2+ did not reveal any significant 
association. The potential for transition metals such as copper and iron to regulate TL by 
disrupting redox potential is intuitive when the Haber-Weiss and Fenton reactions are 
considered. In the presence of reducing agents these metal ions catalyse the production of 
superoxide anions (O2-), H2O2 and hydroxyl radicals in vivo, all potentially damaging 
reactive oxygen species. Copper ions have previously been shown to induce telomere 
attrition, an effect abrogated by subsequent cell culture with a copper ion binding molecule 
(Bar-Or et al, 2001). The effect of cancer risk predicted by the serum level of these metal 
ions has been investigated in the past, however never in the context of telomere attrition. 
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Although iron has not been shown to alter TL in vitro (Liu et al, 2004), there is some 
evidence that increased iron levels can increase cancer risk by altering redox state (Kabat 
& Rohan 2007). Magnesium and selenium ions on the other hand are considered to have 
anti-oxidant capabilities and hence a protective function over TL. Rats fed a magnesium 
deficient diet display evidence of accelerated telomere attrition rates in liver tissue samples 
and cultured cells, with lower activity levels of measured antioxidant enzymes. The authors 
conclude that magnesium deficiency leads to oxidative stress, apoptosis and accelerated 
ageing. Unfortunately there was no mention of cancer incidence in these animals (Martin et 
al, 2008). Selenium has also been shown to exert a protective effect over TL at the in vitro 
level, an effect mediated through increased telomerase activity (Liu et al, 2003). The effect 
of zinc on TL is unclear. In vitro treatment of hepatoma cells with zinc caused telomere 
attrition (Liu et al, 2004), however there are no studies correlating in vivo TL with zinc 
levels in cancer patients. Although the assessment of trace element status in this study is 
made from plasma samples it may be that a more accurate form of intra-cellular 
determination may give a more physiological depiction.   
 
4.3.1.3 Calcium Homeostasis 
 
Analysis has not revealed any significant relationship between PBL TL and plasma 
calcium concentration. Disordered calcium homeostasis could impact on TL through an 
increase in free radical generation and subsequent oxidative damage. Excessive calcium 
has been shown to increase mitochondrial free radical generation through a number of 
mechanisms including; enhanced citric acid cycle activity, increased NADH formation, 
activation of ROS generation enzymes such as α-ketoglutarate dehydrogenase and 
promoting the loss of cytochrome c (Kowaltowski et al, 2009). These sequelae of 
increased calcium concentration at the mitochondrial level could reflect a relative inability 
to bind free calcium caused by lower fetuin-A, with subsequent promotion of a pro-
oxidative state and leading to accelerated telomere attrition. Excess calcium has been 
shown to negatively impact on prostate cancer outcome. Potential reasons for this include 
the fact that both calcium and parathyroid hormone (release of which is stimulated by 
excess physiological calcium) can promote proliferation and metastasis of prostate cells in 
vitro, however an impact on redox state cannot be discounted (Skinner & Schwartz 2009).  
 
Some recent studies have uncovered a potential relationship between levels of vitamin D 
and the ageing process, specifically with TL. Analysis of serum vitamin D levels in the 
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context of TL in the CRC patients in this study did not reveal any significant association. 
This was also the case when vitamin D levels were correlated with patient clinic-
pathological parameters. Correlation of TL with vitamin D levels in a large population-
based cohort of twins has revealed significant strong positive relationship, which became 
stronger as vitamin D level increased. Furthermore, Vitamin D levels were negatively 
correlated with CRP in the study population. It therefore appears that the protective effect 
of Vitamin D over TL results from its ability to act as an anti-inflammatory mediator. 
Indeed vitamin D receptors are ubiquitously expressed on both T and B cells, and can 
down-regulate cytokine production producing an anti-inflammatory effect (Richards et al, 
2007). Thus the effect of Vitamin D on TL appears to be independent of its role in the 
maintenance of plasma calcium levels. However, these studies need to be interpreted with 
caution as evidence has also pointed to promotion of a premature ageing phenotype in 
mutant mice (klotho-/- and FGF23-/-) exposed to hypervitaminosis D3 through dietary 
modification and genetic manipulation of the vitamin D receptor. Although, TL was not 
specifically examined in these models expression of ageing-related genes was altered 
(Tuohimaa 2009). The current study was not sufficiently powered to fully delineate the 
relationship between vitamin D, telomere attrition and CRC, however given recent 
intriguing experimental evidence a potentially manipulatable determinant of TL in cancer 
patients may exist.    
 
 
Within the CRC PBL group patients with lower fetuin-A levels had shorter telomeres. 
These findings are consistent with those in CKD patients where there is an established link 
between low fetuin-A levels, short TL and reduced anti-oxidative capacity. Indeed, in this 
group of patients TL was associated with increased mortality, independent of age and sex 
but dependent on fetuin-A levels (Carrero et al, 2008). The relationship between TL and 
fetuin-A indicates biological ageing is associated with reduced redox capacity within the 
blood of CRC patients. Interleukin 6 (IL-6), a pro-inflammatory cytokine, alters the gene 
expression and synthesis of fetuin-A by hepatocytes, similar to its action on albumin 
(Gangneux et al, 2003). This study showed that decreasing fetuin-A levels correlates with 
decreasing albumin concentration and increasing IL-6 and IL-10 levels, supporting the 
hypothesis of inflammation-dependent down-regulation of fetuin-A expression. These 
observations concur with those described in patients with renal failure on dialysis 
(Hermans et al, 2007) and also with results from a rodent model of lethal systemic 
inflammation where fetuin-A exerted a protective role (Li et al, 2011a). However, the 
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relationship between fetuin-A is not a straightforward one given the finding of elevated 
levels in patients with previous myocardial infarction and obesity (Voros et al, 2011).   
 
In patients with glioblastoma, the most commonly occurring brain tumour low serum 
fetuin-A levels predicted poor survival (Petrik et al, 2008). Moreover, Rho et al (2009) 
report differential expression of fetuin-A between lung adenocarcinoma and adjacent 
normal tissue with both total protein and mRNA abundance reduced in cancer samples 
(Rho et al, 2009). These findings, in conjunction with our own observations, lead to the 
intriguing possibility of utilising fetuin-A as a prognostic/predictive marker for tumours 
from a histologically varied origin. Work is required to determine whether it is by virtue of 
its role in calcium homeostasis and hence redox state, that fetuin-A contributes to the 
determination of TL. Clearly comparison of fetuin-A levels between cancer patients and 
healthy controls would also be essential in any further investigation of the role of fetuin-A 
in cancer. 
 
Rampazzo et al (2010) have identified right-sided colonic tumours as having shorter TL 
than left-sided and rectal cancers, which may result from an alteration in mismatch repair 
pathways (Rampazzo et al, 2010). The molecular and clinical characteristics of right and 
left colon cancers are well established with right sided tumours classically associated with 
microsateillite instability and alteration in CpG island methylator phenotype, and left sided 
cancers with chromosomal instability (Iacopetta 2002). The observation that plasma fetuin-
A levels vary with the anatomical site of the primary tumour is pertinent and may reflect 
differences in the systemic oxidative-inflammatory milieu as a result of differing molecular 
characteristics in the anatomical position of the tumour. This could particularly reflect 
differing rates of telomere attrition which were not elicited in the current study as no 
relationship between tumour site and TL was determined. The pre-operative management 
of colonic and rectal cancers in the context of chemo-radiotherapy differs, hence, further 
molecular differentiation of colon and rectal cancers could lead to the discovery of new 
therapeutic targets thereby improving the outcome of rectal cancer. Obviously, further 
work in a larger patient group is required to substantiate these preliminary findings and 
determine ’cause and effect’ relationship between anatomical differences in tumour site 
and telomere dynamics.  
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4.3.2 Correlation of Telomere Length with Markers of Inflammation 
 
Inflammation is an important determinant of TL which has been implicated in the ageing 
process and as a universally detrimental factor at all stages of the neoplastic process. We 
therefore sought to correlate TL with common bio-haematological markers of 
inflammation, in addition to pro-inflammatory cytokines.   
  
Cellular senescence is a permanent state of growth arrest and hence a potent mechanism of 
tumour suppression. The triggers of senescence in vivo include critical telomere attrition, 
activation of oncogenes, oxidative stress, genotoxic stress and some therapeutic 
interventions for example irradiation and chemotherapy. Recent evidence indicates that 
senescent cells secrete a multitude of signalling factors, termed the “senescence associated 
secretory phenotype” (SASP) (Coppe et al, 2008). These signals are mostly pro-
inflammatory and include factors such as IL-1α and β, IL-6 and IL-8. The SASP provides 
an intuitive explanation of our observed association between short TL and systemic 
inflammation, indicated by a raised neutrophil:lymphocyte ratio. Interestingly, patients 
with ulcerative colitis an inflammatory condition of the colon who exhibit an increased risk 
of CRC display evidence of telomere attrition in leucocytes (Risques et al, 2008a). Even 
minute quantities of pro-inflammatory cytokines released by populations of senescent cells 
in biologically aged individuals could stimulate a more chronic systemic inflammation by 
virtue of positive feedback loops. At the peri-tumoural level these factors could also act in 
a paracrine fashion to create an environment where tumour cells can flourish by 
stimulating hyperproliferation, de-differentiation, immune evasion, migration and invasion 
(Davalos et al, 2010).  
 
It is therefore likely that a complex inter-relationship exists between telomere dynamics 
and inflammation via positive feedback loops. As pro-inflammatory signalling pathways 
are up-regulated and haemopoetic stem cells stimulated to differentiate into lymphocytic 
cells repeated rounds of division will contribute to the acceleration in telomere attrition 
demonstrated in PBLs. Increased numbers of senescent cells would therefore lead to an 
increase in the pro-inflammatory milieu and perpetuation of the pro-inflammatory state 
contributing to the acceleration of biological ageing.   
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CHAPTER 5:  SIRTUIN EXPRESSION IN COLORECTAL CANCER 
5.1 Introduction 
 
Colorectal cancer is the third most common cancer in the UK and is responsible for 16,000 
deaths every year (Cancer Research UK 2010). Improving understanding of the key 
mechanisms underpinning the disease process could lead to the discovery of novel 
prognostic biomarkers or targets for therapeutic intervention. The link between cancer and 
ageing seems intuitive given that age is a risk factor common to most solid organ cancers, 
especially those of an epithelial origin (DePinho 2000). Current lines of investigation 
linking the two processes include the contribution of telomere biology (Shay & Wright 
2010, Maxwell et al, 2011) and manipulation of nutrient sensing pathways, such as 
mammalian target of rapamycin (mTOR) (Zoncu et al, 2011). The sirtuin family of genes 
have been intensely investigated due to their diverse cellular functions and ability to 
influence longevity in certain organisms.   
 
Variability in the sub-cellular localisation of the sirtuins is reflected in the variety of 
critical cellular functions to which the sirtuins contribute. At the mitochondrial level, 
SIRT3 and SIRT4 have been shown to regulate the activity of acetyl-CoA (Hallows et al, 
2006) and glutamate dehydrogenase (Haigis et al, 2006) respectively, whereas SIRT5 is 
implicated in the control of the urea cycle (Nakagawa & Guarente 2009). SIRT6 plays an 
important role in the maintenance of genomic integrity and DNA damage repair 
(Mostoslavsky et al, 2006). SIRT6 has also been shown to modulate telomeric chromatin 
and hence function by histone H3 deacetylation (Michishita et al, 2008a). SIRT1 
contributes to glucose homeostasis by stimulating hepatic gluconeogenesis (Rodgers et al, 
2005) and insulin release from pancreatic β-bells (Moynihan et al, 2005). In addition, by 
virtue of its ability to deacetylate a number of non-histone proteins such as p53, FOXO, 
NF-κB and Ku70, SIRT1 controls the response to cellular stress and dictates cellular fate 
by modulating apoptotic and DNA repair pathways (Yang et al, 2005, Jeong et al, 2007, 
Ghosh et al, 2007, Yi& Luo 2010).  SIRT7 appears to regulate cell growth in response to 
changing metabolic conditions by stimulating ribosome biogenesis (Ford et al, 2006). 
SIRT2 has been shown to exert control over the cell cycle by deacetylating α-tubulin, 
whilst its levels increase during mitosis with overexpression delaying mitosis (North & 
Verdin 2007b).  
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These key cellular processes over which the sirtuins exert a degree of control all play a role 
in normal organismal ageing. It therefore stands to reason that dysregulation of sirtuin 
expression could alter lifespan and contribute to the development of age related diseases. 
Indeed SIRT6 knockout mice die young displaying signs of progeria, whilst SIRT1 has 
been implicated in the lifespan extension of model organisms conferred by caloric 
restriction (Cohen et al, 2004b, Mostoslavsky et al, 2006). The sirtuin family have been 
implicated in the pathophysiology of age-related conditions including cancer.  Attempting 
to delineate the relationship between the sirtuin family and cancer is proving complex. This 
is exemplified by the fact that despite the plethora of studies in numerous experimental 
systems there is still some dubiety as to whether they function primarily as tumour 
promoters or suppressors. Reflecting this dichotomous position SIRT1 has been shown to 
be upregulated in leukaemia, prostate and skin cancer (Bradbury et al, 2005, Hida et al, 
2007, Huffman et al, 2007), while downregulated in colorectal cancer (Firestein et al, 
2008). SIRT2 and SIRT7 have been implicated in the development of gliomas (Hiratsuka 
et al, 2003) and human papillary thyroid cancer cell lines respectively (de Nigris et al, 
2002).  
We have previously hypothesised that the sirtuins link Mitochondria and the Telomere 
nucleoprotein complex with Ribosome biogenesis (Shiels & Davies 2004). This provides a 
plausible mechanistic pathway where the energy balance of a cell in stress is sensed and 
the requisite damage response mechanisms initiated. Aberrant sirtuin expression could, 
therefore, upset the balance of these factors hence tipping the cell into crisis if key repair 
pathways could not be initiated. Moreover, the inability of the cell to respond to DNA 
damage in particular could lead to deleterious chromosomal events and potentially 
carcinogenesis. It is therefore conceivable that the sirtuins play a key role in the 
development and progression of the cancer process.  
Chapter Aims 
• To determine the relative transcription levels of SIRT1-7 in colorectal cancer tissue 
and adjacent normal mucosal tissue, identification of a positive or negative 
relationship between the two tissue types could provide further evidence to support 
a tumour suppressive or promoting role for the sirtuins in CRC.  
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• Expression data was then correlated with a variety of commonly recorded clinico-
pathological, biochemical and haematological variables. Therefore, we aimed to 
place the biology of ageing and cancer in a clinical context. 
• Characterise the relationship between sirtuin expression and TL in CRC tissue. 
• Correlation with pathological and cancer outcome was also made to allow 
evaluation of sirtuin expression as a marker of prognosis. 
 
5.2 Results 
5.2.1 Differential Expression between Colorectal Tumour and Adjacent 
Normal Tissue 
The overall aim of this study was to create an expression profile for SIRT 1-7 from 
colorectal cancer specimens and paired adjacent normal tissue. There was a universal 
significant attenuation in relative expression levels of all seven sirtuins in the tumour tissue 
when compared with normal tissue (SIRT3 n=43, SIRT5 n=46, SIRT1 and SIRT6 n=47, 
SIRT2 and SIRT7 n=48, SIRT4 n=49; Figure 5.1). All but SIRT 2 (p=0.026) displayed a 
significant difference in expression at the p<0.001 level. Within the tumour samples the 
lowest expression levels were evident with SIRT4 (0.14, IQR 0.18) and highest with 
SIRT5 (0.55, IQR 0.51). As indicated in Figure 5.1 SIRT1 (0.41, IQR 0.22), SIRT2 (0.42, 
IQR 0.27) and SIRT3 (0.39, IQR 0.21) all displayed similar expression levels within the 
tumour tissue (Kruskal-Wallis, p=0.962), while there was a significant difference in the 
expression of the mitochondrial sirtuins, with SIRT4 displaying the lowest relative 
transcription levels (Kruskal-Wallis, p<0.001). Analysis of cancer tissue subgroups 
revealed differences in the relative expression between rectal tumour tissue samples from 
patients who had undergone neo-adjuvant therapy prior to their index procedure (Effect of 
Neo-Adjuvant Therapy on SIRT Relative Expression 5.2.3.1). To prevent these differences 
confounding the overall results, therefore giving a more accurate representation of relative 
expression these samples were excluded from the SIRT transcriptional analysis presented 
above. 
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Figure 5.1: Bar chart displaying the median expression level (± 95% C.I) of each of the sirtuins in 
colorectal cancer tissue (solid bar) and adjacent normal tissue. Expression level was 
significantly reduced in all seven sirtuins in cancer tissue compared with normal. 
(Wilcoxon signed  rank Test, **P<0.0001, *P=0.003). 
 
5.2.2 Inter-relationship between sirtuins in tumour and normal tissue 
To determine if there was any inter-relationship between individual sirtuin relative 
expression levels from tumour and normal tissue, cross-correlation analysis was 
performed. The various correlations are outlined in Table 5.1, with a number of strong 
positive correlations revealed. Of particular note, within the tumour samples SIRT1 was 
strongly positively correlated with SIRT2 (Pearson r = 0.827), SIRT3 (Pearson r = 0.647) 
and SIRT4 (pearson r = 0.850), all p<0.001. In addition SIRT3 correlated with all but 
SIRT7 at the p < 0.001 level. There were some major differences in the correlation analysis 
from the normal tissue samples, with the loss of all significant associations between 
SIRT5, SIRT6 and the remainder of the sirtuins (Table 5.1). There was, however, an 
association gained between SIRT3 and SIRT7 (Pearson r = 0.665, p < 0.001).  
 
 
135 
 
Table 5.1: Table displaying correlations between SIRT1-7 in the CRC tumour (A) and normal (B) 
samples. 
A Tumour 
 SIRT2 SIRT3 SIRT4 SIRT5 SIRT6 SIRT7 
SIRT1 
Pearson r 
p-value 
 
0.827 
<0.001 
 
0.647 
<0.001 
 
0.850 
<0.001 
 
0.319 
0.033 
 
0.447 
0.002 
 
0.396 
0.006 
SIRT2 
Pearson r 
p-value 
  
0.610 
<0.001 
 
0.753 
<0.001 
 
0.475 
0.001 
 
0.414 
0.004 
 
0.453 
0.001 
SIRT3 
Pearson r 
p-value 
   
0.609 
<0.001 
 
0.568 
<0.001 
 
0.531 
<0.001 
 
0.438 
0.002 
SIRT4 
Pearson r 
p-value 
    
0.216 
0.170 
 
0.420 
0.006 
 
0.209 
0.178 
SIRT5 
Pearson r 
p-value 
     
0.463 
0.001 
 
0.628 
<0.001 
SIRT6 
Pearson r 
p-value 
  
 
    
0.635 
<0.001 
 
B Normal 
 SIRT2 SIRT3 SIRT4 SIRT5 SIRT6 SIRT7 
SIRT1 
Pearson r 
p-value 
 
0.902 
<0.001 
 
0.509 
<0.001 
 
0.758 
<0.001 
 
0.222 
0.143 
 
0.056 
0.711 
 
0.140 
0.348 
SIRT2 
Pearson r 
p-value 
  
0.665 
<0.001 
 
0.834 
<0.001 
 
0.151 
0.318 
 
0.003 
0.983 
 
0.165 
0.262 
SIRT3 
Pearson r 
p-value 
   
0.744 
<0.001 
 
0.386 
0.008 
 
0.363 
0.012 
 
0.665 
<0.001 
SIRT4 
Pearson r 
p-value 
    
0.199 
0.207 
 
-0.042 
0.793 
 
0.244 
0.116 
SIRT5 
Pearson r 
p-value 
     
0.257 
0.089 
 
0.364 
0.013 
SIRT6 
Pearson r 
p-value 
  
 
    
0.888 
<0.001 
 
P≤0.002 deemed significant after Bonferroni correction (emboldened p value = significant) 
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5.2.3 Differentiation of Tumour Site 
An attempt was made to differentiate between tumour site according to sirtuin relative 
expression level. Tumour site was defined according to operative findings and pathological 
examination of the resected specimen. Rectal cancers were deemed to lie below the 
peritoneal reflection with colon cancers above. Colon cancers were further divided into 
proximal and distal according to their position in relation to the splenic flexure. Analysis 
revealed that colon cancer specimens had significantly lower levels of SIRT2 expression 
(Figure 5.2) (Mann-Whitney, p=0.021) with SIRT4 levels also reduced, the relationship 
displaying a trend towards significance (Mann-Whitney, p=0.056). Further differentiation 
into proximal and distal colon cancers revealed a sequential reduction in SIRT2 expression 
levels from the rectum to the proximal colon, which displayed a clear trend but did not 
reach significance (Kruskal-Wallis, p=0.072). Interestingly, SIRT2 expression in the 
normal tissue samples was also significantly different between colonic and rectal tissue 
samples in a similar pattern to that seen in tumour tissue (Mann-Whitney, p=0.025). 
 
 
Figure 5.2: Differentiation of tumour site using median SIRT2 (± 95% C.I.) relative expression. 
Patients with colon cancer had significantly lower levels of SIRT2 compared to those with 
rectal cancer (Mann-Whitney, p=0.021). 
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5.2.3.1  Effect of Neo-adjuvant therapy on SIRT relative expression 
Using the small group of rectal cancer patients (n=6) who had undergone neo-adjuvant 
therapy an attempt was made to determine if pre-operative chemo/radiotherapy had an 
effect on the expression on SIRT1-7 in the cancer and normal samples. As displayed in 
Table 5.2 there was a significant increase in the relative expression of SIRT1, SIRT3 and 
SIRT4 in the cancer tissue samples when comparing non- and neo-adjuvantly treated 
patients. This was most pronounced for SIRT3 where there was a marked increase in 
expression in tumours exposed to neo-adjuvant therapy (0.85 (±0.36) Vs 0.41 (±0.21), 
p<0.001). Within the normal samples neo-adjuvant therapy significantly increased SIRT6 
expression (0.97 (±0.49) Vs 0.54 (±0.51), p = 0.033). Moreover, neo-adjuvant therapy 
appears to reverse the differential expression of SIRT1-SIRT4, between tumour and 
normal tissue with higher relative transcriptional levels in the tumour samples (Table 5.2). 
However, none of the differences reached a significant level. For a number of reasons these 
data should be interpreted with a degree of caution. The small sample size is an obvious 
limitation as is the lack of detail regarding the specificities of the therapeutic regimens 
employed. Importantly, there are also no direct control pre-neo-adjuvant treatment samples 
from which to make comparisons therefore it is possible SIRT levels could have been 
elevated in the relevant samples prior to neo-adjuvant therapy.  
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Table 5.2: Table displaying the difference in relative expression of SIRT1-7 in each of the cancer and 
normal tissue source, further stratified according to neo-adjuvant therapy. 
  
Tumour 
 
Normal 
 Neo-adjuvant 
 
Non neo-
adjuvant 
 
P 
(<0.05) 
Neo-
adjuvant 
Non neo-
adjuvant 
P 
(<0.05) 
SIRT1 
 0.69 (0.36)
* 0.43 (0.22) 0.022 0.53 (0.68)* 0.69 (0.42) 0.845 
SIRT2 
 0.64 (0.56)
* 0.42 (0.27 0.106 0.50 (0.75)* 0.54 (0.41) 0.501 
SIRT3 
 0.85 (0.40)
* 0.41 (0.21) <0.001 0.80 (0.67)* 0.65 (0.43) 0.088 
SIRT4 
 0.38 (0.30)
* 0.14 (0.17) 0.026 0.32 (0.96)* 0.32 (0.31) 0.960 
SIRT5 
 0.68 (0.80) 0.56 (0.19) 0.408 1.10 (1.08) 0.98 (0.63) 0.854 
SIRT6 
 0.28 (0.10) 0.23 (0.12) 0.263 0.92 (0.49) 0.54 (0.51) 0.033 
SIRT7 
 0.52 (0.39) 0.35 (0.21) 0.106 0.96 (0.66) 0.67 (0.55) 0.133 
 
All values displayed as median (IQR). N=6 in the neoadjuvant treated group 
Differences between the two groups analysed by Mann-Whitney, p<0.05 deemed significant. 
*The relationship between relative expression has been reversed with higher levels within the tumour samples compared 
with the normal (SIRT1-4). None of these reached significance (Wilcoxon signed rank test p>0.05)   
 
 
5.2.4 Association with Clinico-pathological parameters 
We attempted to delineate any relationship between sirtuin expression and commonly 
recorded patient clinico-pathological characteristics. In order to achieve this, our analysis 
was performed with SIRT1-7 expression level included as both a continuous or categorical 
variable where appropriate. Categorisation into high or low expression groups was 
achieved by dividing expression level around the median value for the respective sirtuin. 
Analysis of expression levels of SIRT4 in tumour samples revealed a significant difference 
in expression between patients with lymph node positive and negative disease (Mann-
Whitney, p=0.027), with higher SIRT4 levels apparent in patients with node positive 
disease (Figure 5.3). There were no other significant relationships between SIRT1-7 and 
any of the other parameters outlined in Table 2.2.  
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Figure 5.3: Bar chart demonstrating the significant difference in median SIRT4 expression (± 95% C.I) 
in cancer tissue differentiated by pathological nodal status (Mann-Whitney, p=0.027). 
 
5.2.5 Correlation with Survival 
The median survival of the patient group was 54.1 months (0.33-84.40). Survival analysis 
was performed using the sirtuin expression data in the categorical form as before. Analysis 
revealed that higher expression levels of SIRT4 were associated with a poorer outcome in 
terms of survival, with more deaths in this group compared with low expression levels. 
(log rank p =0.025, Figure 5.4). There was no association with survival for the remaining 
sirtuins. 
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Figure 5.4 Kaplan-Meier survival curve comparing survival with SIRT4 expression at high or low 
levels. Significantly more deaths in the  SIRT4 expression group (log rank p=0.025). 
 
5.2.6 Sirtuin Expression and Indices of Biological Ageing 
5.2.5.1 Correlation with Systemic Inflammation 
On analysis of sirtuin expression levels in the context of common indices of inflammation 
(WCC, neutrophils, CRP, albumin and mGPS) there was a significant relationship between 
CRP level and relative expression levels of SIRT2, SIRT3, SIRT4 and SIRT7 in the 
normal colorectal tissue. Whereby, patients with higher levels of CRP and hence higher 
levels of inflammation displayed lower expression levels of the respective sirtuins (Mann-
Whitney, SIRT2 p=0.025, SIRT3 p=0.012, SIRT4 p=0.021 and SIRT7 p=0.047) (Figure 
5.5A). Consistent with these findings there was an inverse relationship between CRP and 
both SIRT2 (Pearson r -.346, p=0.093) and SIRT4 (Pearson r -.323, p=0.088) (Figure 
5.5B), which did not reach significance. There was no relationship between tumour sirtuin 
expression level and indices of inflammation. 
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Figure 5.5:  (A) Bar chart indicating the significant difference in expression levels in normal colorectal 
tissue of SIRT2 (p=0.025), SIRT3 (p=0.012), SIRT4 (p=0.021) and SIRT7 (p=0.047) 
between those patients with high (>10 mg/l) and low (<10 mg/l) levels of C-reactive 
protein ± 95% C.I. (B) Scatter plot demonstrating the inverse relationship between SIRT2 
(Pearson r -.251, p=0.093), SIRT4 (Pearson r -.266, p=0.088) and C-reactive protein. 
 
5.2.5.2 Correlation with chronological and biological ageing 
No significant relationship was demonstrated between chronological age and any of the 
individual sirtuins, in either the tumour or normal tissue samples. DNA was available for 
determination of TL in twenty-nine matched samples from the original batch of thirty-two. 
As was previously reported TL was significantly shorter in tumour samples (median=0.41, 
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IQR=0.26) when compared with normal adjacent normal tissue (median=0.63, IQR=0.22) 
(Mann-Whitney, p<0.001). Thus, indicating tumour cells were more biologically aged than 
adjacent normal cells. Expression levels of all seven sirtuins were correlated with TL from 
both the cancer and normal tissue cohort. Analysis revealed a significant inverse 
relationship between TL and SIRT3 relative expression in cancer tissue (Pearson r -.353, 
p=0.047) (Figure 5.6). 
 
 
Figure 5.6: Scatter plot demonstrating the significant inverse relationship between SIRT3 relative 
expression and telomere length in colorectal cancer specimens (Pearson r -.353. p=0.047). 
 
5.3 Discussion 
5.3.1 Differential Relative Expression of SIRT1-7 in Tumour and Normal 
Tissue 
We have constructed an expression profile for all seven mammalian sirtuins in the index 
cohort of CRC patients. These results demonstrate that relative expression levels of all 
seven sirtuins were significantly attenuated in tumour tissue when compared with normal 
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adjacent tissue. These data corroborate previous studies which have implicated the sirtuins, 
in particular SIRT1 as potential tumour suppressors (Kabra et al, 2009).  
5.3.1.2 Reduced relative expression of SIRT1 in Colorectal cancer tissue 
Given the pro-apoptotic effect of SIRT1 a tumour suppressive function is not difficult to 
rationalise. The reduced expression in the colorectal tumour samples compared with 
normal tissue in this study indicate a reduced apoptotic capacity and therefore reduced 
ability to eliminate damaged cells. Aberrancy of the SIRT1-NFκB axis could explain the 
tumour suppressive effect of SIRT1. SIRT1 represses NFκB and facilitates TNF-α induced 
apoptosis, therefore attenuation of SIRT1 expression would result in the loss of this 
important pro-apoptotic pathway (Yeung et al, 2004). Loss of SIRT1 could also promote 
neoplastic transformation by a reduced capacity to maintain genomic integrity. Wang et al 
(2008) report that not only is SIRT1 expression reduced in a variety of human cancers 
compared with controls but that SIRT1 deficient mice display chromosomal aberrations 
with a reduced ability to repair DNA double strand breaks (DSBs) characterised by 
diminished γH2AX, BRCA1, RAD51 and NBS1 foci (Wang et al, 2008a).  
Consistent with our demonstration of a reduced relative expression of SIRT1 in CRC 
samples, two published studies have investigated the potential for SIRT1 to act as a tumour 
suppressor specifically in CRC. Using cultured colorectal cancer cells (HCT116 cells) 
Kabra et al (2009) report that over-expression of SIRT1 induced efficient G1 cell cycle 
arrest. Treatment of these cultured cells with a specific SIRT1 inhibitor stimulated 
proliferation, an effect not seen in SIRT1 null MEFs. A tumour xenograft assay also 
demonstrated tumour growth was increased upon inoculation of athymic nude mice with 
HCT116 cells in which the SIRT1 gene was inactivated by shRNA. Finally, colorectal 
cancer specimens and controls were stained for SIRT1 revealing high expression in normal 
tissue and benign adenomas, with 30% of tumour samples showing less intense staining 
than control samples. The authors conclude that the tumour suppressive role for SIRT1 in 
this setting results from activation of E2F1 and hyper-phosphorylation of pRb. Attenuated 
expression of SIRT1 in this scenario would allow cells to by bypass senescence in the face 
of stress leading to increased proliferation and neoplastic transformation (Kabra et al, 
2009).  
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Firestein et al (2008) have also demonstrated suppression of intestinal tumourigenesis by 
SIRT1 using a comprehensive array of methodologies.  This group generated transgenic 
mice (APCmin/+SIRT1ΔSTOP) which over-expressed SIRT1 in the setting of a β-catenin 
driven model of intestinal tumourigenesis. These animals displayed fewer tumours than 
controls and similar levels to APCmin/+ mice fed a calorie restricted diet. Ectopic induction 
of SIRT1 in a β-catenin driven model of colorectal cancer greatly reduced proliferation, 
giving some insight into a potential mechanism of tumour suppression. The authors also 
report a significant inverse correlation between nuclear SIRT1 and β-catenin in colon 
cancer specimens (Firestein et al, 2008). Analysis of the drivers of colorectal neoplasia 
used was not performed in our study group, however constitutive activation of the 
canonical Wnt/β-catenin pathway has been demonstrated in the majority of colorectal 
cancers (McDonald & Silver 2011). This means that the attenuation of SIRT1 in cancer 
cells in our group of colorectal cancer patients could in theory facilitate neoplastic 
transformation via de-repression of the Wnt/β-catenin pathway.   
Although there is compelling evidence to support SIRT1 as a tumour suppressor one might 
expect that aberrant expression of genes which promote longevity should, as a by-product 
of encouraging cell survival lead to an increase in neoplasia in populations of dividing cells 
i.e. act as a oncogene. In this regard, SIRT1 can deacetylate and therefore inhibit p53 
leading to the bypassing of apoptosis, a fundamental tumour suppressor mechanism (Luo 
et al, 2001, Vaziri et al, 2001). Consistent with this, levels of SIRT1 have been shown to 
be significantly elevated in human skin cancer (Hida et al, 2007), colon cancer (Stunkel et 
al, 2007) and prostate cancer (Huffman et al, 2007). Furthermore, SIRT1 deficient mice 
exhibit p53 hyperacetylation and increased radiation induced apoptosis (Cheng et al, 
2003). Whilst, Zhao et al (2008) report that deleted in breast cancer-1 (DBC-1) inhibits 
SIRT1 activity with concomitant increased p53 functionality which is reversed by knock-
down of DBC-1 using RNA-interference (Zhao et al, 2008). Both of these studies suggest 
SIRT1 expression may increase cancer risk by inhibiting p53.  Dysregulation of the HIC1-
SIRT1-p53 regulatory loop has also been implicated in cancer development and outcome 
with the finding that deregulation of this feedback loop equates with poor prognosis from 
lung cancer (Tseng et al, 2009).  
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5.3.1.2 Reduced relative expression of SIRT2 in colorectal cancer tissue 
The data presented here pertaining to the reduced relative expression of SIRT2 in CRC 
specimens confirms that previously reported in glioma samples and cell lines, at both the 
protein and RNA level (Hiratsuka et al, 2003). SIRT2 is implicated in tumour formation 
through its role as a mitotic checkpoint regulator via modification of α-tubulin. Attenuated 
SIRT2 expression could therefore confer on tumour cells the ability to escape mitotic 
checkpoints in the face of otherwise fatal genotoxic damage. Consistent with this ectopic 
expression of SIRT2 exerts an anti-proliferative effect on glioma cells (Inoue et al, 2007, 
Inoue et al, 2009).  Attenuated SIRT2 expression could result from the telomerase driven 
shortening of cell cycle check point time due to hyper-proliferation. As SIRT2 does not 
have time to function adequately its expression is therefore down-regulated.   
 
However, the effect of SIRT2 expression on tumour cells mirror that of SIRT1 in that 
recent evidence has also indicated that SIRT2 inhibition can induce apoptosis in HeLa and 
other cancer cells caused by the accumulation of p53. An effect caused by the p38 MAPK 
dependent degradation of p300 and subsequent MDM2 degradation (Li et al, 2011). This 
evidence implicates SIRT2 as a promoter of tumour cell survival.                                                                                                                                                                                                                                                                                     
Attenuation of SIRT2 function with specific inhibitors has shown promise as novel anti-
cancer therapies by promoting cell cycle arrest and apoptosis in prostate, pancreatic and 
lung cancer cell lines (Zhang et al, 2009).  
 
Clearly there is contrasting evidence relating to the role of SIRT2 in the neoplastic process. 
This may relate to the different model systems used as Hela cells of squamous origin will 
differ in their biology in comparison with neuronal cells such as those used in the glioma 
cell experiments described above. It is therefore difficult to extrapolate these results into 
the CRC setting used in our study as the histological origin, risk factor profile and 
molecular drivers of these tumours differs from those of CRC.  
5.3.1.3 Reduced relative expression of SIRT3 in colorectal cancer tissue 
SIRT3 relative expression was reduced in tumour tissue when compared with normal 
colorectal tissue. This finding validates those by Kim et al (2010) who also confirmed that 
SIRT3 expression was reduced in breast, testicular, glioblastoma multiforme, prostate, 
head and neck squamous cell, clear cell renal and hepatocellular cancer (Kim et al, 2010). 
The ability of SIRT3 to suppress damage induced by ROS seems key to its tumour 
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suppressor effect as isolated MEFs from SIRT3-/- mice show increased stress induced 
superoxide levels and genomic instability, augmented superoxide dismutase expression 
abrogated some of these effects (Kim et al, 2010). This intricate relationship between 
SIRT3 and oxidative stress is confirmed by a decrease in tumour development induced by 
over-expression of SIRT3 in tumour xenograft models, an effect mediated by regulation of 
HIF-1α (Bell et al, 2011). These and our data implicate SIRT3 as a tumour suppressor, an 
effect mediated through an integrated cellular response encompassing key mitochondrial 
mechanisms to suppress ROS generation and subsequent neoplasia inducing genotoxic 
damage.  
In contrast to the evidence supporting a tumour suppressor role for SIRT3 a further recent 
study has reported an over-expression of SIRT3 in oral squamous cell carcinoma tissue 
microarrays and cell lines. In vivo models showed reduced tumour burden upon transgenic 
down-regulation of SIRT3 (Alhazzazi et al, 2011). These findings indicate this particular 
tumour type requires SIRT3 for its ongoing survival.  
5.3.1.4 Reduced relative expression of SIRT4 and SIRT5 in colorectal cancer 
tissue 
All data pertaining to SIRT4 and SIRT5 relates to their role in the regulation of fuel 
utilisation, mitochondrial metabolism, control of the urea cycle and control of insulin 
secretion (Ahuja et al, 2007, Haigis & Sinclair 2010). Our demonstration of reduced 
expression in CRC tissue is therefore the first description of aberrant SIRT4 or SIRT5 
expression in cancer. The potential relationships can only be speculated upon given the 
lack of pertinent data. The reduced expression may reflect a compensatory mechanism by 
the tumour to regulate energy utilisation in the face of variability in supply depending the 
degree and functionality of neoangiogenesis. The lack of identification of functional 
relationship between SIRT4, SIRT5 and any factors know to regulate cell survival makes it 
unlikely they act in a tumour suppressive fashion, however this may change as 
enhancement of the understanding of these relationships develops.  
5.3.1.5 Reduced relative expression of SIRT6 in colorectal cancer tissue 
Demonstration of a reduced expression of SIRT6 in colorectal tumour samples compared 
with normal tissue is confirmatory of a tumour suppressive function of SIRT6. A number 
of histone and non-histone interactions explain this function:  
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1. As described previously SIRT6 has a well recognised effect on DNA repair and 
hence is regarded as maintainer of genomic integrity. This effect is mainly 
mediated through the ability of SIRT6 to modulate both BER and DSB repair 
pathways (Tennen & Chua 2011). DSB repair by homologous recombination is 
reliant on the SIRT6 dependent deacetylation of C-terminal binding protein 
interacting protein (CtIP), which is required to resect DNA at sites of damage and 
facilitate repair (Kaidi et al, 2010). Clearly loss of this function could contribute to 
genomic instability which is considered a hallmark and instigator of most human 
cancers, including colorectal (Pino & Chung 2010).  
2. SIRT6 has been shown to interact with Grap2 and cyclin-D interacting protein 
(GCIP), a helix-loop-helix protein and putative tumour suppressor under-expressed 
in a number of human tumour types, including colorectal (Ma et al, 2007). Loss of 
the positive regulatory effect of GCIP on SIRT6 could explain lower expression 
levels in CRC tissue and putative tumour suppressive effect.  
3. SIRT6 over-expression in cancer cells initiates a massive apoptotic response 
resulting in attenuated proliferation of cultured cells, but not in normal cells. This 
response is dependent on the ADP-ribosyl transferase activity of SIRT6 through an 
interaction with both p53 and p73 (Van Meter et al, 2011).  
4. SIRT6 can deacetylate H3K9 at the NF-κB promoter attenuating its transcription. 
Thus SIRT6 deficiency is associated with enhanced NF-κB downstream 
modulation of gene expression which results in enhanced resistance to apoptosis. 
This loss of a potential tumour suppressor mechanism could contribute to the 
development of neoplasia. This, however is tempered by increased levels of 
senescence which could compound this effect (Kawahara et al, 2009). 
5. The role of SIRT6 in tumour cell metabolism will be discussed in due course.  
Attenuated SIRT6 expression confirms previous work in our laboratory demonstrating a 
similar expression pattern in breast carcinoma samples compared with normal and non-
malignant samples. Furthermore, SIRT6 expression proved a superior predictor of outcome 
when compared with current clinical scoring methods such as the Nottingham prognostic 
index (Zino 2010). Aside from this there is currently a lack of data placing SIRT6 
expression in cancer in a clinical context. Further molecular dissection of the DNA repair 
148 
 
pathways involved in cancer could lead to as yet undiscovered interactions with SIRT6 and 
in particular its capability as a potential tumour suppressor.  
5.3.1.6 Reduced relative expression of SIRT7 in colorectal cancer tissue 
Predictably, studies investigating the role of SIRT7 in cancer have provided dichotomous 
results. Contrary to the currently presented findings of reduced SIRT7 expression in CRC 
tissue, SIRT7 has also been shown to be over-expressed in both breast and thyroid 
malignant tissue (de Nigris et al, 2002, Frye 2002, Ashraf et al, 2006). These observations 
could be explained by the original description of SIRT7 as a positive regulator of cell 
proliferation via its effect on Pol1 and apoptosis (Ford et al, 2006). 
However, SIRT7 knockout mouse-derived MEFs display increased viability under standard 
and stressful culture conditions. Furthermore, tumour cells from different histological 
backgrounds (P19 (teratocarcinoma), NB41A3 (neuroblastoma), C3H/MCA (transformed 
fibroblast-derived cell line) displayed lower SIRT7 expression levels compared with non-
tumour parental controls (Vakhrusheva et al, 2008a). The continued proliferation of SIRT7 
deficient cells in the face of conditions of stress could be reminiscent of the conditions 
facing a cell in the early throes of neoplastic transformation. The divergence in published 
effect of SIRT7 expression may in part be explained by p53 status (Vakhrusheva et al, 
2008a).  
 
5.3.1.7 Role of the Sirtuins in Oncogenesis   
 
It is difficult to reconcile the relationship identified between the individual sirtuins in the 
CRC group in this study. The demonstration of attenuated relative expression between the 
tumour and normal samples could indicate a mechanism whereby normal expression is 
suppressed in tumour cells. This could form part of a process conferring a survival 
advantage of tumour cells by repressing the tumour suppressive function of the sirtuins 
particularly SIRT1, SIRT2, SIRT3 and SIRT6. This is not inconceivable, as DBC-1 has 
been shown to inhibit SIRT1 activity and suppress its function (Kim et al, 2008, Zhao et 
al, 2008), thus a molecule up-regulated during the neoplastic process could exert a similar 
effect. 
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The combination of our demonstration of attenuated sirtuin expression with the studies 
mentioned above paints a clear picture of the involvement of the sirtuins in the 
development of cancer. However, the complexities of the up-stream regulation and down-
stream targets of the sirtuins make it unlikely that a single unifying mechanism of tumour 
suppression (or promotion) will be demonstrated. Rather it is more likely that the effect of 
a particular sirtuin is context and tissue type driven. Specific examples of this would 
include the implication of the tumour suppressive effect in β-catenin driven colon cancer 
and BRCA1 associated breast cancers (Firestein et al, 2008, Wang et al, 2008a).  
 
Recent evidence has, however, suggested one area where there could be a convergence of 
pathways mediated by different sirtuins, cancer cell metabolic reprogramming. Otto 
Warburg first demonstrated that cancer cells become reprogrammed to preferentially 
metabolise glucose via glycolysis irrespective of the surrounding oxygen tension. This 
altered pathway therefore metabolises glucose into lactate to provide ATP for the cellular 
energy requirements. This is termed the Warburg effect and is considered as a hallmark of 
a transformed malignant cell (Warburg 1956). Metabolic reprogramming requires 
upregulation of the enzymatic components of the glycolytic pathway such as hexokinase 
and phosphofructokinase, with concomitant upregulation of lactate dehydrogenase (LDH). 
Downregulation of the enzymes involved in the tri-carboxylic cycle (TCA) is also essential 
to allow the preferential metabolism of glucose to lactate (Bayley & Devilee 2012). Key 
recent evidence has suggested that the sirtuins, namely SIRT3 and SIRT6 may evoke a 
tumour suppressor effect by preventing the metabolic reprogramming of cancer cells. 
Finley et al (2011) have shown that SIRT3 can influence the cancer cell glycolytic 
pathway via the regulation of HIF-1, an effect mediated by mitochondrial ROS. HIF-1 is 
one of the main drivers of the metabolic switch, and this study demonstrates that loss of 
SIRT3 drives HIF-1 activation leading to a change in the gene expression profile in SIRT3 
K/O mice compared with wild type littermates. In addition, treatment with the anti-oxidant 
N-acetylcysteine abolishes this effect, confirming the dependence on ROS. Over-
expression of SIRT3 in breast cancer cell lines reduced proliferation and suppressed the 
Warburg effect. Furthermore, the authors show that SIRT3 protein expression is reduced in 
human breast cancer samples with a concomitant increase in HIF-1 and its downstream 
targets (Finley et al, 2011).  
 
Metabolic switch to aerobic glycolysis and lactate production is one of the key features 
identified in the phenotype of the SIRT6 KO mouse. Furthermore this effect is also 
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dependent on HIF-1. Although not directly tested in tumour cells in this study, SIRT6 
deficient embryonic stem cells did exhibit an increased resistance to apoptosis when 
exposed to hypoxia/hypoglycaemia (Zhong et al, 2010). However, the tumour suppressor 
effect of SIRT6 with particular reference to its regulation of tumour cell aerobic glycolysis 
has recently been characterised. In collaboration with our laboratory and through a number 
of experiments, Sebastian et al demonstrated that SIRT6 deficiency leads to tumour 
formation in non-transformed cells both in vitro and in vivo, with a concomitant increase in 
glycolysis. Furthermore, deletion of a conditional SIRT6 allele in a well characterised 
mouse model of colorectal adenomatous disease increases the size, aggressiveness and 
number of tumours. In addition, SIRT6 also plays a role in ribosome biogenesis through 
co-repression of MYC transcriptional activity. Finally, this study replicates our 
demonstration of attenuated SIRT6 expression in human cancer samples, with SIRT6 
protein expression predicting both prognosis and tumour-free survival rates (Sebastian et 
al, 2012).    
 
Thus attenuated expression of SIRT3 and SIRT6, as we have shown in CRC could provide 
a survival advantage for cancer cells by mediating the switch from oxidative to the 
preferred glycolytic metabolic pathway. Interestingly, in the correlation analysis presented 
in Table 5.1 SIRT3 and SIRT6 exhibit a strongly positive relationship in tumour tissue but 
not in normal tissue. This could indicate a common mechanism of repressed expression in 
the cancer cells thereby promoting cancer cell survival potentially through metabolic re-
programming.  
 
 
5.3.2 Sirtuin Expression & Tumour Site 
The observation of SIRT2 and SIRT4 differential expression between colon and rectal 
cancers is intriguing, particularly when the previous demonstration of altered plasma 
fetuin-A levels in patients with colon and rectal cancers are considered (Chapter 4- 
4.2.2.2). A difference in the molecular pathways involved in the pathogenesis of right and 
left sided colon including rectal cancers is well established. Right sided cancers 
characteristically display features of microsatellite instability due to alteration in mismatch 
repair genes and variation in the CpG island methylator phenotype. Whereas, left sided and 
rectal cancers display evidence of chromosomal instability and accumulation of mutations 
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in genes implicated in the adenoma-carcinoma sequence such as adenomatous polyposis 
coli (APC), p53 and deleted in colorectal carcinoma (DCC) (Iacopetta 2002, Li & Lai 
2009). Frattini et al report less k-ras and more APC gene mutations in rectal compared with 
colon cancers (Frattini et al, 2004). Consistent with this the APC/β-catenin pathway has 
been implicated in the pathogenesis of rectal cancers (Kapiteijn et al, 2001). This is 
important given the reported relationship between SIRT1 and β-catenin driven CRC 
(Firestein et al, 2008). These distinct pathways explain to some degree the differing natural 
history and behaviour of CRC. For example, right sided cancers are more sensitive to 5-
fluorouracil based chemotherapeutic agents with a concomitant improvement in survival 
with adjuvant therapy (Elsaleh et al, 2000).  
We have demonstrated that SIRT2 expression levels reduce sequentially in specimens from 
the right colon, left colon and rectum. This finding adds further validity to the growing 
body of evidence supporting the argument that CRC should in fact be classed as three 
entities; right colon, left colon and rectal cancer (Li & Lai 2009). Whether our observations 
implicate SIRT2 in either of the distinct molecular pathways contributing to colorectal 
cancer remains to be fully elucidated. Current data evaluating the sirtuins in this context 
are lacking. There are no reports of downstream regulation of any of the transcriptional 
factors involved in microsatellite instability by SIRT2. However, SIRT1 expression has 
been shown to correlate with CpG island methylator phenotype and microsatellite 
instability in human CRC, however no relationship with tumour site was identified (Nosho 
et al, 2009). Continued enhancement of the molecular profile of colonic and rectal cancers 
is particularly important when the differing treatment algorithms between the two tumour 
sites are considered. 
5.3.2.1 Effect of Neo-adjuvant Therapy 
In the current study levels of SIRT1, SIRT3 and SIRT4 were significantly increased in 
tumour tissue exposed to chemo-radiotherapy treatments compared with those not treated. 
In addition SIRT6 expression was increased within the normal samples. Perhaps of more 
relevance is the fact that the relationship between expression of SIRT1-4 in tumour and 
normal samples from patients who had undergone neo-adjuvant therapy was reversed, with 
SIRT1-4 expression higher in tumour samples. However, it should be borne in mind that 
the number of patients who had undergone neo-adjuvant therapy in the group were small 
(n=6) and as such this data should be regarded as preliminary and interpreted with caution. 
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It should also be emphasised that only patients with rectal cancer undergo neo-adjuvant 
treatment for the reasons outlined in the introduction to this chapter. 
The finding of sirtuin up-regulation in samples of both tumour and normal rectal tissue 
from patients who had undergone neo-adjuvant therapy is logical when the function, 
particularly of SIRT1 is considered. The anti-proliferative effects of chemo/radiotherapy 
are mediated through DNA damage and subsequent induction of senescence or apoptosis 
(Begg et al, 2011). SIRT1 has been shown to play a role in the stress and DNA damage 
response induced by ionizing radiation, a feature that has led investigators to conclude that 
aberrant SIRT1 expression may in part modulate tumour cell resistance to 
chemo/radiotherapy (Olmos et al, 2011). Indeed, much of the work pertaining to the in 
vivo expression of SIRT1 and the response to chemo/radiotherapy has been performed in 
the context of treatment resistant tumours. Chu et al (2005), analysed expression of SIRT1 
in cancer specimens from patients who had not responded to chemotherapeutic treatment. 
In these chemo-resistant patients SIRT1 levels as detected by western blot analysis were 
found to be significantly increased in tumour tissue after chemotherapy treatment and were 
associated with expression of the multidrug resistant molecule P-glycoprotein (Chu et al, 
2005). The small number of patients who had undergone neo-adjuvant treatment and a lack 
of clinical data related to treatment regimes prevented a more in depth analysis of 
resistance to treatment in the current CRC group. However, the finding of differential 
expression of SIRT1 could indicate a potential role of SIRT1 in the tumour cell response to 
chemotherapy.  
Data pertaining to the remainder of the sirtuins and the response to chemotherapy are 
sparse. In the Chu et al study mentioned above none of the remaining sirtuins were 
differentially expressed in response to chemotherapy (Chu et al, 2005). SIRT3 has been 
shown to translocate to the mitochondria in cells treated with etoposide or UV irradiated, 
an indication of SIRT3 involvement in the stress response (Scher et al, 2007).  Meanwhile, 
SIRT6-null mouse cells are hypersensitive to DNA damage by ionizing radiation 
(Mostoslavsky et al, 2006). These findings could in part explain the finding of augmented 
levels of SIRT3 and SIRT6 in tumour specimens from patients exposed to chemo-
radiotherapy.  
Drawing firm conclusions regarding the interaction between the sirtuins and the cellular 
response to chemo-radiotherapy is difficult using the data presented in this chapter. Clearly 
153 
 
further characterisation in larger numbers of therapy exposed tissue with relevant controls 
is required. It would also be interesting to gain further information regarding sirtuin 
expression and the pathological response to treatment as manipulation of sirtuins 
expression could therefore be used to improve tissue responsiveness to neo-adjuvant 
treatment. 
 
5.3.3 Sirtuin Expression as a Marker of Prognosis 
Correlation of our sirtuin expression profile with pathological parameters has demonstrated 
a significant association between SIRT4 and node positive disease, with SIRT4 expression 
higher in node positive disease. Furthermore, the group of patients with higher SIRT4 
expression also had poorer survival. Currently, patients who are deemed to have more 
aggressive disease determined by either nodal status or adverse pathological features such 
as those quantified by the Peterson Index are offered adjuvant chemotherapy, co-morbidity 
permitting (Petersen et al, 2002). In node positive disease adjuvant therapy results in a 
survival gain of 10-15%, however the benefits in node negative disease are much less clear 
with a survival gain of only 3.6% (Cunningham et al, 2010). We have previously 
demonstrated increased SIRT3 in node positive breast cancer patients (Ashraf et al, 2006), 
whilst Cha et al have shown SIRT1 protein expression to correlate with nodal status and 
other markers of disease severity, as well as being a significant prognostic indicator in 
gastric carcinoma (Cha et al, 2009). Attenuated SIRT2 expression identified using gene 
expression array analysis has also been proposed as a poor prognostic indicator in 
oesophago-gastric carcinoma (Peters et al, 2010). 
The relevance of the relationship between SIRT4, nodal status and survival is not entirely 
clear, as although SIRT4 has well recognised effects on metabolism and response to CR in 
mice (Haigis et al, 2006), it has not been shown to have any direct effect on the oncogenic 
process. The preponderance of deaths in the group of patients with higher SIRT4 
expression is almost certainly as a result of more aggressive disease as indicated by nodal 
status. It should be borne in mind that there were relatively few deaths in the high SIRT4 
expression group with none in the low expression group, meaning this could be an 
anomaly. Increasing the study numbers could help to fully delineate this relationship. 
Further work to fully characterise SIRT4 post-translational expression levels in cancer 
specimens will determine whether it may be used as a novel molecular marker of risk 
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stratification or predictor of outcome, which could be used to select patients who may 
benefit from adjuvant therapy, or be used as a pathological marker of severity.  
The demonstrated difference in SIRT4 expression with stage of disease could indicate that 
it is not only the level of expression but the timing of this response that is important in the 
oncogenic process. SIRT1 expression has been shown to sequentially decrease from 
normal tissue, through non-malignant adenomas to high grade malignant disease (Kabra et 
al, 2009). This could indicate that SIRT1 levels are maintained at a high level in normal 
tissue and pre-cancerous lesions to prevent malignant transformation. The exact stimulus 
for this change in expression can only be speculated upon but could be related to cellular 
stress levels and the subsequent activation of downstream damage response pathways. The 
adenoma-carcinoma multi-hit sequence of events in colorectal oncogenesis could be 
particularly important in this scenario as mutations of genes such as p53, APC and k-RAS 
could interact and alter sirtuin expression with obvious downstream effects. In this study it 
is not clear if this is the reason for the noted differential expression of SIRT4. Within the 
tumour cells SIRT4 expression could be upregulated from its suppressed state to allow to 
the tumour to continue to proliferate indicated by advanced stage. The data pertaining to 
the remainder of the sirtuins and the relationship with tumour stage i.e. similar expression 
levels throughout stages could indicate the sirtuins are important for initiation and 
development of CRC, not just at the later stages. 
 
5.3.4 Inter-Relationships between Sirtuins 
Using the generated expression profile for the individual sirtuins association analysis was 
performed to determine any significant inter-relationships. This analysis yielded multiple 
significant associations between individual sirtuins. Whilst it is difficult to speculate upon 
the exact significance of these findings a number of general conclusions can be drawn. A 
striking feature is that all the associations deemed significant by statistical analysis were of 
a positive nature, where for example as SIRT1 levels increase so do SIRT2, SIRT3 and 
SIRT4 (Table 5.1), in a highly significant relationship. Within the tumour samples the 
relationship was most prominent with SIRT2, SIRT3 and SIRT4 in whom there was a 
highly significant relationship with all but one of the other sirtuins (Table 5.1). These data 
could indicate a common regulator of sirtuin expression responsible for controlling the 
transcriptional response to appropriate stimuli. 
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Whilst some of the individual downstream regulators of individual sirtuins are mentioned 
above, common control pathways between the sirtuins have been difficult to identify, if 
indeed they do exist. The most obvious ubiquitous control mechanism for sirtuin activity is 
the dependence by the sirtuins on the metabolic intermediary NAD+ as a cofactor for 
activity. As mentioned earlier this introduces the potential for nutritional manipulation to 
alter sirtuin activity. Further layers of expressional control are conferred by some of key 
effectors of the cellular stress response, SIRT1 and SIRT2 have both been shown to be 
transcriptionally up-regulated by the acetyl transferase p300 with concomitant effects on 
p53 activity (Han et al, 2008b).  
Table 5.1 shows a clear correlative relationship between the mitochondrial sirtuins (SIRT3, 
SIRT4 and SIRT5) in the tumour samples. This could indicate commonality of 
transcriptional control and function, however no such relationship has been previously 
identified. As mentioned above SIRT3 has been recently implicated in the metabolic 
reprogramming essential for tumour cell proliferation (Finley et al, 2011). The 
demonstrated correlation between the mitochondrial sirtuins in our CRC tumour samples 
could implicate their involvement in this process. Very little is known regarding common 
pathways involving the mitochondrial sirtuins. However, Nakamura et al (2008) have 
demonstrated that intra-cellular shuttling of SIRT3 is dependent of co-expression with 
SIRT5 (Nakamura et al, 2008). This raises the possibility SIRT5 may not possess a tumour 
suppressor function per se but it is required in some capacity for SIRT3 to function, 
indicated by their demonstrated relationship in CRC tumour cells.  
A common expression mechanism between the sirtuins could be responsible for the 
positive inter-associations demonstrated, however, given the complexities of sirtuin 
regulation and functionality it seems unlikely that such a simple control mechanism would 
be utilised.  
 
5.3.5 Sirtuin Expression and Biological Age 
Our data demonstrate a link between low sirtuin expression levels and systemic 
inflammation. Sirtuin expression and control of the inflammatory cascade are intricately 
linked through the control of NF-κB transcription by SIRT1 (Yeung et al, 2004) and 
SIRT6 (Kawahara et al, 2009). This relationship has been investigated in a clinical context 
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by Singh et al who have reported that SIRT1 is implicated in the pathogenesis of colitis by 
inversely regulating NF-κB and that inducing SIRT1 activity by resveratrol abrogates the 
process in a well characterised mouse model of colitis (Singh et al, 2010). Lower SIRT1 
levels have also been reported in the lungs and macrophages of patients with COPD 
(Rajendrasozhan et al, 2008). The presence of a systemic inflammatory response in cancer 
patients confers poor survival independent of factors such as tumour stage. This systemic 
inflammation is thought to represent a host characteristic (Roxburgh & McMillan 2010). 
The association between altered sirtuin expression in normal colorectal tissue and indices 
of systemic inflammation could implicate the sirtuins in this host response. The sirtuin 
expression profile namely suppressed SIRT2, SIRT3, SIRT4 and SIRT7 could highlight a 
previously undiscovered role in the control of pro-inflammatory pathways for these genes, 
an effect which requires validation in in vivo models. 
We have observed, in the context of low expression in tumour samples a significant 
inverse relationship between SIRT3 and TL. This finding is a pertinent one given that short 
TL indicates advanced biological age of these cells, as a result of uncontrolled cell 
turnover. Higher SIRT3 expression levels in this scenario could be a response to 
dysregulated mitochondrial function evident in these biologically aged neoplastic cells. 
This association between sirtuin expression and TL lends further support to our hypothesis 
that the sirtuins link TL and hence DNA damage response with energy utilisation via the 
MTR. 
 
5.3.6 Conclusion 
The expression data presented above provides clear evidence that sirtuin expression is 
attenuated in the colorectal cancer specimens under investigation, indicating a tumour 
suppressive effect. In order to lose the tumour suppressive effect with the result of 
oncogenic transformation of a colorectal epithelial cell to a malignant cancer cell, sirtuin 
expression must be repressed to result in the attenuated expression levels we have 
demonstrated.  As with many aspects of the sirtuin story this is almost certainly a process 
with a great variety of complicating factors not only dependant on the molecular 
characteristics of tumour type but factors closely associated with the sirtuins themselves. 
Namely, the up-stream regulatory mechanisms which can control expression, the sub-
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cellular localisation and the presence or otherwise of sirtuin isoforms may complicate 
interpretation.   
Information regarding the regulation of sirtuin expression is scanty with much more known 
about their functional downstream targets. A number of mediators act at the promoter level 
to repress SIRT1 transcription. Both HIC-1 (Chen et al, 2005a) and miR34-a (Yamakuchi 
& Lowenstein 2009) exert a tumour suppressive effect via feedback loops in a p53 
dependant fashion to reduce SIRT1 transcription. This relationship could be of particular 
importance as recent evidence suggests that levels of miR34a increase relative to 
chronological age with a reciprocal attenuation in SIRT1 protein levels (Li et al, 2011b). 
Thus age related reduction in SIRT1 expression through a miR34a dependent mechanism 
would mean a loss of its tumour suppressor effect and could also partly explain the 
increasing incidence of cancer with chronological age. One potential complicating problem 
is the presence or absence of mutated p53. 
Other mechanisms of suppressed sirtuin gene expression can only be speculated upon. 
Environmental factors are known to affect sirtuin expression, the most famous example 
being the induction of sirtuin expression in particular SIRT1, SIRT3 and SIRT6 by calorie 
restriction (Cohen et al, 2004b, Kanfi et al, 2008b, Qiu et al, 2010). As mentioned 
previously calorie restriction has consistently been shown to increase lifespan in a number 
of different model systems. In addition, it has also been shown to reduce the incidence of 
cancer in higher organisms (Omodei & Fontana 2011). This could imply that the tumour 
suppressor effect of calorie restriction is in part mediated through induction of sirtuin 
expression. Conversely, a diet high in fat has been shown to induce tumour progression 
and features of metastasis in various animal models of colon cancer (Park et al, 2011, Tang 
et al, 2012). Furthermore, recent studies have indicated this may be mediated through 
induction of β-catenin targets regulating colon epithelial cells and Wnt signalling pathway 
(Liu et al, 2011, Padidar et al, 2012). Whilst sirtuin modulation has not been shown to be 
directly affected by high fat diet in animal models of cancer, suppression of SIRT1 
function has been demonstrated in atherosclerotic lesions. In animals fed a high fat diet 
p53 acetylation at K382 (the acetylation site specific to SIRT1) was significantly reduced 
indicating this dietary regimen could influence sirtuin expression (Xu et al, 2011). 
Similarly, mice fed a high fat diet exhibit attenuated hepatic SIRT3 expression and activity 
(Kendrick et al, 2011). It is enticing to think that diet could suppress sirtuin expression to 
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the extent that the tumour suppressive capacity would be lost in a tissue specific context 
contributing to the oncogenic process.  
It is clear there is a dearth of knowledge regarding the controlling mechanisms of sirtuin 
expression. Other complicating factors which could influence not only sirtuin expression 
but activity are;  
• Epigenetic phenomena such as silencing of the respective sirtuin genes, could alter 
their expression through chromatin remodelling. As yet there are no reports in the 
literature either in vitro or in vivo. 
• Post-translational modification such as phosphorylation at specific residues within 
the SIRT1 enzyme can alter activity. Indeed, cyclinB/Cdk1 has been identified as a 
key regulator of SIRT1 phosphorylation (Sasaki et al, 2008). In addition, a recent 
key study by Back et al (2011), demonstrated that phosphorylation of SIRT1 by 
mTOR promotes prematurely senescent squamous cell carcinoma cell survival. 
This effect was seen in the absence of functional p53 and could re-constitute the 
scenario of human in vivo cancer recurrence where tumour cells re-enter the cell 
cycle causing recurrent disease (Back et al, 2011).      
The effect of the sub-cellular localisation of the sirtuins on their function and potential 
tumour suppressor role has not been established. The basic pattern of sub-cellular 
localisation is well established, however evidence is emerging that there are some caveats 
to this picture. Byles et al (2010) have demonstrated that SIRT1, which was previously 
thought to be predominantly nuclear in location, is present in the cytoplasm of DU-145 
(prostate cancer) cells. This occurs as result of increased protein stability and is regulated 
by elevated mitotic activity (Byles et al, 2010). Whilst, SIRT2 has previously been shown 
to shuttle between the nucleus and cytoplasm depending on the stage of the cell cycle 
(North & Verdin 2007a). These studies demonstrate the dynamic nature of sirtuin sub-
cellular localisation, it seems likely that the localisation is dependent on tissue type and 
prevailing cellular conditions. This phenomenon has already been demonstrated with 
regards to SIRT3 which has been shown to shuttle from the nucleus to mitochondria on 
sensing of cellular stress (Scher et al, 2007). 
Clearly there is ambiguity in the literature as to whether the sirtuins, in particularly SIRT1 
are tumour suppressive or oncogenic. This is reflected in studies which have attempted to 
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pharmacologically manipulate sirtuin activity to alter the oncogenic process. The sirtuin 
modulator which has garnered the most publicity is the polyphenol resveratrol. Whilst 
several anti-cancer properties have been related to resveratrol there is considerable 
controversy in the scientific literature regarding the SIRT1 dependency of its mechanism 
of action. Claims and counter claims argue that SIRT1 is activated downstream of AMPK 
which is initially activated by resveratrol due to its ability to inhibit phosphodiesterases 
thereby increasing cAMP availability. The overall effect is an increase in NAD+ levels 
leading to SIRT1 activation (Chung 2012, Park et al, 2012). Nonetheless, trials are 
underway to determine whether treatment of patients with resveratrol can recapitulate the 
chemo-preventative effects seen in vitro and in murine models. In this regard resveratrol 
has been shown to be safe in the quantity required to produce a biological effect in vivo. 
Furthermore, resveratrol also caused a modest reduction in cell proliferation in CRC tissue 
samples. Unfortunately this study did not examine any of the purported downstream targets 
of resveratrol (Patel et al, 2010). Pharmaceutical companies have sought to utilise the 
beneficial effects of SIRT1 activation by developing activating compounds (STACs). A 
number of these have been developed, one such compound, ST1720 has been shown to 
reduce the proliferation of multiple myeloma cells in vitro via SIRT1 dependent apoptosis 
(Chauhan et al, 2011).  
Whilst our data support the notion that activation or upregulation of SIRT1 could produce 
beneficial effects, it is not clear what effect this may have on the rest of the sirtuins. The 
demonstration of correlation between sirtuin expression patterns could theoretically 
indicate that activation of SIRT1 may influence the expression of the remaining sirtuins. 
However, despite a number of studies investigating the effect of pharmacological SIRT1 
activation none have examined the effect of activation of any of the other sirtuins or what 
the effect of SIRT1 activation has on downstream SIRT2-7 levels. As indicated there are 
clear mechanistic pathways by which the remainder of the sirtuins affect the oncogenic 
process with particularly strong evidence supporting the tumour suppressive effect of 
SIRT3 and SIRT6. It may be pharmacological augmentation of SIRT responsiveness could 
alter the oncogenic process at various stages. For example increasing SIRT6 expression 
specifically in colorectal adenomas could promote genetic stability and prevent onward 
progression through the adenoma-carcinoma sequence.  
In summary, we have created a unique expression profile for SIRT1-7 in colorectal cancer 
patients. This has provided clear evidence that expression of all seven sirtuins is reduced in 
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cancer specimens when compared with normal tissue. These findings support the argument 
that sirtuins act as tumour suppressors in colorectal cancer. However, the in vivo role of 
the sirtuins in oncogenesis is likely to be complex. Further work is required to fully 
delineate whether there is molecular ‘cross-talk’ between individual sirtuins and whether 
their role will be dependent on tumour type and distinct molecular pathways driving 
oncogenesis. Our analysis has highlighted novel associations linking sirtuin expression 
with factors indicative of biological ageing namely inflammation and TL. Furthermore we 
have utilised sirtuin expression to differentiate between tumour site and pathologically 
more aggressive disease. Thus study providing clear evidence that targeting of individual 
sirtuins could prove useful in the quest to identify novel chemotherapeutic agents. 
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CHAPTER 6: GENERAL DISCUSSION 
The data presented in this thesis supports the original hypothesis of biological ageing 
contributing to the pathogenesis of CRC in the study population. This relationship has been 
demonstrated by aberrancy of two molecular pathways shown to influence biological 
ageing namely accelerated telomere attrition and altered sirtuin expression.   
6.1 Miles on the Clock Hypothesis 
The paradigm whereby altered telomere biology could lead to the development of cancer is 
intuitive, with the multi-factorial determination of TL and rate of attrition a key concept. 
Whilst there was no significant relationship between socio-economic status and TL in the 
group under investigation in this study, the well documented pro-inflammatory and 
oxidative state found in this population is likely to reflect chronic exposure to a variety of 
environmental and lifestyle stressors, for example cigarette smoke and poor diet. The level 
of socio-economic deprivation in the study population may of course confound results by 
not giving an accurate representation of the population in general but it does provide an 
ideal environment to test the proposed hypothesis. A pro-inflammatory and oxidative state 
could impact on telomere attrition rates in a number of ways. Clearly increased 
inflammatory cell turnover would lead to progressive telomere attrition in the 
haemopoietic compartment. This progressive telomere attrition could then lead to a state of 
crisis and senescence with subsequent release of pro-inflammatory mediators 
compounding the pro-inflammatory state. Low socio-economic status is typified by a poor 
quality, high fat content and sugar rich diet. This has been shown to result in enhanced 
production of ROS resulting in a pro-oxidative state. As described in depth previously 
ROS are directly toxic to telomeric DNA resulting in acceleration of telomere attrition. 
This pro-inflammatory state and cumulative oxidative burden is therefore thought to be key 
to the acceleration in biological ageing and increased cancer risk in the current study 
group. Indeed socio-economic deprivation such as that seen in the cancer patients under 
investigation has recently been associated with accelerated telomere attrition (Shiels et al, 
2011). This state in which patients display evidence of biological ageing in the form of 
progressive telomere attrition has been equated colloquially with the concept of a car 
running up miles on the clock, hence this has been termed the ‘miles on the clock’ 
hypothesis. Generalised telomere dysfunction could then impact on cancer risk and 
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progression as outlined previously by promoting chromosomal instability and altering the 
peri-tumoral milieu via cellular senescence.  
 
6.2 MTR Hypothesis 
As described earlier the sirtuins provide an intuitive link between the energy dependent 
sensing of DNA damage and initiating the optimal response of the cell to either repair the 
damage or prevent replication of potential mutations by facilitating either apoptosis or 
senescence. Optimal responsiveness of the MTR trinity would require normal functioning 
of each of the triumvirate as well as fine control of sirtuin expression. Alteration in any of 
these components could lead to knock-on effects on the remainder of the pathway. It is 
appealing to speculate that aberrancy of this pathway could play a role in biological ageing 
and the development of some of the pathological processes associated with it, particularly 
cancer. 
The results presented in this thesis provide clear and compelling evidence that accelerated 
telomere attrition and attenuated sirtuin expression are implicated in the pathogenesis of 
CRC. Aberrancy of these pathways supports the hypothesis that dysregulation of the MTR 
could play a role in CRC development. Interplay between elements of the MTR is evident 
with the identified association between SIRT3 expression and tumour tissue TL. As 
mentioned earlier elevated SIRT3 expression could be a response to dysregulated 
mitochondrial function in neoplastic cells or could indicate a novel functional relationship 
between SIRT3 and telomere biology required for uncontrolled cellular proliferation. Such 
a relationship has recently been identified in hepatocellular carcinoma where SIRT1 was 
shown to be involved in telomere maintenance (Chen et al, 2011).  
 
6.3 Clinical Translation 
Utilisation of some of the aspects of biological ageing investigated in this thesis could 
prove useful in the continued quest to treat cancer of different histological subtypes and at 
various interventional stages. 
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6.3.1 Epidemiology  
The concept of biological ageing as a risk factor for cancer is an attractive proposition as it 
opens the possibility of identifying a window of opportunity where through lifestyle 
modification the process of biological ageing could be retarded thereby reducing cancer 
risk. Possibilities to achieve this could be through further rationalisation of the 
determinants of TL or identification of new contributing factors, such as the potential 
interaction with fetuin-A identified in this study. Ornish et al (2008), report that 
comprehensive lifestyle modifications can increase telomere maintenance mechanisms in 
the white cells of patients with prostate cancer (Ornish et al, 2008). This study provides 
preliminary evidence that lifestyle modification could alter the process of biological 
ageing.  Further support for the ability of lifestyle modification to alter the course of the 
bio-ageing process comes from a recent study by Du et al (2012). The authors report a 
modestly significant association between self-reported activity levels and TL, with 
increasing levels of activity associate with longer TL after adjustment for confounding 
factors such as age and BMI (Du et al, 2012). If confirmed in larger population based 
randomised controlled trials these data would support the more intensive adoption of 
public health measures to improve cancer risk through lifestyle modification.      
6.3.2 Diagnosis & Prognosis of Cancer 
This study has demonstrated an association between aspects of biological ageing (PBL 
telomere length and SIRT4 expression) and pathologically more aggressive disease. 
Stratifying patients using molecular markers of severity could allow the identification of 
patients who may benefit from a more aggressive management strategy which could in turn 
facilitate overall improvements in outcome. Clearly more work is required to validate these 
molecular markers in large numbers of patients and potentially in different types of cancer. 
The ability to differentiate between anatomical tumour sites in this group of CRC patients 
using factors involved in biological ageing (fetuin-A, SIRT2 and SIRT4) supports further 
work to improve the molecular characterisation of these tumours. These differences could 
be exploited to propose different management strategies for CRC depending not only on 
anatomical tumour site as is currently the case but also in conjunction with molecular 
differences.   
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6.3.3 Therapeutic targets  
One of the defining aims of this study is to provide further information of the expression of 
ageing related genes in CRC with the aim of identifying potential targets for intervention. 
The demonstration of attenuated sirtuin expression in CRC raises the possibility that 
enhancing sirtuin signalling could provide a tumour suppressor effect. The difficulty with 
this lies in the fact that depending on the cancer type and model used sirtuin expression has 
opposing effects. It is likely, therefore, that a ‘one size fits all’ approach to developing 
agents which could alter sirtuin activity will not yield the desired results. Hence an 
approach using the concept of personalised chemotherapy where cancers are targeted on an 
individual basis depending on the genetic and epigenetic profile could prove useful. In the 
case of the sirtuins determination of p53 status, acetylation status, molecular driver of the 
cancer e.g. β-catenin or the recognition of polymorphic forms of the sirtuin genes could 
dramatically affect the activity of proposed agents. Further refinement may also be 
possible using techniques such as RNA interference to target and deliver specific genes. 
The era of personalised chemotherapy in clinical practice is in its infancy, however KRAS 
mutation testing and subsequent intervention using anti-EGFR monoclonal antibodies is 
now a management option in metastatic CRC (Van Schaeybroeck et al, 2011). The finding 
of increased sirtuin expression in patients who had undergone neo-adjuvant treatment 
indicates a potential role for the sirtuins in the response to chemo-radiotherapy. It may 
therefore be possible to exploit this to allow more efficient delivery and hence improve 
response to current treatment regimes.  
 
6.4 Limitations & Future Work 
A constant theme through the telomere and sirtuin components of this thesis has been the 
contribution played by p53 to both of these pathways. Therefore, determination of the p53 
status of the tumours and also patient p53 genotyping would allow a more comprehensive 
approach to elucidating the interplay between the biological aging and cancer pathways. 
Similarly, relating SIRT1 expression to the numerous other non-histone proteins such as 
FOXO, NF-κB or Bcl, over which it has been shown to influence would provide greater 
understanding of the mechanistic pathways involved in the cancer model used in this 
investigation.  
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With regards to the investigation into the contribution of telomere attrition in CRC the 
main area in which could be improved is to have a completely matched group with blood 
cells and tumour tissue from the same patient. Increasing the overall numbers would also 
enhance the capability to tease out relationships between TL and patient sub-groups which 
were not identified during analysis of the current data. Identifying further clinically 
important relationships could improve the therapeutic potential of telomere biology in the 
cancer setting. It may also be possible that the methods used to delineate any relationship 
between TL and oxidant status were not sensitive enough. Methods to detect fine changes 
in ROS or their intermediaries at the sub-cellular level may provide a more accurate 
representation of the flux in oxidative potential and the effect on TL.  
To gain a more accurate representation of sirtuin expression incorporation of a non-
malignant group from a patient source with no history of cancer with which to compare 
sirtuin relative expression levels from the cancer and adjacent normal tissue would have 
been useful. This further comparison would have negated any potential effect of a field 
change in sirtuin gene expression which extended from the peri-tumoural area to adjacent 
normal tissue. Incorporation of such a group was however, not possible through the local 
Biobank repository for ethical reasons. Further improvements in the overall picture of 
sirtuin expression would be to quantify protein expression using western blot analysis. 
Comparing the current mRNA expression profile with the protein expression profile could 
also determine the presence and significance of post-translational modification. In addition, 
immunohistochemical staining of tissue arrays could address the issue of sub-cellular 
localisation of the sirtuins in cancer cells. As mentioned in the relevant discussion section 
pre-neoadjuvant treatment biopsies would have allowed a more accurate conclusion to be 
drawn as to the effect on sirtuin expression by this treatment. This could be complemented 
by in vitro analysis of cultured cells exposed the chemo-radiation. Recent evidence has 
also suggested that variation in SIRT1 genotype may have an effect on its clinical effect 
(Zillikens et al, 2009). Whilst this was not considered in this thesis a more refined picture 
of sirtuin expression may be possible by examining the effect of sirtuin genotype in cancer 
patients. 
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6.5 Final Conclusion 
The results reported in this thesis support the initial hypothesis of biological ageing playing 
a role in the pathogenesis of CRC in our patient group. We have observed that patients 
with CRC have significantly shorter telomeres than control subjects, congruent with 
accelerated biological ageing in the pathogenesis of CRC. These observations are in 
keeping with the hypothesis of telomere attrition predisposing to disease. Furthermore, 
patients with shorter telomeres display evidence of systemic inflammation and 
pathologically more advanced disease. An imbalance in redox control mechanisms and 
calcium homeostasis may be a contributing factor to telomere dynamics in our group of 
patients. Further refinement of the factors determining TL and subsequent manipulation 
could alter the risk profile of CRC. 
Furthermore, we have created a unique expression profile for the ageing associated genes 
SIRT1-7 in CRC patients. We have provided clear evidence that expression of all seven 
sirtuins is attenuated in cancer specimens when compared with normal tissue, lending 
further support to the argument that sirtuins act as tumour suppressors in colorectal cancer. 
However, the in vivo role of the sirtuins in oncogenesis is likely to be complex with 
molecular ‘cross-talk’ between individual sirtuins, tumour type and the molecular profile 
of an individual tumour all important factors in determining the overall effect of the 
individual sirtuins. This analysis has highlighted novel associations linking sirtuin 
expression with factors indicative of biological ageing namely inflammation and TL. 
Furthermore sirtuin expression proved a useful molecular mechanism to differentiate 
between tumour site and pathologically more aggressive disease. This study provides clear 
evidence that targeting of individual sirtuins could prove useful in the quest to identify 
novel chemotherapeutic agents. 
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Appendix 1 
 
β-actin Fwd -  GGTCACCCACACTGTGCCCAT 
β-actin Rev – GGATGCCACAGGACTCCATGC 
 
 
Gene Fwd Primer 5’-3’ Rev Primer 3’-5’ TaqmanTM probe 
SIRT1 TAGAGCCTCACATGCAAGCTCTA GCCAATCATAAGATGTTGCTGAAC ACTCCAAGGCCACGGATAGGTCCATATACTT 
SIRT2 CCTCGCCTGCTCATCAACA TCCTCCGAGGCCCATAATC TGGCCAGTCGGACCCTTTCCTG 
SIRT3 CATTCGGGCTGACGTGATG AACCACATGCAGCAAGAACCT TGCACCGGCGTTGTGAAGCC 
SIRT7 CGTCCGGAACGCCAAATAC GACGCTGCCGTGCTGATT TGGTCGTCTACACAGGC 
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